

**PROGRAMME BOOK**

**EVER  
2012  
NICE**

[www.ever.be](http://www.ever.be)

SCIENCE FOR SIGHT

**OCTOBER 10-13**

21 CME credits



**EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH**



# Innovative. Dedicated. Worldwide.

For more than 30 years **URSAPHARM** has been developing innovative pharmaceutical concepts, converting these into successful pharmaceutical and medicinal products for the ophthalmology and general medicine sectors - for the well-being of patients throughout the world.

[www.ursapharm.de](http://www.ursapharm.de)



*Leopold SCHMETTERER  
EVER President 2012*

Dear EVER members,

As EVER President it is my great pleasure to welcome you to the 2012 EVER meeting in Nice, France. The 21st century brought significant advances in many areas of Medicine. This is particularly true for Ophthalmology and Visual Science and the insight into basic mechanisms of ocular disease as well as the improvement in diagnosis and treatment will translate into reduced blindness and vision loss.

The EVER congress in Nice will provide a platform to discuss future developments in eye research based on the success of these previous years. It will again allow for an intense exchange of ideas with experts from Europe and beyond in the splendid EVER atmosphere. The list of speakers that agreed to join our meeting in Nice guarantees the scientific excellence of the congress. It was always a major goal of our society to provide the opportunity for younger scientists at the PhD or residency level to present their data. This aim will also be implemented in the 2012 EVER meeting with extensive poster sessions and rapid fire presentations. We will keep the prizes for young scientists that we have successfully implemented. I have seen some of the previous prize winners developing their international career in vision science in the recent years.

As other societies, EVER is faced with the problems of the financial and economic crisis. This makes it more difficult for the organizers but also more difficult for the scientists to join the meeting because of budget restrictions at our Universities. With all this we must not forget that Research and Development in Biomedical Science is one of the ways out of the crisis. We should not forget to communicate this and increase our efforts to get our work funded. To form European Consortia is undoubtedly a promising way to obtain research money and EVER is a good starting point for such efforts.

What makes EVER unique is not only related to the scientific program, but also to the social activities associated with the congress. We will keep this spirit for 2012 and I am convinced that we will all spend enjoyable days at our new conference venue in Nice.

Leopold SCHMETTERER  
EVER President 2012





|  |            |
|--|------------|
| Word from the President .....                                | 1          |
| About EVER .....   | 5          |
| Board Members 2012 .....                                     | 6          |
| General Information .....                                    | 8          |
| Grants.....  | 11         |
| Partnership.....   | 12         |
| Programme Committee 2012 .....                               | 16         |
| About the Programme Book.....                                | 17         |
| Floor plan .....   | 18         |
| Exhibition.....  | 19         |
| <b>Wednesday, October 10.....</b>                            | <b>21</b>  |
| Courses overview .....                                       | 22         |
| Courses.....   | 23         |
| Opening Ceremony .....                                       | 31         |
| <b>Thursday, October 11.....</b>                             | <b>33</b>  |
| First morning session .....                                  | 34         |
| Keynote Lecture: Joan Miller .....                           | 39         |
| Second morning session .....                                 | 40         |
| Lunchtime session: CIS Théa .....                            | 43         |
| EVI Award Lecture .....                                      | 44         |
| First afternoon session.....                                 | 45         |
| Second afternoon session .....                               | 48         |
| Poster session 1.....  | 53         |
| Evening session .....  | 58         |
| <b>Friday, October 12 .....</b>                              | <b>63</b>  |
| Early morning session: Breakfast CIS Alcon .....             | 65         |
| First morning session .....                                  | 66         |
| Keynote lecture: Rando Allikmets .....                       | 69         |
| Second morning session .....                                 | 70         |
| Lunchtime session: CIS Allergan.....                         | 73         |
| First afternoon session.....                                 | 74         |
| Business Meetings of the scientific sessions.....            | 79         |
| Ophthalmic Research Lecture: George L. Spaeth .....          | 81         |
| Poster session 2.....  | 83         |
| Second afternoon session .....                               | 88         |
| <b>Saturday, October 13.....</b>                             | <b>93</b>  |
| Early morning session: Breakfast CIS Croma .....             | 95         |
| First morning session .....                                  | 96         |
| Keynote Lecture: Jayakrishna Ambati .....                    | 99         |
| Second morning session .....                                 | 100        |
| Lunchtime session: CIS Bayer.....                            | 105        |
| First afternoon session.....                                 | 107        |
| Poster session 3.....  | 111        |
| Second afternoon session .....                               | 116        |
| Evening session: EVER General Assembly and Prize Giving..... | 119        |
| Presenting first authors .....                               | 125        |
| Presenting authors by country .....                          | 131        |
| Congress Time Schedule .....                                 | 132        |
| Sponsors .....   | back cover |

**EVER**



The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is the largest European scientific organization which covers all subspecialties of ophthalmology and visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress.

## Membership

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research.


Applications for membership - available on [www.ever.be](http://www.ever.be) - may be submitted at any time, membership is on calendar year basis and starts on January 1.

Every member must select one of the 11 Scientific Sections that best represents his or her primary area of interest.

### The benefits of EVER membership are:

- submission of abstracts to EVER annual meeting
- reduced registration fee for EVER annual meeting
- organizing Special Interest Symposia (SIS) and courses during the EVER annual meeting
- participating in the EBO review courses
- EACCME granted 21 European CME credits (ECMEC) recognized by the American Medical Association- for the EVER annual meetings
- voting rights for the election of the Board Members (except members-in-training and emeritus members)
- 25 travel grants for best papers to attend the EVER annual meeting
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 2.629)
- quarterly E-Newsletter
- e-alerts
- member of CONCORDIA

## Participants:



Clinical with or without research: 73 %  
Research only: 27 %

## Elections

This year new representatives of the scientific sections Cornea / Ocular Surface and Glaucoma will be elected through electronic voting. Voting 2012 will close on October 12, midnight.

The result of the elections will be announced at the General Assembly on Saturday October 13, 2012.

The scientific sections will hold their Business Meetings on Friday, October 12, 2012 from 15:10 - 15:50. The agenda is available on page 79.


The following 2 sections will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2013:

- Lens and Cataract
- Retina / Vitreous

The term of the Secretary General is coming to an end. Elections for a new Secretary General are open to all full members.

The statutes and by-laws are available on the website: [www.ever.be](http://www.ever.be) » about » statutes.

## MEMBERS ACCORDING TO SCIENTIFIC SECTIONS



# BOARD MEMBERS 2012



**Leopold  
SCHMETTERER**

- President



**Bahram  
BODAGHI**

- Secretary  
General



**Jean-Jacques  
GICQUEL**

- Treasurer



**Marcela  
VOTRUBA**

- Programme  
Secretary



**Philippe  
KESTELYN**

- President Elect



**Carl  
HERBORT**

- Vice President



**Thierry  
ZEYEN**

- Vice-President  
Elect



**Lene  
MARTIN**

- Past President

EXECUTIVE COMMITTEE



**Marlene  
VERLAECKT**

- Executive Officer



**Lies  
VAN EYCKEN**

- Executive Assistant

Kapucijnenvoer 33,  
3000 Leuven,  
Belgium  
ever@ever.be  
tel +32 16 233 849  
fax +32 16 234 097

OFFICE

 **Resilion**

IT and website support by RESILION



**SECTION CHAIRS**



**Nadja  
KNOP**

- Anatomy / Cell Biology



**Philippe  
KESTÉLYN**

- Cornea / Ocular Surface



**Werner  
SPILEERS**

- Electrophysiology, Physiological Optics, Vision Sciences



**Thierry  
ZEYEN**

- Glaucoma



**Andrew  
DICK**

- Immunology / Microbiology



**Bart  
LEROY**

- Molecular Biology / Genetics / Epidemiology



**Aki  
KAWASAKI**

- Neuro-ophthalmology / Strabismology / Paediatric / History



**Laurence  
DESJARDINS**

- Pathology / Oncology



**Gerhard  
GARHÖFER**

- Physiology / Biochemistry / Pharmacology



**Constantin  
POURNARAS**

- Retina / Vitreous



**Alfred  
WEGENER**

- Lens and Cataract



**Rimvydas  
ASOKLIS**

- East Europe

**REGIONAL  
REPRESENTATIVE**



**Ioannis  
PALLIKARIS**

- Greece, Crete

**LOCAL  
REPRESENTATIVE**

### Venue

EVER 2012 will be held at the Acropolis Convention Center in Nice, France

⇒ visit the website on [www.nice-acropolis.com](http://www.nice-acropolis.com)

The scientific programme of the EVER congress starts on Wednesday, October 10 at 12:00 and concludes on Saturday, October 13 at 19:30.

### Registration

Everyone attending the scientific sessions - whether or not an EVER member, invited speaker, accompanying person or presenter - must register and pay the registration fee.

On-site registration starts on Wednesday, October 10, 09:00.

#### Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- if you register as an Eye-Care/Technician, you need to prove your status with a document signed by the Head of your Department

### Registration fees on-site

|                                       | EUR | EUR   |
|---------------------------------------|-----|-------|
| EVER member / SIS-invited speaker     | 455 | 390 * |
| Member-in-training                    | 250 | 200 * |
| Non-member                            | 800 | 645 * |
| Non-member-in-training                | 400 | 310 * |
| Eye-Care / Technician (non MD)        | 270 | 210 * |
| Congress Dinner (member / non-member) | 90  | 90    |
| Congress Dinner (in training)         | 60  | 60    |

\* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Congo, Egypt, Georgia, Iran, Libya, Macedonia, Moldova, Montenegro, Morocco, Ouzbekistan, Pakistan, Serbia, Tunisia, Ukraine

### Cancellation policy

Refunds – up to 75% of the advance registration fee will be granted for cancellation received in writing prior to September 21, 2012. Refunds will not be granted for later cancellations or no-shows.

### Website

The EVER website [www.ever.be](http://www.ever.be) has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2012 meeting and view the status (session, hour, place) of your presentation
- pay on-line and obtain an overview of past payments
- look for other EVER members
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- cast your vote for officers
- print CME certificate after each congress you attended

### Housing / Travel

#### GLOBALCYNERGIES™

Global Cynergies has negotiated special rates for accommodation in several categories of hotels.

The Nice Côte d'Azur Airport is located 15 minutes from the Acropolis, at 7 km from the city centre.

The tramway line connects most of the hotels with the Acropolis Convention Center.

### Weather

Nice enjoys an exceptional microclimate. A Mediterranean city opening onto the sea, it is protected from the main winds by its mountains. It is renowned for its mild climate in winter and its sunshine.

### Tourist information

The city of Nice is located on the French Riviera in Provence-Alpes-Côte d'Azur. Blessed by a sunny, temperate climate, Nice attracts visitors from around the world. Among its many attractions are its beautiful beaches, lovely seaside promenade, interesting museums, famous city landmarks and other tourist attractions.

Day excursions are available from Nice to Antibes, Juan-les-Pins, Monte Carlo, Cannes and to other towns.

## Welcome Reception

The Welcome Reception is open for all participants

- **Wednesday 19:00 - 21:00**  
in Acropolis Convention Center

## Congress Dinner

Registration for the Congress Dinner is required.

Congress Dinner for members or non-members: 90 EUR

Congress Dinner for trainees: 60 EUR

Space is limited.

- **Friday 20:30 in Hotel NEGRESCO**

## Coffee

Included in the registration fee are the coffee and soft drinks offered during the breaks.

## Internet access

Wi-Fi internet access is available in the Convention Center.

## Photographs



It is strictly forbidden to take photographs or videos of the presentations in all lecture halls.

## Publication of the abstracts

The abstracts of the EVER 2012 congress are published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access for members-only through EVER homepage.

## Business Meetings

EVER Business Meetings of the scientific sections  
Friday, 15:10 - 15:50

- ACB/PO..... Gallieni 4
- COS ..... Erato
- EOVS/LC ..... Gallieni 3
- G ..... Clio
- IM/NSHP ..... Thalie
- MBGE/PBP ..... Gallieni 1&2
- RV..... Uranie

Agenda see page 79

## EVER General Assembly and Prize Giving

Saturday, 18:00 - 19:30 in room Uranie

Agenda see page 119

## Withdrawals

First authors unable to attend EVER for reasons beyond their control, may request the permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 21, 2012.

## No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

## CME - Continued Medical Education credits

The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 21 European CME credits (ECMEC) to the EVER 2012 congress on Oct 10-13 in Nice, France.

CME credit certificates can be printed from the EVER website after the congress.

## Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants should make their own arrangements with respect to health and travel insurance.

## Poster Prizes

A poster prize of 200 EUR will be awarded for the best poster in each section. One additional EOVS poster prize will be generously sponsored by the Alta Eficacia Tecnologia, SL, Spain.

The winners will be chosen by the moderators and will be announced in the General Assembly and followed by the prize giving ceremony on Saturday October 13. Please make sure to attend.

No prize will be given after the congress.

## EVER 2012 congress App for iPhone / iPad



App Store







## Travel grants for best paper

We are pleased to announce that the following 11 members have received a travel grant of 500 EUR each, from the 11 EVER sections:

- **ACB - Kai KAARNIRANTA - Finland**  
4481 - AICAR induces effectively autophagy clearance in ARPE-19 cells
- **COS - Benoît CHAPPELLIER - France**  
2631 - Meganuclease targeting HSV-1 limits viral endo-thelitis in vivo
- **EOVS - Cécile DELETTRE - France**  
4285 - Characterization of visual impairment in a Wfs1 mouse model of Wolfram syndrome
- **G - Thuy Linh TRAN - Denmark**  
2651 - Aquaporins in glaucoma eyes
- **IM - Arnaud SAUER - France**  
2843 - IL-17A as a possible target of anti-inflammatory and anti-parasitic treatment in toxoplasmic uveitis
- **LC - Germain BARREAU - France**  
3483 - Intracameral cefuroxime injection at the end of cataract surgery reduces the incidence of endophthalmitis, a French study
- **MBGE - Xiaohe YAN - Germany**  
2464 - A mutation in peroxidase causes microphthalmia and anterior segment dysgenesis in mice
- **NSPH - Guzel BIKBOVA - Japan**  
4475 - Neuroprotective and regenerative effect of neurotrophin-4 on neuronal degeneration induced by advanced glycation end-products in adult rat retinas
- **PBP - Amandio ROCHA DE SOUSA - Portugal**  
4263 - Ghrelin's expression in the eye and its implication in the reduction of intraocular pressure
- **PO - Pathma RAMASAMY - Ireland**  
3282 - Proteomic analysis of uveal melanoma
- **RV - Agnes BOLTZ - Austria**  
3664 - Relevance of complement factor H polymorphisms in the response to intravitreal bevacizumab in exudative age-related macular degeneration



## Alta Eficacia Tecnología SL, Spain, travel grant

Alta Eficacia Tecnología is pleased to announce a travel grant of 400 EUR for the best paper in the EOVS section

- **Stamatina KABANAROU - Greece**  
2422 - Colour contrast sensitivity and electrophysiological abnormalities in patients undergoing long term desferrioxamine treatment



SUOMEN SILMÄLÄÄKÄRIYHDISTYS RY  
FINLANDS ÖGONLÄKARFÖRENING RF

## The Finnish Ophthalmological Society 100th Anniversary Travel Grants

The Finnish Ophthalmological Society is pleased to announce a travel grant of 1.000 EUR to the following groups of authors

- **F079 - Polyphenolic compounds reduce inflammation in ARPE-19 cells**  
HÄNLER M, SUURONEN T, SALMINEN A, KAARNIRANTA K, KAUPPINEN A—Kuopio
- **2842 - Inflammasome activation by oxidative stress in ARPE-19 cells**  
KAUPPINEN A, LAAKSO N, KINNUNEN K, SALMINEN A, KAARNIRANTA K—Kuopio





[www.ever.be](http://www.ever.be)

## EVER - European Association for Vision and Eye Research

We aim to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. EVER currently has members from over 50 countries and is represented by 11 scientific sections. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.

In 2010, the EVER Foundation was created to raise money to promote these goals, [www.ever-f.eu](http://www.ever-f.eu).

## In CONCORDIA pro VISU

The following societies collaborate with EVER to unify European ophthalmology by promoting quality education in ophthalmology and its scientific foundations (the societies are listed in alphabetical order):



[ebo-online.org](http://ebo-online.org)

## EBO - European Board of Ophthalmology

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organised review courses open to all delegates during the EVER congress, see pages 23, 25, 26 and 50.

EBO 2013, Paris, May 10-11, 2013



[www.eupo.eu](http://www.eupo.eu)

## EUPO - European University Professors of Ophthalmology

EUPO is the organiser of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe.

The EUPO 2013 course will be on Cornea, Conjunctiva and Refractive Surgery and will take place in Copenhagen, Denmark on June 7-8.



[www.soevision.org](http://www.soevision.org)

## SOE - Societas Ophthalmologica Europea

SOE aims to promote ophthalmology in Europe and to stimulate co-operation between European ophthalmologists and between their National Societies. Today, its mission is to become a central point in European ophthalmology through education and by fostering collaboration with subspecialty societies and supranational organisations both within Europe and beyond.

SOE 2013 Congress, June 8-11, Copenhagen, Denmark

**Acta Ophthalmologica**[eu.wiley.com](http://eu.wiley.com)**ACTA OPHTHALMOLOGICA - EVER's journal**

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.

[www.arvo.org](http://www.arvo.org)**ARVO - Association for Research in Vision and Ophthalmology**

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005, see page 75.

[www.evicr.net](http://www.evicr.net)**EVICR.net - European Vision Institute Clinical Research Network**

EVICR.net is a network of European Ophthalmological Clinical Research Sites, dedicated to perform clinical research in ophthalmology with the highest standards of quality, following the European and International Directives for Clinical Research according to harmonized SOPs. It is a platform for the development of translational research and a useful Industry resource in order to promote the development of new drugs and medical devices. The 7th EVICR.net Members Meeting will be held in conjunction with EVER 2012, in Nice, France, on 11th and 12th of October 2012. Four sessions of the EVER 2012 program are organized by EVICR.net, see pages 15, 48, 58, 66, 70 and 74.

[www.fro-online.org](http://www.fro-online.org)**FRO - Belgian Fund for Research in Ophthalmology**

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002, see pages 37 and 42.

[www.iscev.org](http://www.iscev.org)**ISCEV - International Society for Clinical Electrophysiology of Vision**

ISCEV was founded in 1958 to promote co-operation and communication amongst workers in the field of clinical and basic electrophysiology. There are about 400 members who are physicians, scientists, engineers, optometrists and other professional personnel. Its major symposium is held annually at different venues throughout the world. The European Chapter of ISCEV has met with EVER since 1998, see page 40.

[www.kpro.org](http://www.kpro.org)**KPro Study Group**

The KPro Study Group was established in 1990 to foster clinical and basic research on keratoprosthesis, synthetic corneas and artificial corneal implants. This International Group aims to foster the development and improvement of keratoprosthesis worldwide for the benefit of eyecare and patients. The KPro Study Group is collaborating with EVER since 2004. See pages 107 and 117.

**OOG - The Ophthalmic Oncology Group**

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multi-center studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions, see pages 102, 109 and 118.

[www.soie-soif.org](http://www.soie-soif.org)**SOIE - Society for Ophthalmo-Immunoinfectiology in Europe**

The aims are to form an association of ophthalmologists and other doctors or scientists having an interest in the field of ophthalmo-Immuno-Infectiology and to share mutual experiences in order to contribute to the progress of each member in this field, to promote education by organising or sponsoring symposia or courses or by contributing to publications in this field and to promote contacts between clinical centres in order to realise collaborative studies. SOIE is collaborating with EVER since 2008. See page 100.







# EVICR.net

EUROPEAN VISION  
CLINICAL RESEARCH

**EVICR.net - EUROPEAN VISION INSTITUTE CLINICAL RESEARCH NETWORK, EEIG**

#### **Chairman**

Jose Sahel, MD, PhD

#### **Steering Committee**

Jose Sahel, MD, PhD

José Cunha-Vaz, MD, PhD

Esther Hoffmann, MD, PhD

Jorge Alió, MD, PhD

Joaquim Murta, MD, PhD

Tunde Peto, MD, PhD, FHCO, FHCD

Cecília Martinho, BSc

\*\*\*\*\*

#### **Expert Committees**

- AMD and Retinal Dystrophies

- Diabetic Retinopathy

- Glaucoma

- Cornea, Cataract and  
Refractive Surgery

- Ocular Surface and  
Inflammation

- Reading Centres

\*\*\*\*\*

#### **EVICR.net**

AIBILI, Azinhaga de Santa

Comba, Celas

3000-548 Coimbra, Portugal

Tel.: +351 239 480 101/15

Fax: +351 239 480 117

E-mail: [evicrnet@aibili.pt](mailto:evicrnet@aibili.pt)

Website: [www.evicr.net](http://www.evicr.net)

EVICR.net is an European Network of Clinical Research in Ophthalmology performing **multinational clinical trials** in compliance with ICH-GCP Standard Operating procedures.

There are **77 Clinical Research Sites from 16 European countries**.

EVICR.net has a Centralized Infrastructure for management of multicenter clinical trials.

At the moment there are **4 ongoing Clinical Trials**:

**1. ECR-CCR-2010-01 – Gullstrand**

Investigator-Driven Clinical Trial

ClinicalTrials.Gov Identifier: NCT01173614

**2. ECR-RET-2010-02 - DR Progressors**

Investigator-Driven Clinical Trial

ClinicalTrials.Gov Identifier: NCT01145599

**3. ECR-RET-2011-03 – EUROCONDOR**

European Union FP7 Funded Project

EudraCT N°: 2012-001200-38

**4. ECR-GLC-2012-04 – STRONG**

European Union FP7 Funded Project

EVICR.net has developed **Organizational Clinical Site SOPs, Technical SOPs** as well as Organizational **Reading Centre SOPs** for its Reading Centre Network.

EVICR.net has been performing **Certification of Technicians** for Refraction and Visual Acuity.





*Programme Committee meeting, June 2012*

## Programme secretary, Marcela VOTRUBA


### Section programme secretaries

|      |  |                           |
|------|--|---------------------------|
| ACB  | Anatomy/Cell Biology   | Ulla AAPOLA               |
| COS  | Cornea/Ocular Surface  | Jean-Jacques GICQUEL      |
| EOVS | Electrophysiology, Physiological Optics, Vision Sciences                             | Miguel CASTELO-BRANCOO    |
| G    | Glaucoma   | Sayeh POURJAVAN           |
| IM   | Immunology/Microbiology  | Piergiorgio NERI          |
| LC   | Lens and Cataract  | Ralph MICHAEL             |
| MBGE | Molecular Biology/Genetics/Epidemiology  | Marzena GAJECKA           |
| NSPH | Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/<br>History of Ophthalmology | Andrzej GRZYBOWSKI        |
| PBP  | Physiology/Biochemistry/Pharmacology   | Neville OSBORNE           |
| PO   | Pathology/Oncology   | Karin LÖFFLER             |
| RV   | Retina/Vitreous  | Catherine CREUZOT-GARCHER |

This programme book is organised chronologically



### The sessions are colour-coded



FP = Free Paper session

SIS = Special Interest Symposium

CIS = Commercial Interest Symposium

= EVER travel grant recipient

= Alta Eficacia Tecnología SL, Spain, travel grant recipient

*rf* = Rapid Fire presentation


★ Conflict of interest disclosed

### Scientific sections


- ACB = Anatomy/Cell Biology
- COS = Cornea/Ocular Surface
- EOVS = Electrophysiology, Physiological Optics, Vision Sciences
- G = Glaucoma
- IM = Immunology/Microbiology
- LC = Lens and Cataract
- MBGE = Molecular Biology/Genetics/ Epidemiology
- NSPH = Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History of Ophthalmology
- PBP = Physiology/Biochemistry/Pharmacology
- PO = Pathology/Oncology
- RV = Retina/Vitreous

# FLOOR PLAN

## LEVEL 2




## LEVEL 3



- 1 Registration
- 2 Speakers room
- 3 Housing
- 4 ePosters
- 5 Exhibition
- 6 Poster area



- Alimera Sciences (3)
- Allergan (8)
- ARVO (6)
- Bausch + Lomb (11)
- Horus Pharma (4)
- Imedos Systems (2)
- iSTAR Medical (9)
- ISOPT
- Karger (5)
- Metrovision (10)
- Théa (1)
- Wisepress (7)





The background is an abstract composition of thin, overlapping white and light green lines that create a sense of motion and depth. A white rectangular area is positioned in the upper right quadrant, containing the date information in a bold, green, sans-serif font.

**WEDNESDAY**  
**OCT 10**  
**2012**

# COURSES OVERVIEW

---

The 15 courses throughout the EVER 2012 congress:

## Wednesday, October 10, 12:00 - 14:15

|           |   |    |
|-----------|---|----|
| <b>EB</b> | 1. IM: EBO review course: Intraocular inflammation and Infection (Part I).....  | 23 |
|           | 2. ACB: Morphological techniques in eye research.....                           | 23 |
|           | 3. COS: Challenges of herpetic eye disease.....                                 | 24 |
|           | 4. COS: Common corneal procedures.....  | 24 |
| <b>EB</b> | 5. RV: EBO course: Retinal detachment: first to describe and then to treat..... | 25 |
|           | 6. PO: Eyelid tumours.....  | 25 |

## Wednesday, October 10, 14:30 - 16:45

|           |  |    |
|-----------|--|----|
| <b>EB</b> | 7. IM: EBO course: Intraocular Inflammation and Infection (Part II).....               | 26 |
|           | 8. ACB: Experimental models for eye research.....                                      | 26 |
|           | 9. COS: Endothelial keratoplasty: the hidden face.....                                 | 27 |
|           | 10. COS: Corneal infectious diseases update.....                                       | 27 |
|           | 11. G: A glaucoma tool kit for beginners.....  | 28 |
|           | 12. NSPH: The ocular motility examination and common disorders of ocular motility..... | 28 |
|           | 13. PO: Management of pigmented fundus lesions.....                                    | 29 |

## Saturday, October 13, 08:15 - 09:45

|  |   |    |
|--|---|----|
|  | 14. ACB: MGD - Pathophysiology, diagnosis and clinical treatment..... | 98 |
|--|---|----|

## Saturday, October 13, 16:20 - 17:50

|  |   |     |
|--|---|-----|
|  | 15. IM: Surgery of inflammatory eyes..... | 118 |
|--|---|-----|



**Course 1** **EBO course: Intraocular inflammation and Infection (Part I)**  
**IM** Bahram BODAGHI, Carl P HERBORT

Uranie

Intermediate



The aim of this course is to review major topics of intraocular inflammation and infection. A paper composed of multiple choice questions will evaluate the basic knowledge of the participants initially. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The pathophysiology will be described and different classifications will be presented. Clinical characteristics will be highlighted.

Diagnostic tests will be discussed and imaging techniques will revisit the pathophysiology of different entities involving the retina and the choroid. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and aimed at pathologies that are frequent.

|       |      |   |
|-------|------|---|
| 12:00 | 1511 | Pathophysiology of uveitis<br>DICK A–Bristol  |
| 12:20 | 1512 | Classification of uveitis<br>ANDROUDI S–Thessaloniki                                  |
| 12:40 | 1513 | Symptoms and signs of anterior uveitis<br>NERI P, ARAPI I, CAPUANO V, PIRANI V–Ancona |
| 13:00 |      | Break   |
| 13:15 | 1514 | Symptoms and signs of posterior uveitis<br>KHAIRALLAH M, KAHLOUN R–Monastir           |
| 13:35 | 1515 | Laboratory work-up and specialized investigations<br>PLEYER U–Berlin                  |
| 13:55 | 1516 | Imaging in uveitis: techniques and indications<br>HERBORT CP–Lausanne                 |

**Course 2** **Morphological techniques in eye research**  
**ACB** Erich KNOP, Nadja KNOP

Euterpe

Beginners

Morphological techniques are a gold standard in eye research for the evaluation of the normal architecture and cellular differentiation of tissues as well as of specific changes under certain pathological conditions. Even though advanced high-tech molecular-biological techniques are increasingly applied in order to answer very specific questions it is indispensable for example to localize functional proteins or their pathological changes in the actual cell and tissue structures of the eye. Since biochemical techniques have increasingly been the focus of interest in eye research, basic information on morphological techniques as well as their performance and interpretation of results is partly lost in ophthalmological research departments.

The present course intends to introduce basic morphological techniques together with their methodological requirements, their practical application and their results as well as their potential limitations.

|       |      |  |
|-------|------|--|
| 12:00 | 1521 | Preparation, fixation, embedding, sectioning and staining – basic requirements of morphological tissue investigation<br>KNOP N, KNOP E–Berlin      |
| 12:30 | 1522 | Immunohistochemical identification of tissue antigens – principal methodological requirements, considerations and results<br>KNOP E, KNOP N–Berlin |
| 13:00 |      | Break  |
| 13:15 | 1523 | Immuno electron microscopy – tracking the sub-cellular localization of antigens in high resolution<br>AKHTAR S–Riyadh                              |
| 13:45 | 1524 | Morphological techniques for endothelial cell analysis of corneal grafts<br>THURET G–Saint Etienne   |

WEDNESDAY

**Course 3**  
**COS**     **Challenges of herpetic eye disease**

Erato

Petja VASSILEVA

Intermediate

Human herpes virus infections are a relatively frequent cause of ocular pathology (conjunctivitis, keratitis, scleritis, uveitis, optic neuritis). Ocular herpetic infection may involve all structures of the eye and its diagnosis is based mainly on the clinical examination. Ocular herpes is a recurrent disease, complications of which may lead to blindness, and yet, it is often "missed". The aim of the course is to present our experience in the diagnosis, management, controversies in treatment and complications of the various manifestations of herpetic eye infection.

|       |      |  |
|-------|------|--|
| 12:00 | 1531 | Herpetic eye disease<br>VASSILEVA P–Sofia                                    |
| 12:30 | 1532 | Diagnosis<br>BODAGHI B–Paris   |
| 13:00 |      | Break  |
| 13:05 | 1533 | Treatment: medical therapy<br>HERGELDZHIEVA T–Sofia                          |
| 13:35 | 1534 | Treatment: surgical methods<br>DEKARIS I, RATKOVIC M, PAUK M, DRACA N–Zagreb |

**Course 4**  
**COS**     **Common corneal procedures**

Thalie

Jean-Jacques GICQUEL, Harminder S DUA

Intermediate

The goal of this course is to offer a practical and comprehensive update on common corneal surgical procedures. It should be of interest for ophthalmologists in training as well as for the more experienced ophthalmologists who want to increase their skills.

|       |      |  |
|-------|------|--|
| 12:00 | 1541 | Limbal stem cell transplantation techniques<br>DUA H–Nottingham                        |
| 12:20 | 1542 | Modern pterygium surgery<br>GICQUEL JJ–Poitiers  |
| 12:40 | 1543 | Anterior and posterior lamellar keratoplasty<br>NUBILE M–Chieti                        |
| 13:00 |      | Break  |
| 13:20 | 1544 | Corneal collagen cross linking: traditional vs transepithelial<br>MENCUCCI R–Florence  |
| 13:40 | 1545 | Indications and limitations of amniotic membrane transplantation<br>YEUNG A–Nottingham |

**Course 5** **EBO course: Retinal detachment: first to describe and then to treat**

Clio

RV

Catherine CREUZOT, Constantin POURNARAS



Authors will present different features to consider in a retinal detachment (namely tear location, vitreous involvement, proliferative vitreoretinopathy) prior to treatment. We will then focus on the different way to surgically remove subretinal fluid. Finally we will report on potential postoperative complications.

Beginners

|       |      |  |
|-------|------|--|
| 12:00 | 1551 | How to localise retinal tears ?<br>KOROBELNIK JF–Bordeaux                  |
| 12:20 | 1552 | To analyse the role of vitreous in a retinal detachment<br>BERROD JP–Nancy |
| 12:40 | 1553 | How to remove subretinal fluid?<br>POURNARAS CJ–Geneva                     |
| 13:00 |      | Break  |
| 13:20 | 1554 | How to prevent proliferative vitreoretinopathy ?<br>JONAS JB–Mannheim      |
| 13:40 | 1555 | How to prevent postoperative complication?<br>CREUZOT C–Dijon              |

**Course 6** **Eyelid tumours**

Gallieni 1&amp;2

PO

Frédéric MOURIAUX, Karin LOEFFLER

Basic information on diagnosis, pathology and surgery of eyelid tumours

Beginners

|       |      |   |
|-------|------|---|
| 12:00 | 1561 | Eyelid tumours : The relative value of clinical signs<br>LASUDRY J–Brussels |
| 12:30 | 1562 | Bases of pathological diagnosis of eyelid tumours<br>LOEFFLER K–Bonn        |
| 13:00 |      | Break   |
| 13:15 | 1563 | Margins or not margins<br>MOURIAUX F–Caen                                   |
| 13:45 | 1564 | Bases of surgery for eyelid reconstruction<br>BRISCOE D–Afula               |

WEDNESDAY

**Course 7 EBO course: Intraocular Inflammation and Infection (Part II)**  
**IM** Bahram BODAGHI, Carl P HERBORT

Uranie

Intermediate



The first part on general aspects of uveitis will be followed by a quiz and case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine.

|       |      |   |
|-------|------|---|
| 14:30 | 1611 | Infectious uveitis<br>KESTELYN P–Ghent                    |
| 14:50 | 1612 | B27-associated uveitis<br>WILLERMAIN F–Brussels           |
| 15:10 |      | Break   |
| 15:30 | 1613 | Behçet disease, sarcoidosis, VKH<br>ABU EL ASRAR A–Riyadh |
| 15:50 | 1614 | White dot syndromes<br>MARKOMICHELAKIS N–Athens           |
| 16:10 | 1615 | Paediatric uveitis<br>BODAGHI B–Paris                     |

**Course 8 Experimental models for eye research**  
**ACB** Hannu UUSITALO, Ulla AAPOLA

Euterpe

Intermediate

Experimental models of disease are an essential part of basic and translational eye research. They are widely used when the pathogenesis or new therapeutic and diagnostic modalities of diseases are investigated. The course is designed to give practical information and advice on selected experimental methods of eye research. This year the course will focus on the techniques used in ocular inflammation, glaucoma and retinal diseases. Lecturers will give detailed practical advice and instructions of their techniques in course material.

|       |      |  |
|-------|------|--|
| 14:30 | 1621 | Experimental glaucoma models<br>KALESNYKAS G–Kuopio                              |
| 15:00 | 1622 | Methods to study neuroprotection<br>ZACK DJ–Baltimore                            |
| 15:30 |      | Break  |
| 15:45 | 1623 | Experimental models of intraocular inflammation<br>BEUERMAN R, YUAN ZH–Singapore |
| 16:15 | 1624 | Oxygen induced retinopathy (OIR) mouse model<br>UUSITALO-JÄRVINEN H–Tampere      |



### Course 9 Endothelial keratoplasty: the hidden face

Erato

**COS** Jean-Louis BOURGES, Joaquim MURTA

Advanced

Endothelial keratoplasty (EK) has become a major surgical procedure in corneal practice. Various techniques have been developed worldwide. Besides demonstrating a demanding learning curve, surgical procedures and clinical outcomes still need to be further assessed, improved and evaluated. The course offers a broad review of EK's remaining issues, personal reports of experienced surgeons and discusses related scientific research.

|       |      |   |
|-------|------|---|
| 14:30 | 1631 | Femtosecond laser and microkeratome preparation of ultrathin (UT) DSAEK Grafts, the six months clinical results<br>MURTA J, ROSA A, QUADRADO M, BRITO S, CARDOSO A—Coimbra          |
| 14:50 | 1632 | Femtolaser assisted preparation and quality of endothelial button<br>BOURGÉS JL—Paris   |
| 15:10 | 1633 | FEMTO-DSEK: is endothelial cut possible?<br>BAIKOFF G—Marseille   |
| 15:30 |      | Break   |
| 15:50 | 1634 | Endothelial cell viability of endothelial lenticules<br>THURET G, HE Z, CAMPOLMI N, HA THI BM, PISELLI S, DUMOLLARD JM, PEOC'H M, MURAINÉ M, TOUBEAU D, GAIN P—Saint-Etienne, Rouen |
| 16:10 | 1635 | Rho Kinase Inhibitors: the end of endothelial keratoplasty?<br>GICQUEL JJ—Poitiers  |

### Course 10 Corneal infectious diseases update

Thalie

**COS** Jean-Jacques GICQUEL, Harminder S DUA

Intermediate

Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we'll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections.

|         |      |   |
|---------|------|---|
| 14:30   | 1641 | Corneal bacterial infections<br>GICQUEL JJ—Poitiers                       |
| 15:00   | 1642 | Herpes and zoster keratitis<br>LABETOULLE M—Le Kremlin Bicêtre            |
| 15:30   |      | Break   |
| 15:45 ★ | 1643 | Infectious keratitis in children<br>BREMONT-GIGNAC D—Amiens               |
| 16:15   | 1644 | Infectious crystalline keratopathy and its management<br>DUA H—Nottingham |

WEDNESDAY

Beginners

**Course 11 A glaucoma tool kit for beginners**

Clio

**G** Alain BRON

This course is designed for beginners in glaucoma who are mostly interested in daily clinical practice. It is really possible to improve your own glaucoma management with basic examinations. After this course you probably will better use your slit lamp to find useful clinical signs for glaucomas. Gonioscopy is a key step in the diagnosis and the management of the glaucomas as well. A better understanding of functional and structural tests is mandatory when you have to order those tests. Four teachers, all glaucoma experts will lead you during this course with very simple and clear recommendations. They would like to provide you with a ready-to-use clinical tool kit for glaucomas.

|       |      |  |
|-------|------|--|
| 14:30 | 1651 | Do not forget your slit lamp<br>BRON A–Dijon                         |
| 15:00 | 1652 | How to become familiar with gonioscopy?<br>HOMMER A–Vienna           |
| 15:30 |      | Break  |
| 15:45 | 1653 | Visual field examination in daily practice<br>ZEYEN T–Leuven         |
| 16:15 | 1654 | How to evaluate structure in glaucomas?<br>SUNARIC MEGEVAND G–Geneva |

Intermediate

**Course 12 The ocular motility examination and common disorders of ocular motility**

Gallieni 1&amp;2

**NSPH** Aki KAWASAKI

A careful assessment of ocular motility is an important part of the ophthalmologic examination. This course intends to provide a clear, systematic approach for testing the different ocular motor systems within the setting of a general eye clinic. Videos will be used to demonstrate normal versus abnormal findings. In addition, we will review the anatomy and disorders of cranial nerves 3, 4 and 6 as well as common supranuclear disorders, such as skew deviation and internuclear ophthalmoplegia, in a series of didactic lectures.

Thereafter, cases will be presented to the audience who will use the information given in the preceding lectures to generate open discussion on diagnosis and management. Each case will emphasize a specific aspect of the evaluation that is important to the differential diagnosis or will highlight a particularly urgent diagnosis that should not be missed.

The aim of this course is to give the attendee a useful and practical approach to the patient with diplopia or disturbance of ocular motility in a format that includes both formal teaching and interactive case discussion with experienced experts.

|         |      |   |
|---------|------|---|
| 14:30   | 1661 | A step-by-step approach to examining eye movements<br>BORRUAT FX–Lausanne |
| 15:00 ★ | 1662 | Cranial nerves 3,4 and 6: from brainstem to orbit<br>KAWASAKI A–Lausanne  |
| 15:30   |      | Break   |
| 15:50   | 1663 | Supranuclear eye movement disorders<br>BORRUAT FX–Lausanne                |

**Course 13 Management of pigmented fundus lesions**  
**PO** Laurence DESJARDINS, Bertil DAMATO

Gallieni 4

Intermediate

The course will cover benign and malignant, congenital and acquired pigmented lesions of the fundus.

Congenital pigmented lesions of the fundus are rare and can sometimes be confused with naevus or melanoma.

The pathology of all these lesions will be described.

The differential diagnosis between benign naevi and suspicious naevi and the description of the follow up of such lesions will allow the audience to get precise guidelines for the management of choroidal naevi.

Focus will then be made on malignant uveal melanoma including clinical aspects with the prognostic factors and treatment options. Radiotherapy techniques and surgical techniques will be developed in detail.

|       |      |  |
|-------|------|--|
| 14:30 | 1671 | Congenital pigmented lesions<br>BECHRAKIS NE–Innsbruck                                       |
| 14:50 | 1672 | Pathology of pigmented fundus lesions<br>COUPLAND SE–Liverpool                               |
| 15:10 | 1673 | Suspicious choroidal naevi<br>KIVELÄ T–Helsinki  |
| 15:30 |      | Break  |
| 15:45 | 1674 | Malignant melanoma of the uvea: diagnosis, characterization and prognosis<br>MIDENA E–Padova |
| 16:05 | 1675 | Malignant melanoma of the uvea: radiotherapy techniques<br>DESJARDINS L–Paris                |
| 16:25 | 1676 | Malignant melanoma of the uvea: surgical techniques<br>DAMATO B–Liverpool                    |





WEDNESDAY



17:00

Welcome by the President EVER 2012  
Leopold SCHMETTERER - President 2012

Uranie

## WELCOME



17:15



## EVER lecture

Visual fields for Ever - and more  
Lene MARTIN - Past-President  
Introduction by Leopold SCHMETTERER

Uranie



17:50

## European Ophthalmologic Heritage Lecture

Ophthalmology: a philatelic view  
Thierry ZEYEN - Leuven  
Introduction by Marcela VOTRUBA

Uranie



18:10

Acta Ophthalmologica

## EVER/ACTA Lecture

The changing roles of perimetry and perimeters in glaucoma management  
Award giving  
Anders HEIJL - Malmö  
Introduction by Einar STEFANSSON

Uranie



18:50

Welcome address by the city of Nice

Uranie

19:00 - 21:00 Welcome Reception, Sponsored by the city of Nice in Acropolis Convention Center



The background is a light green gradient with a complex pattern of thin, white, overlapping lines that create a sense of motion and depth. A white rectangular box is positioned in the upper right quadrant, containing the date information in a bold, green, sans-serif font.

**THURSDAY  
OCT 11  
2012**

THURSDAY

**SIS** **Anterior segment complications in vitreoretinal surgery -** **Uranie**  
**RV** **why they occur and how to deal with them**

Nikolaos E. BECHRAKIS, Heinrich HEIMANN

|       |      |  |
|-------|------|--|
| 08:15 | 2211 | Dealing with cataracts in vitreoretinal surgery<br>TADAYONI R—Paris                    |
| 08:33 | 2212 | The iris-diaphragm in vitreoretinal surgery<br>BECHRAKIS NE—Innsbruck                  |
| 08:51 | 2213 | Anterior segment problems with vitreous substitutes<br>HEIMANN H—Liverpool             |
| 09:09 | 2214 | How to achieve optimal visualization in vitreoretinal surgery<br>BLATSIOS G—Innsbruck  |
| 09:27 |      | All speakers: Tips for the anterior segment surgeon from the vitreoretinal perspective |

**SIS** **Doctor, I don't like bright lights** **Euterpe**  
**EOVS**

Graham HOLDER

|         |      |   |
|---------|------|---|
| 08:15   | 2221 | The first consultation<br>SPILEERS W—Leuven                             |
| 08:37   | 2222 | Photophobia in inherited retinal disease<br>LEROY BP—Ghent              |
| 08:59 ★ | 2223 | Photophobia in neuro-ophthalmological conditions<br>KAWASAKI A—Lausanne |
| 09:21   | 2224 | The role of electrophysiology<br>HOLDER GE—London                       |

**FP** **Ocular surface and corneal bioengineering** **Erato**  
**COS**

Jean-Jacques GICQUEL, Mario NUBILE

|         |                   |  |
|---------|-------------------|--|
| 08:15   | 2231              | Highly elastic epoxy cross-linked collagen hydrogels for corneal tissue engineering<br>RAFAT M, KOH LB, ISLAM MM, LIEDBERG BO, GRIFFITH M—Linköping  |
| 08:27   | 2232              | Donor bone marrow derived dendritic cells promote corneal allograft survival in the rat<br>O'FLYNN L, TREACY O, RYAN A, MORCOS M, NOSOV M, RITTER T—Galway   |
| 08:39   | 2233              | Concentration gradient of endogenous noradrenaline from periphery to centre in the rabbit cornea<br>FIGUEIRA L, MATOS J, SERRAO P, FALCAO-REIS F, MOURA D—Porto  |
| 08:51 ★ | 2234              | The fish scale-derived Biocornea as a scaffold for human corneal cells<br>VAN ESSEN TH, SPARKS SJ, LIN CC, HUSSAIN AK, COMMANDEUR S, HORNG JL, LUYTEN GPM, GHALBZOURI AEI, JAGER MJ—Leiden   |
| 09:03   | 2235              | Cultivation and characterization of corneal limbal epithelial stem cells on lens capsule in animal material-free medium<br>ALBERT R, VERÉB Z, CSOMÓS K, MOE MC, JOHNSEN EO, NICOLAISSEN B, RAINAVÖLGYI É, FESUS L, BERTA A, PETROVSKI G—Debrecen, Oslo                                     |
| 09:15   | 2236<br><i>rf</i> | Identification of label-retaining endothelial cells in adult human corneas: a new clue for the existence of endothelial stem cells<br>HA THI BM, HE Z, CAMPOLMI N, PISELLI S, GAIN P, PEOC'H M, DUMOLLARD JM, ACQUART S, GARRAUD O, THURET G—Saint-Etienne                                 |
| 09:21   | 2237<br><i>rf</i> | Coupling innovative imaging: in vivo multilaser confocal microscopy and ex vivo confocal Raman spectroscopy of cornea and skin in nephropathic cystinosis<br>ESPINASSE M, CINOTTI E, PERROT JL, LABELLE B, CAMBAZARD F, DUMOLLARD JM, PEOC'H M, CAMPOLMI N, THURET G, GAIN P—Saint-Etienne |



**SIS  
PBP****Ocular pharmacology and drug delivery****Thalie**

Francine BEHAR-COHEN

|       |      |   |
|-------|------|---|
| 08:15 | 2241 | Potential role of transporters in ocular pharmacokinetics<br>URTTI A—Helsinki   |
| 08:30 | 2242 | New formulations for topical drug administration<br>GURNY R—Geneva  |
| 08:45 | 2243 | Intraocular administration of biodegradable microspheres to increase drug bioavailability and extend therapeutic effect<br>HERRERO-VANRELL R—Madrid |
| 09:00 | 2244 | Mini-pump revisited for ocular drug delivery<br>HUMAYUN M—Los Angeles   |
| 09:15 | 2245 | Suprachoroidal delivery: new directions and challenges<br>OLSEN T—Århus   |
| 09:30 | 2246 | Electroporation for ocular drug delivery<br>BEHAR-COHEN F—Paris   |

**SIS  
G****Glaucoma: Looking beyond an ocular disease****Clio**

Kaya N ENGIN

|       |      |  |
|-------|------|--|
| 08:15 | 2251 | Genetic basis of glaucomas<br>TEKELI OYA—Ankara                |
| 08:45 | 2252 | Vascular issues in glaucoma<br>KOCABORA S—Istanbul             |
| 09:15 | 2253 | Damage integrity from eye to visual cortex<br>ENGIN K—Istanbul |

**JM  
COS****European Eye Bank Association**

Iva DEKARIS, Vincent BORDERIE

**Gallieni 1&2**

|         |      |   |
|---------|------|---|
| 08:15   | 2261 | Use of bevacizumab (anti-VEGF treatment) in high-risk corneal grafts<br>DEKARIS I, DRACA N, RATKOVIC M, PAUK M—Zagreb   |
| 08:25   | 2262 | Stem cell culture for limbal deficiency<br>BORDERIE V—Paris   |
| 08:35   | 2263 | Biomaterials for ocular surface reconstruction<br>FUCHSLUGER T—Düsseldorf   |
| 08:45   | 2264 | Pan-endothelial viability assessment with the triple HEC staining of organ cultured precut DSAEK vs full thickness corneas<br>CAMPOLMI N, HE Z, GAIN P, MURAINÉ M, TOUBEAU D, PIPPARRELLI A, ACQUART S, GARRAUD O, PISELLI S, DUMOLLARD JM, PEOC'H M, THURET G—Saint-Etienne, Rouen |
| 08:55   | 2265 | European study on reliability assessment of endothelial cell count in eye banks: the Euro-Keratotest study<br>THURET G, HE Z, BERNARD A, CAMPOLMI N, HA THI BM, PEOC'H M, DUMOLLARD JM, DELESALLE N, GAIN P—Saint-Etienne, Saint-Denis  |
| 09:05   | 2266 | Worldwide Eye Banking (WEB) project: international survey of demand and supply<br>JULIENNE R, ALDOSSARY M, NEFZAOUI C, HE Z, HA THI BM, CAMPOLMI N, THURET G, GAIN P—Saint-Etienne  |
| 09:15   | 2267 | Light microscopy of the corneal pathologies that we meet in our daily practice as an eye banker<br>JIRSOVA K—Prague   |
| 09:25 ★ | 2268 | A new and quantitative method to evaluate the overall quality of corneal tissues for clinical applications and research testing<br>PAREKH M—Zelarino—Venice   |
| 09:35   | 2269 | Serum-free cornea culture with hydroxyethyl starch as a deswelling agent<br>HERMEL M, SALLA S, BAUER L, HAMSLEY N, STEINFELD P, WALTER P—Aachen   |



FP  
IM**Advances in diagnosis and management of uveitis**

Gallieni 4

Piergiorgio NERI, Carlos PAVESIO

|         |                   |  |
|---------|-------------------|--|
| 08:15   | 2271              | Novel interpretation of fundus autofluorescence (FAF) findings in choriocapillaritis<br>MANTOVANI A, STAURENGHI G, HERBORT CP—Milano, Lausanne   |
| 08:27   | 2272              | Appraisal of choroiditis in birdshot retinochoroiditis is essential and only possible using indocyanine green angiography<br>HERBORT CP, PAPADIA M—Lausanne, Genova  |
| 08:39   | 2273<br><i>rf</i> | Paediatric rheumatology clinic outcome at Leeds Teaching Hospitals, UK<br>JEEVA I, HARDISTY A, KOLB S, HOOLE J, LONG V, WOOD M—Leeds   |
| 08:45 ★ | 2274              | Voclosporin: newer analyses of a randomized, controlled trial for noninfectious uveitis<br>BODAGHI B, LUMINATE INVESTIGATOR GROUP—Paris, New Jersey  |
| 08:57   | 2275              | Long term efficacy and tolerability of anti-TNF therapy in the treatment of non-infectious uveitis – a surveillance study<br>DAMATO EM, DICK A, LEE RJW, SHARMA SM—Bristol, Baltimore  |
| 09:09 ★ | 2276              | Final results of an investigator initiated, multicenter randomised controlled trial of the efficacy of Adalimumab in active uveitis refractory to standard treatment (ADUR)<br>MACKENSEN F, BECKER MD, JAKOB E, DOBNER BC, HEINZ C, LORENZ HM, HEILIGENHAUS A, MAX R—Heidelberg, Zürich, Münster |
| 09:21   | 2277<br><i>rf</i> | Tocilizumab for anterior uveitis and juvenile idopathic arthritis – a case report<br>KNOLL A, LUTZ T, GRULICH-HENN J, MACKENSEN F—Heidelberg   |

JM

**FRO - Belgian Fund for Research in Ophthalmology 1**

Gallieni 3

Marie - José TASSIGNON, Philippe KESTELYN









# KEYNOTE LECTURE

Uranie

New treatments for age related macular degeneration  
Joan MILLER

|       |        |   |
|-------|--------|---|
| 09:50 |        | Introduction by Constantin POURNARAS                                    |
| 10:00 | ★ 2311 | New treatments for age related macular degeneration<br>MILLER JW–Boston |
| 10:30 |        | Award of the EVER certificate of honour                                 |

THURSDAY

**SIS RV** **Peelings in macular surgery** **Uranie**  
Catherine CREUZOT, Ramin TADAYONI

|       |      |   |
|-------|------|---|
| 11:00 | 2411 | How to detach vitreous in macular diseases<br>GANDORFER A—München |
| 11:18 | 2412 | How to stain ILM in macular surgery<br>HARITOGLOU C—München       |
| 11:36 | 2413 | ILM peeling in macular surgery: side-effect<br>TADAYONI R—Paris   |
| 11:54 | 2414 | ILM peeling in macular surgery: benefits<br>CREUZOT C—Dijon       |
| 12:12 | 2415 | What to peel in macular surgery?<br>GAUDRIC A—Paris               |

**JM EOVS** **ISCEV** **Euterpe**  
Graham HOLDER



|       |      |   |
|-------|------|---|
| 11:00 | 2421 | The flicker ERG and retinal blood flow relationship in diabetic patients without retinopathy<br>ZUEVA M, KOLCHIN A, KISELEVA T, LESENKO M, TSAPENKO I, RYABINA M—Moscow                             |
| 11:18 | 2422 | Colour contrast sensitivity and electrophysiological abnormalities in patients undergoing long term desferrioxamine treatment<br>KABANAROU SA, ROBSON AG, HOGG CR, EGAN C, HOLDER GE—Athens, London |
| 11:36 | 2423 | Genotype-phenotype correlations in Stargardt disease/ABCA4-related retinopathy<br>HOLDER GE, FUJINAMI K, ROBSON AG, WEBSTER AR, MICHAELIDES M—London  |
| 11:54 | 2424 | Recovery of the ERG from very low SNR recordings using a robust frequency domain approach: an Internet open source implementation<br>FISHER A, ELEUTERI A, TEYMOURI R, HAGAN RP—Liverpool           |
| 12:12 | 2425 | Mechanisms & recovery of vitamin A deficiency<br>LEROY BP, DE ZAEYTIJD J, DE LOOZE D, DELANGHE J, KESTELYN P—Ghent  |

**SIS COS** **Wavefront aberrometry and quality of vision** **Erato**  
Jean-Jacques GICQUEL, Pierre Jean PISELLA

|       |        |   |
|-------|--------|---|
| 11:00 | 2431   | An update on the vision simulator<br>CHATEAU N—Orsay  |
| 11:15 | 2432   | Spherical aberration and binocularity<br>VANDERMEER G, NOCHEZ Y, GICQUEL JJ, LEGRAS R, PISELLA PJ—Tours, Poitiers, Orsay    |
| 11:30 | 2433   | Shack-Hartmann aberrometry vs OQAS : the quarrel of the ancients and the moderns?<br>GICQUEL JJ, PISELLA PJ—Poitiers, Tours |
| 11:45 | ★ 2434 | Should you decide to perform cataract surgery on your patients, based only on straylight?<br>VAN DEN BERG TJTP—Amsterdam    |
| 12:00 | 2435   | Impact of higher-order aberrations on accommodation in phakic presbyopic patients<br>PISELLA PJ—Tours                       |
| 12:15 | 2436   | Quality of vision and 3D<br>COCHENER B, LAMARD M, FERRAGUT S, IORGOVAN D, FATTAKHOVA Y, DE BOUGRENET DE LA TOCNAYE JL—Brest |

**SIS** **New advances in managing scleritis and peripheral ulcerative keratitis** **Thalie**

**IM** Piergiorgio NERI, Carlos PAVESIO

**BAUSCH + LOMB**

|       |      |  |
|-------|------|--|
| 11:00 | 2441 | Scleritis: general concepts<br>PAVESIO C—London                                |
| 11:15 | 2442 | Imaging and scleritis<br>HERBORT CP—Lausanne                                   |
| 11:30 | 2443 | Infectious scleritis<br>WATSON P—Cambridge                                     |
| 11:45 | 2444 | Scleritis and systemic diseases<br>LEE R—Bristol                               |
| 12:00 | 2445 | Conditions mimicking scleritis<br>CASSOUX N—Paris                              |
| 12:15 | 2446 | PUK from diagnosis to treatment<br>NERI P, CAPUANO V, ARAPI I, PIRANI V—Ancona |

**FP** **Imaging 1 / Treatment in glaucoma** **Clio**

**G** Jost B JONAS, Anton HOMMER

|         |                   |   |
|---------|-------------------|---|
| 11:00   | 2451              | Is spectral domain optical coherence tomography useful in improving the contour line with the Heidelberg Retina Tomograph?<br>BRON A, FRANCOZ A, NICOT F, KOEHRER P, AHO S, CREUZOT-GARCHER C—Dijon   |
| 11:12   | 2452              | The relationship between standard automated perimetry and retinal ganglion cell—inner plexiform layer thickness measured by the cirrus spectral domain optical coherence tomograph<br>SHIN HY, PARK HY, JUNG KI, PARK CK—Seoul  |
| 11:24   | 2453              | Choroidal thickness in glaucoma patients and glaucoma suspects measured by spectral domain optical coherence tomography<br>FRANCOZ A, NICOT F, CATTANEO A, CREUZOT-GARCHER C, AHO S, BRON A—Dijon   |
| 11:36 ★ | 2454              | Reproducibility and repeatability of retinal nerve fiber layer parameters measured by scanning laser polarimetry with enhanced corneal compensation in glaucomatous eyes<br>ARA GABARRE M, SATUE PALACIAN M, BAMBO M, FERRANDEZ ARENAS B, GIL-ARRIBAS L, FERRERAS AMEZ A—Zaragoza |
| 11:48   | 2455<br><i>rf</i> | Defects in macular-retinal layer analysis of glaucoma patients compared to normative database<br>HOLZER S, PEREIRA I, KISS B, VASS C—Wien   |
| 11:54 ★ | 2456<br><i>rf</i> | Manual placement of SD-OCT peripapillary circle scan: possible influence on RNFLT classification and profile shape<br>SCHULZ S, ZINSER G—Heidelberg   |
| 12:00   | 2457<br><i>rf</i> | Clinical trial for the evaluation of neuroprotective effects of palmitoylethanolamide: Visual Field and Pattern-ERG<br>GAGLIANO C, LONGO A, UVA MG, REIBALDI M, AMATO R, RUSSO V, BIONDI P, AVITABILE T—Catania, Foggia   |
| 12:06   | 2458<br><i>rf</i> | Case from hell in narrow angle glaucoma patient<br>VAN DE VEIRE S, WEBERS C, BECKERS H—Maastricht   |

THURSDAY

FP  
MBGE**Genetics and epidemiology**

Gallieni 1&amp;2

Marzena GAJECKA, Graeme C M BLACK

|       |                   |   |
|-------|-------------------|---|
| 11:00 | 2461              | Bilateral progressive coats-type exudative retinopathy in Usher syndrome type IIIA from c.528T>G Clarin 1 (CLRN1) mutation<br>KIVELÄ T, TÄLL M, LINDAHL P, IMMONEN I, LOUKOVAARA S, SANKILA EM—Helsinki   |
| 11:12 | 2462              | The effect of a Gas6 c.834+7G>a polymorphism and the interaction of known risk factors on AMD pathogenesis in Hungarian patients<br>LOSONCZY G, BALOGH I, VAJAS A, BERTA A—Debrecen   |
| 11:24 | 2463              | Ocular morbidity Brazilian study: causes of visual impairment<br>VERONESE RODRIGUES ML, ARRUDA MELLO PA, COSTA PASSOS AD, REY DE FARIA MA, SOUZA CARVALHO R, KARA JOSÉ N, COLLABORATIVE GROUP N—Ribeirao Preto, Sao Paulo, Natal, Eighteen Cities |
| 11:36 | 2464              | A mutation in peroxidase causes microphthalmia and anterior segment dysgenesis in mice<br>YAN X, GRAW J—Munich-Neuherberg   |
| 11:48 | 2465<br><i>rf</i> | Activity and epidemiology of a recently-opened ophthalmic emergency center in an University Hospital<br>AMELOOT F, AGRINIER N, MAALOUF T, ANGIOI K—Nancy  |
| 11:54 | 2466<br><i>rf</i> | Polymorphism of endothelial nitric oxide synthase T786C in patients with normal tension glaucoma and primary open angle glaucoma<br>LUKASIK U, KOSIOR-JARECKA E, WROBEL-DUDZINSKA D, KUSMIREK K, KOCKI J, ZARNOWSKI T—Lublin                      |
| 12:00 | 2467<br><i>rf</i> | Diabetic retinopathy in Greek Caucasian type 2 diabetic patients, relationship with polymorphism in the plasminogen activator inhibitor 1 and 2 genes<br>SOKOLAKIS TH, TSIRONI E, DARDIOTIS E, CHATZOULIS E, ZINZARAS E—Athens, Larissa           |

SIS  
ACB**Lid margin, meibomian glands and dry eye**

Gallieni 4

Erich KNOP, Nadja KNOP

**BAUSCH + LOMB**

|       |      |  |
|-------|------|--|
| 11:00 | 2471 | The Lid Wiper — a specialized structure at the inner eyelid margin for distribution of the tear film<br>KNOP E, KORB DR, BLACKIE CA, KNOP N—Berlin, Boston, MA |
| 11:18 | 2472 | Non invasive tear film break-up time and blinking<br>NEPP J—Vienna   |
| 11:36 | 2473 | Lubricin: translating an idea into a cure<br>SULLIVAN DA, SCHMIDT T, KNOP E, KNOP N, SULLIVAN BD—Boston, MA, Calgary, Alberta, Berlin, San Diego, CA           |
| 11:54 | 2474 | The lid margin and Demodex<br>HORWATH-WINTER J, RABENSTEINER DF, SCHWANTZER G, BOLDIN I, FISCHL M, WACHSWENDER C, HALLER-SCHOBER EM, SCHMUT O—Graz             |
| 12:12 | 2475 | Meibography follow up studies in dry eye patients<br>RABENSTEINER DF, HORWATH-WINTER J, BOLDIN I, WOLTSCHKE N, SCHMUT O—Graz                                   |

JM

**FRO - Belgian Fund for Research in Ophthalmology 2**

Gallieni 3

Philippe KESTELYN, Marie - José TASSIGNON



## LUNCHTIME CIS

Euterpe



What's new in ocular surface?

Moderator: Harminder S DUA

|       |      |   |
|-------|------|---|
| 12:35 | 2521 | Clinical results on the efficacy of Thealoz vs autologous serum in moderate to severe dry eye<br>LEONARDI A, LAZZARINI D, PILIEGO F, FREGONA I—Padova, Roma |
| 12:50 | 2522 | A new matrix therapy agent in the treatment of corneal ulcers resistant to conventional treatments<br>COCHENER B, MURAINÉ M—Brest, Rouen                    |
| 13:05 | 2523 | Ocular surface in surgery<br>DUA H—Nottingham   |
| 13:35 |      | End of session  |



THURSDAY



## EVI AWARD LECTURE

Euterpe

Frank SCHAEFFEL

### European Vision Award 2012

- |       |      |  |
|-------|------|--|
| 13:35 |      | Introduction by Thomas H. Wheeler-Schilling  |
| 13:40 | 2621 | From chickens to humans - learning about the puzzles of myopia<br>SCHAEFFEL F-Tübingen |
| 14:10 |      | Award ceremony   |

### Carl Zeiss European Young Investigator Award 2012 on Ophthalmic Research

- |       |  |   |
|-------|--|---|
| 14:15 |  | Introduction by Thomas H. Wheeler-Schilling                       |
| 14:20 |  | Carl Zeiss European Young Investigator Award 2012 - Award Lecture |
| 14:40 |  | Award ceremony  |

FP  
RV**Imaging 1**

Carl ARNDT, Constantin POURNARAS, Catherine CREUZOT

Uranie

|       |                   |   |
|-------|-------------------|---|
| 13:35 | 2611              | Optical coherence tomography: signal signature on neuronal ageing and blood-retinal barrier status<br>BERNARDES R, SANTOS T—Coimbra   |
| 13:47 | 2612              | High-resolution spectral domain optical coherence tomography findings in reticular pattern dystrophy<br>ZERBIB J, MASSAMBA N, QUERQUES G, BLANCO-GARAVITO R, SROUR M, BONNET C, SOUIED EH—Creteil           |
| 13:59 | 2613              | Assessment of the spectralis spectral domain oct segmentation software in a retrospective cohort study of exudative amd patients<br>TILLEUL J, QUERQUES G, CANOUI-POITRINE F, LEVEZIEL N, SOUIED EH—Créteil |
| 14:11 | 2614              | Natural evolution of idiopathic lamellar macular holes (LMH) and macular pseudoholes (MPH)<br>GARCIA FERNÁNDEZ M, CASTRO NAVARRO J—Oviedo   |
| 14:23 | 2615              | Coats disease: fluorescein angiography guided management<br>SUZANI M, MOORE AT—London   |
| 14:35 | 2616<br><i>rf</i> | Influence of cataract in reproducibility of Optical Coherence Tomography measurements<br>BAMBO M, FERRANDEZ B, GARCIA-MARTIN E, GIL-ARRIBAS L, ARA M, SATUE M—Zaragoza                                      |
| 14:41 | 2617<br><i>rf</i> | Subfoveal choroidal thickness: the Beijing Eye Study<br>JONAS JB, WEI W, XU L, SHAO L, DU K, WANG S, CHEN C, XU J, WANG Y, ZHOU J, YOU Q—Mannheim, Beijing  |

JM

**EVI Award Lectures**

Euterpe

**European Vision Award 2012**

|       |      |  |
|-------|------|--|
| 13:35 |      | Introduction by Thomas H. Wheeler-Schilling  |
| 13:40 | 2621 | From chickens to humans - learning about the puzzles of myopia<br>SCHAEFFEL F—Tübingen |
| 14:10 |      | Award ceremony   |


**Carl Zeiss European Young Investigator Award 2012 on Ophthalmic Research**

|       |  |   |
|-------|--|---|
| 14:15 |  | Introduction by Thomas H. Wheeler-Schilling                       |
| 14:20 |  | Carl Zeiss European Young Investigator Award 2012 - Award Lecture |
| 14:40 |  | Award ceremony  |

FP  
COS**Inflammatory ocular surface**

Eric GABISON, Gilles THURET

Erato


|       |  |   |
|-------|--|---|
| 13:35 |  2631 | Meganuclease targeting HSV-1 limits viral endothelitis in vivo<br>CHAPELLIER B, LABETOULLE M, GAILLEDRAT M, GABISON E—Paris, Le Kremlin Bicêtre   |
| 13:47 | 2632   | Cis-urocanic acid inhibits conjunctivitis and blepharitis in rat model of acute eye irritation<br>JAUHONEN HM, VIIRI J, KAARNIRANTA K, LAIHIA JK, LEINO L—Kuopio, Turku   |
| 13:59 | 2633   | Scleritis, clinical features, etiological diagnosis and treatment : a review of 32 cases<br>LEAL C, LE ROUX K, RAHMI A, SÈVE P, DENIS P, KODJIKIAN L—Lyon   |
| 14:11 | 2634   | In vivo confocal microscopic examination of corneal Langerhans cell density, distribution and evaluation of dry eye in rheumatoid arthritis<br>MARSOVSZKY L, RESCH M, NEMETH J, KOVACS L, TOLDI G, MEDGYESI E, BALOG A—Budapest, Szeged |
| 14:23 | 2635   | The effects of autologous serum eye drops in the treatment of ocular surface diseases: a retrospective study<br>BASLI E, LAROCHE L, LAURENT M, DESPIAU MC, BORDERIE V—Paris   |
| 14:35 | 2636<br><i>rf</i>  | Severe corticoreistant Mooren Ulcers: management with Rituximab and peripheral lamellar graft<br>BEN MHAMED M, PEREIRA D, DOAN S, COCHEREAU I, GABISON E—Paris  |
| 14:41 | 2637<br><i>rf</i>  | Comparison of viral vectors for gene transfer to corneal endothelial cells<br>FUCHSLUGER T—Düsseldorf   |

THURSDAY

**FP** **New frontiers in ocular infectology** **Thalie**  
**IM** Uwe PLEYER, Regis KOWALSKI

|       |                   |  |
|-------|-------------------|--|
| 13:35 | 2641              | Ocular toxoplasmosis: patient age and other risk factors for a severe course of disease<br>PLEYER U, MÄNZ M, FELS G, METZNER S, HAZIROLAN D, JOHNSEN J—Berlin  |
| 13:47 | 2642              | Etiologic diversity in patients presenting with atypical and severe anterior uveitis<br>FEL A, ROZENBERG F, TOUITOU V, LE HOANG P, BODAGHI B—Paris   |
| 13:59 | 2643              | Positive interferon-gamma release assay (IGRA) test in a case of non-tuberculous mycobacterium associated uveitis<br>BOUCHENAKI N, KUZNETCOVA T, SAUTY A, HERBERT CP—Lausanne, Morges  |
| 14:11 | 2644              | Evaluation of a complete-kill assay for anti-acanthamoeba solutions<br>KOWALSKI R, ABDEL AZIZ S, ROMANOWSKI E, SHANKS RM—Pittsburgh  |
| 14:23 | 2645              | 16S RNA PCR in the diagnosis of bacterial keratitis and endophthalmitis<br>ROBERT PY, SABATIER A, GARNIER F, PLOY MC—Limoges   |
| 14:35 | 2646<br><i>rf</i> | Miltefosine and polyhexamethylene biguanide, a new drug combination for the treatment of Acanthamoeba keratitis. Results from in-vivo toxicological and efficacy studies<br>OBWALLER A, POLAT ZA, WALOCHNIK J, VURAL A, DURSUM A, ARICI MK—Vienna, Sivas |
| 14:41 | 2647<br><i>rf</i> | Time profile of viral DNA in aqueous humor of patients treated for VZV acute retinal necrosis using quantitative real-time PCR<br>CHIQUET C, LABETOULLE M, GERMI R, BERNHEIM D, MORAND P, ROMANET JP—Grenoble, Paris                                     |

**FP** **Diagnosis in glaucoma** **Clio**  
**G** Andrew MCNAUGHT, Thierry ZEYEN

|       |  |   |
|-------|--|---|
| 13:35 |  2651 | Aquaporins in glaucoma eyes<br>TRAN TL, BEK T, HAMANN S, HEEGAARD S—Copenhagen, Aarhus  |
| 13:47 | 2652   | Ocular perfusion pressure – a risk factor for open-angle glaucoma or a statistical artifact?<br>JANSONIUS NM, RAMDAS WD, WOLFS RCW, HOFMAN A, DE JONG PTVM, VINGERLING J—Groningen, Rotterdam   |
| 13:59 | 2653   | Analysis of eye hydrodynamics on the basis of tests with a mechanical load applied<br>STEIN A, LYUBIMOV G, MOISEEVA I, IOMDINA E, NAZARENKO L—Moscow  |
| 14:11 | 2654   | Evaluation of retrobulbar hemodynamics and aqueous humor levels of Endothelin-1 in exfoliation syndrome, exfoliative glaucoma and primary open-angle glaucoma<br>NASR MB, KOUKOULA SC, TRANOS PG, LABIRIS G, KOZOBOLIS VP—Thessaloniki, Alexandroupolis |
| 14:23 | ★ 2655   | SPARCS: a new method of evaluating contrast sensitivity in patients with glaucoma<br>SPAETH G, RICHMAN J—Philadelphia   |
| 14:35 | 2656   | Evaluation of the flicker defined form test versus matrix, in normal and glaucoma eyes<br>MAY F, GIRAUD JM, FENOLLAND J, EL CHEHAB H, SENDON D, FRANCOZ M, RENARD JP—Paris  |

**SIS** **Next-generation sequencing in retinal genetics** **Gallieni 1&2**  
**MBGE** Bart LEROY, Graeme C M BLACK

|       |      |  |
|-------|------|--|
| 13:35 | 2661 | Who wants it?<br>HALL G—Manchester   |
| 13:57 | 2662 | Delivering it: retinitis pigmentosa<br>BLACK GCM—Manchester                              |
| 14:19 | 2663 | Delivering it: Stargardt disease<br>NEMETH AH, DOWNES S—Oxford                           |
| 14:41 | 2664 | Using it: NGS in the inherited retinal degeneration clinic<br>DOWNES S, NEMETH AH—Oxford |

**SIS  
PBP****Proceedings in functional and structural imaging****Gallieni 4**

Gerhard GARHOFER, Sveinn HARDARSON

- |       |   |      |   |
|-------|---|------|---|
| 13:35 | ★ | 2671 | Investigation of intra-cellular metabolism by time-resolved autofluorescence<br>SCHWEITZER D—Jena |
| 14:05 | ★ | 2672 | Retinal oximetry technology<br>HARDARSON S—Reykjavik  |
| 14:35 |   | 2673 | New developments in optical coherence tomography<br>SCHMETTERER L—Vienna                          |

**FP  
ACB****Lessons from human and animal studies****Gallieni 3**

Erich KNOP, Giedrius KALESNYKAS

- |       |  |      |   |
|-------|--|------|---|
| 13:35 |  | 2681 | Expression of Lubricin mRNA and protein in human ocular surface tissues<br>KNOP E, KNOP N, SCHMIDT T, MORRISON S, SULLIVAN BD, RAHIMI DARABAD R, SULLIVAN DA—Berlin, Calgary, San Diego, Boston   |
| 13:47 |  | 2682 | Aquaporin-1 expression in membranes from proliferative vitreoretinopathy and in epiretinal membranes<br>MOTULSKY E, SALIK D, JANSSENS X, PION B, DUFRANE R, CHAPUT F, BOLAKY N, GREGOIRE F, CASPERS L, PERRET J, WILLERMAIN F, DELPORTE C—Bruxelles |
| 13:59 |  | 2683 | Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase<br>ABU EL ASRAR A, MOHAMMAD G, NAWAZ MI, SIDDIQUEI M, KANGAVE D, OPDENAKKER G—Riyadh, Leuven   |
| 14:11 |  | 2684 | Retinal pathways involved in the control of eye growth and myopia<br>MORGAN IAN—Canberra  |
| 14:23 |  | 2685 | Retinal ganglion cell differentiation and protection using neuronally differentiated human dental pulp stem cells<br>HONG S—Seoul   |
| 14:35 |  | 2686 | Intermembranaceous spaces of human optic nerve intracanal part<br>HUSEVA YA, DENISOV SD—Minsk   |

*rf*

THURSDAY

FP  
RV**Imaging 2**

Michel PAQUES, Heinrich HEIMANN

Uranie

|         |                   |  |
|---------|-------------------|--|
| 15:15   | 2711              | Foveal changes during ocular movements in normal eyes. A prospective study. Kinetics of posterior pole during ocular movements in various diseases: a videomorphing technique<br>THEOCHARIS IP—Athens              |
| 15:27   | 2712              | 3D blood vessels segmentation from optical coherence tomography<br>GUIMARAES P, RODRIGUES P, BERNARDES R, SERRANHO P—Coimbra   |
| 15:39   | 2713              | Vascular network of the human macula from OCT<br>RODRIGUES P, GUIMARAES P, BERNARDES R, SERRANHO P—Coimbra   |
| 15:51 ★ | 2714              | Observation of fundus using a novel high-speed and high resolution optical coherent tomography: a preliminary report<br>YONEYA S, BABA M, SUZUKI M, KURODA H—Moroyama, Iruma, Saitama                              |
| 16:03   | 2715              | Follow-up study of MEWDS using adaptive optics retinal imaging<br>GOCHO-NAKASHIMA K, AUDO I, MOHAND-SAID S, KAMEYA S, YAMAKI K, TAKAHASHI H, SAHEL JA, PAQUES M—Paris, Inzai, Chiba, Tokyo                         |
| 16:15   | 2716<br><i>rf</i> | Assessment of different methods for inter-individual registration of OCT topography for statistical analysis<br>HALDAR S, DAVIES N—London  |
| 16:21   | 2717<br><i>rf</i> | Atrophic areas and/or with neovascular AMD. Characteristics, evolution of atrophic lesions associated to neovascular AMD treated by series of 3 Ranibizumab IVT protocol, 4 years follow-up<br>GONZALEZ C—Toulouse |

JM

**EVICR.net: Clinical trials in glaucoma, anterior segment and ocular surface**

Esther HOFFMANN, Jorge ALIO SANZ, Joaquim MURTA

Euterpe



|       |      |   |
|-------|------|---|
| 15:15 | 2721 | Therapeutic targets in glaucoma<br>HOFFMANN E—Mainz   |
| 15:25 | 2722 | Trends in anterior segment surgery: what is coming?<br>ALIO SANZ J—Alicante                       |
| 15:35 | 2723 | Femtosecond laser and microkeratome preparation of ultrathin (UT) DSAEK grafts<br>MURTA J—Coimbra |
| 15:45 | 2724 | Perspectives for new treatments at Alcon - part 1<br>RICH C—Fort Worth                            |
| 15:55 | 2725 | The STRONG study<br>LORENZ K—Mainz  |
| 16:05 | 2726 | Gullstrand (ECR-CCRS-2010-01)<br>ROZEMA J—Antwerp   |
| 16:15 |      | Open discussion   |



**SIS** **Optic neuropathies mistaken for optic neuritis** **Erato**  
**NSPH** Antonella BOSCHI, Aki KAWASAKI

|         |      |  |
|---------|------|--|
| 15:15 ★ | 2731 | Compressive lesions<br>KAWASAKI A—Lausanne                                     |
| 15:37   | 2732 | Inflammatory optic neuropathies<br>BORRUAT FX—Lausanne                         |
| 15:59   | 2733 | Optic neuropathy in Devic's disease: a diagnostic challenge<br>VIGHETTO A—Lyon |
| 16:21   | 2734 | Retinopathies<br>BOSCHI A—Brussels   |

**SIS** **Progress in corneal transplantation: immunology and inflammation** **Thalie**  
**IM** Thomas FUCHSLUGER, Uwe PLEYER

|         |      |   |
|---------|------|---|
| 15:15   | 2741 | Graft rejection in keratoplasty - what are the benefits of systemic immune modulation?<br>GRUENERT A—Düsseldorf   |
| 15:33   | 2742 | Graft rejection in keratoplasty - is there a place for topical immune modulation?<br>PLEYER U—Berlin  |
| 15:51 ★ | 2743 | Current concepts and future directions in the pathogenesis and treatment of infectious and non-infectious intraocular inflammation<br>DICK A—Bristol              |
| 16:09   | 2744 | Novel therapeutic strategies for the induction of tolerance in corneal transplantation<br>RITTER T, TREACY O, O'FLYNN L, WILK M, MORCOS M, RYAN A, NOSOV M—Galway |
| 16:27   | 2745 | Immune modulatory effects of gene therapy to corneal grafts<br>FUCHSLUGER T—Düsseldorf  |

**SIS** **Dealing with advanced glaucoma** **Clio**  
**G** Ejaz ANSARI

|       |      |  |
|-------|------|--|
| 15:15 | 2751 | Definition and investigative techniques in advanced glaucoma<br>ZEYEN T—Leuven |
| 15:37 | 2752 | Treatment options in advanced disease<br>BRON A—Dijon                          |
| 15:59 | 2753 | Differential diagnosis of advanced glaucoma<br>HOLDER GE—London                |
| 16:21 | 2754 | Counselling the patient with advanced disease<br>ANSARI E—Maidstone            |

THURSDAY

**SIS  
ACB****Retinal barriers**

Hannu UUSITALO, Kai KAARNIRANTA

Gallieni 1&amp;2



|       |      |  |
|-------|------|--|
| 15:15 |      | Retinal barriers in health and disease - introduction by Hannu Uusitalo / Kai Kaarniranta  |
| 15:30 | 2761 | Natural compounds as lead therapeutic agents against diabetic eye disease<br>PETRASH M—Aurora, Colorado                          |
| 15:55 | 2762 | Protective role of steroids on mouse primary RPE cells under hypoxic stress<br>BEUERMAN R, CHEW J, WEON SR, BARATHI VA—Singapore |
| 16:20 | 2763 | R-Ras in retinal angiogenesis<br>UUSITALO-JÄRVINEN H—Tampere   |

**WS****EBO: What can education organisations do for young ophthalmologists?**

Peter RINGERS, Marko HAWLINA

Gallieni 4



|       |      |   |
|-------|------|---|
| 15:15 | 2771 | EBO exam: how to succeed?<br>ACLIMANDOS W—London  |
| 15:30 | 2772 | Inventorisation of European education programs<br>TASSIGNON MJ—Antwerp  |
| 15:45 | 2773 | Surgical skills among European students<br>CREUZOT C—Dijon  |
| 16:00 | 2774 | UEMS-EACCME's new criteria for the accreditation of Live Educational Events (LEEs)<br>BARISANI-ASENBAUER T—Vienna |
| 16:15 | 2775 | Evaluation remains a key point<br>MATHYSEN D—Antwerp  |
| 16:30 | 2776 | I have got a grant<br>GRIGORIU D—Bucharest  |
| 16:37 | 2777 | I have passed the exam<br>MUSELIER A—Dijon  |

**FP**  
**MBGE**

**Genetics, Genotypes and Phenotypes**

**Gallieni 3**

Marcela VOTRUBA, Bart LEROY

|       |                   |   |
|-------|-------------------|---|
| 15:15 | 2781              | A strategy for molecular diagnosis and search for new genes/loci in autosomal dominant retinitis pigmentosa<br>MANES G, DHAENENS CM, BOCQUET B, MARQUETTE V, BAUDOIN C, RICHARD AC, HEBRARD M, MEUNIER I, HAMEL C—Montpellier, Lille  |
| 15:27 | 2782              | Search for the identification of new genes causing autosomal recessive retinitis pigmentosa<br>BOCQUET B, MARZOUKA N, HEBRARD M, MANES G, SENECHAL A, BAUDOIN C, MARQUETTE V, MEUNIER I, HAMEL C—Montpellier                          |
| 15:39 | 2783              | Complexity of genetics in keratoconus<br>GAJECKA M, KAROLAK JA, MOLINARI A, PITARQUE JA, BEJJANI BA, POLAKOWSKI P, SZAFLIK J, SZAFLIK JP, NOWAK DM—Poznan, Quito, Spokane, Warsaw   |
| 15:51 | 2784              | OPA1-related sensorineural hearing loss<br>LERUEZ S, BONNEAU D, AMATI-BONNEAU P, DEFOORT-DHELLEMMES S, CROCHET M, DROUIN V, BLANCHET C, JUUL G, LARSEN M, LAENERS G, REYNIER P, MILEA D—Angers, Lille, Rouen, Montpellier, Copenhagen |
| 16:03 | 2785<br><i>rf</i> | Detection of a novel premature stop codon in the OPA1 gene in autosomal dominant optic atrophy<br>OLDAK M, FEDEROWICZ A, SZULBORSKI K, WIERZBOWSKA J, KOSINSKA J, PIOSKI R, SZAFLIK JP, SZAFLIK J—Warsaw                              |
| 16:09 | 2786<br><i>rf</i> | Analysis of lincRNA at 13q32 keratoconus locus<br>KAROLAK JA, NOWAK DM, MOLINARI A, PITARQUE JA, BEJJANI BA, GAJECKA M—Poznan, Quito, Spokane   |
| 16:15 | 2787<br><i>rf</i> | RDH12 mutation and early-onset retinal degeneration<br>GARCIA FERNÁNDEZ M, CASTRO NAVARRO J, BAJO FUENTE A—Oviedo   |



**Molecular Biology / Genetics / Epidemiology**

**Moderators:**

**Graeme BLACK, Marzena GAJECKA**

- T001 Relationships between estradiol, progesterone, and plasminogen activator inhibitor longitudinally during normal human pregnancy  
STEIBER Z, SILVER DM, TOZSER J, BAGOSSI P, JAKAB A, BERTA A, CSUTAK A—Debrecen, Laurel
- T002 Pirfenidone inhibits the induction of COX-2 stimulated by IL-1 $\beta$  at a step of NF- $\kappa$ B DNA binding in orbital fibroblast  
KOOK K, PARK S, CHOI A—Suwon
- T003 *rf* Detection of a novel premature stop codon in the OPA1 gene in autosomal dominant optic atrophy  
OLDAK M, FEDEROWICZ A, SZULBORSKI K, WIERZBOWSKA J, KOSINSKA J, PIOSKI R, SZAFLIK JP, SZAFLIK J—Warsaw
- T004 *rf* Analysis of lincRNA at 13q32 keratoconus locus  
KAROLAK JA, NOWAK DM, MOLINARI A, PITARQUE JA, BEJANI BA, GAJECKA M—Poznan, Quito, Spokane
- T005 The Brittle Cornea Syndrome: Study of a family with five affected siblings  
ALHARBI A, DENIS D, AZAR N, MAUMENEE IH—Marseille, Chicago
- T006 Unusual phenotype in a family with the R124C mutation in the TGFB1 gene  
UDZIELA M, OLDAK M, FEDEROWICZ A, PLOSKI RAFAL, SZAFLIK JP, SZAFLIK J—Warsaw
- T007 NHS gene mutations in non syndromic cataract  
HABAY T, LAUMONIER F, LALA E, SPEEG-SCHATZ C, TOUTAIN A, PISELLA PJ—TOURS, Strasbourg
- T008 *rf* RDH12 mutation and early-onset retinal degeneration  
GARCIA FERNÁNDEZ M, CASTRO NAVARRO J, BAJO FUENTE A—Oviedo
- T009 Progression of geographic atrophy and polymorphisms of genes CFH, BF, C3, FHR 1-3, FRH3 and ARMS2/HTRA in Age-Related Macular Degeneration  
RECALDE S, FERNANDEZ-ROBREDO P, CAIRE J, GARCIA-GARCIA L, MORENO-ORDUÑA M, FERNANDEZ-GARCIA V, GARCIA-LAYANA A, SPANISH MULTICENTER GROUP ON AMD S—Pamplona
- T010 *rf* Diabetic retinopathy in Greek Caucasian type 2 diabetic patients, relationship with polymorphism in the plasminogen activator inhibitor 1 and 2 genes  
SOKOLAKIS TH, TSIRONI E, DARDIOTIS E, CHATZOULIS E, ZINZARAS E—Athens, Larissa
- T011 Non-syndromic retinitis pigmentosa: Phenotype-genotype correlation in twelve Tunisian families  
EL MATRI L, CHEBIL A, FALFOUL Y, LARGUECHE L, MUNIER F, SCHORDERET D—Tunis, Lausanne
- T012 Vascular endothelial growth factor A genetic polymorphisms and AMD in Tunisians  
EL MATRI L, HABIBI I, CHEBIL A, SFAR I, KORT F, GORGI Y—Tunis
- T013 *rf* Polymorphism of endothelial nitric oxide synthase T786C in patients with normal tension glaucoma and primary open angle glaucoma  
LUKASIK U, KOSIOR-JARECKA E, WROBEL-DUDZINSKA D, KUSMIREK K, KOCKI J, ZARNOWSKI T—Lublin
- T014 Nailfold capillaroscopic examination and T786C endothelial nitric oxide synthase polymorphism in normal tension glaucoma patients  
LUKASIK U, KOSIOR-JARECKA E, BARTOSINSKA J, KOCKI J, WROBEL-DUDZINSKA D, CHODOROWSKA G, ZARNOWSKI T—Lublin

- T015 *rf* Activity and epidemiology of a recently-opened ophthalmic emergency center in an University Hospital  
AMELOOT F, AGRINIER N, MAALOUF T, ANGIOI K—Nancy
- T016 Prevalence and risk factors for refractive errors among the university students of Iran  
YEKTA AA, GHASEMI S, KHABAZKHOOB M, OSTADIMOGHADDAM H, YEKTA R, DERA KHSHAN A, HERAVIAN J, AZIMI A, RASHID TORABI M—Mashhad, Tehran
- T017 Prevalence of visual impairment among the elderly: can it be corrected?  
YEKTA AA, HASHEMI H, KHABAZKHOOB M, SHAFARAE SH, OSTADIMOGHADDAM H, AZIMI A, HERAVIAN J, REZVAN F, YEKTA R—Mashhad, Tehran, Mashad
- T018 Ocular symptoms are not predictive of ocular inflammation in inflammatory bowel disease. A large cross-sectional survey  
CLOCHÉ V, BIGARD MA, PEYRIN-BIROULET L, ANGIOI K—Vandoeuvre les Nancy

**Anatomy / Cell Biology**

**Moderators:**

**Nadja KNOP, Kai KAARNIRANTA**

- T019 *rf* Intermembranaceous spaces of human optic nerve intracanal part  
HUSEVA YA, DENISOV SD—Minsk
- T020 *rf* CD34 marks angiogenic tip cells in human vascular endothelial cell cultures: a new model to study mechanisms of ocular angiogenesis  
SCHLINGEMANN RO, SIEMERINK MJ, GRIFFIOEN AW, KLAASSEN I, VAN NOORDEN CJF—Amsterdam
- T021 Blood basement membrane alterations in human retinal microaneurysms during aging  
RUBERTE J, LOPEZ-LUPPO M, RAMOS D, MENDES-JORGE L, NAVARRO M, CARRETERO A, RODRIGUEZ-BAEZA A, NACHER V—Barcelona, Lisboa
- T022 Normative data for macular thickness by Spectral Domain OCT in healthy children.  
PEREZ GARCIA D, PINILLA I, IBAÑEZ ALPERTE J, ASCASO F, CRISTOBAL JA—Zaragoza
- T023 Choroidal thickness measurements in children using Spectral-Domain OCT  
PEREZ GARCIA D, PINILLA I, IBAÑEZ ALPERTE J, PEIRO C, ASCASO F, REMON GARIJO L, CRISTOBAL JA—Zaragoza
- T024 Measurement of scleral curvature using anterior segment optical coherence tomography  
CHOI HJ, KANG MH, KIM SH—Seoul
- T025 Hypoxia Inducible Factor-1a (HIF-1a) and Heat Shock Proteins 90, 70 (HSP 90, 70) expression in ocular pterygium and normal conjunctiva.  
PAGOULATOS D, PHARMAKAKIS N, ARGYROPOULOU A, ASSIMAKOPOULOU M—Patra
- T026 Comparative endonasal analysis of the inferior lateral wall of the nasal fossae in adults with and without epiphora  
HUBAULT B, VALLE D, MEROL JC, ARNDT C, DUCASSE A—Reims
- T027 Long-term nanostructural effects of high radiofrequency treatment on the rabbit skin tissues  
JAE HO S—Seoul



## THURSDAY

- T028 Morphometric changes of optic nerve in experimentally induced type 2 diabetic rats  
KANG MH, LIM HU—Guri
- T029 Blood-retinal barrier serum ferritin transport in mouse retina  
MENDES-JORGE L, RAMOS D, LUPPO M, VALENÇA A, CATITA J, DUARTE CM, SIMÕES M, CARRAPIÇO B, PIRES VMR, NACHER V, NAVARRO M, CARRETERO A, RODRIGUEZ-BAEZA A, RUBERTE J—Lisboa, Barcelona

**Cornea / Ocular Surface****Moderators:**

**Thomas FUCHSLUGER, Mario NUBILE,  
Jean-Jacques GICQUEL**

- T030 *rf* Tear film break-up time evaluation by real-time wavefront aberrometry in adult patients with meibomian gland  
GICQUEL JJ, DJABAROUTI M, DUPONT L, ZAKARI W, PISELLA PJ, BREMOND-GIGNAC D—Poitiers, Tours, Amiens
- T031 *rf* Tear film break-up time evaluation by real-time wavefront aberrometry in normal subjects  
DJABAROUTI M, ZAKARI W, NOCHEZ Y, PISELLA PJ, GICQUEL JJ—Poitiers, Tours
- T032 *rf* Corneal respiratory function by FAD autofluorescence lifetime  
BATISTA A, LOUREIRO C, DOMINGUES JP, SILVA JS, MORGADO AM—Coimbra
- T033 *rf* Comparison of viral vectors for gene transfer to corneal endothelial cells  
FUCHSLUGER T—Düsseldorf
- T034 *rf* Coupling innovative imaging: in vivo multilaser confocal microscopy and ex vivo confocal Raman spectroscopy of cornea and skin in nephropathic cystinosis  
ESPINASSE M, CINOTTI E, PERROT JL, LABEILLE B, CAMBAZARD F, DUMOLLARD JM, PEOC'H M, CAMPOLMI N, THURET G, GAIN P—Saint-Etienne
- T035 Changes in meibography in pediatric blepharokeratoconjunctivitis  
BOLDIN I, RABENSTEINER DF, WOLTSCHKE N, PÖSCHL E:M, HORWATH-WINTER J—Graz
- T036 *rf* ★ Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping  
DAULL P, FERAILLE L, ELENA P, BAUDOUIN C, GARRIGUE JS—Evry, La Gaude, Paris
- T037 ★ Ocular surface effects of antiglaucoma combination therapies in a rat model of corneal scraping  
DAULL P, GARRIGUE JS, FERAILLE L, BAUDOUIN C, ELENA P—Evry, La Gaude, Paris
- T038 Granulomatous conjunctivitis associated with chronic blepharitis in children  
BAIZ H, MAURAGE CA, LAUMONIER E, ROULAND JF, L ABALETTE P—Lille
- T039 *rf* Secreted frizzled proteins in control and keratoconus (KC) tears and corneas  
MADIGAN MC, YOU JJ, WEN L, HODGES C, ROUFAS A, MCAVOY JW, SUTTON G—Sydney
- T040 *rf* Investigation of bacterial contamination of corneal donors using molecular biology  
ROBERT PY, DUBOIS A, CHAIGNIER D, GARNIER F, PLOY MC—Limoges
- T041 Evaluation of limbal stem cell deficiency: a new diagnostic tool based on keratin 13 immunostaining in corneal impression cytology  
POLI M, JUSTIN V, DAMOUR O, BURILLON C—Lyon
- T042 Identification of factors regulating differentiation and growth of limbal stem cells for corneal surface regeneration  
HOLAN V, TROSAN P, KRULOVA M, ZAJICOVA A—Prague
- T043 Gene transfer of HSV1-specific meganuclease to the murine cornea  
ROUSSEAU A, ERGANI A, GABISON E, CORRAL M, GAILLEDRAT M, DESSEAUX C, ROY P, CHAPPELLIER B, LABETOULLE M—Le Kremlin-Bicêtre, Gif-sur-Yvette, Paris
- T044 Nicorandil: a new case of corneal ulceration  
TRECHOT F, BAZARD MC, BATA B, ANGIOI K—Nancy
- T045 The effect of infliximab on corneal neovascularization in rabbits  
LEE MA, CHUNG SK—Seoul
- T046 The ocular surface drug correction in patients after LASIK  
SERGEEVA M, KOVALEVSKAYA M, CHERNIKOVA I—Voronezh
- T047 The role of compliance in optimizing the ocular surface after two-step LASIK  
SERGEEVA M, KOVALEVSKAYA M, CHERNIKOVA I—Voronezh
- T048 Use of lissamine green before conjunctival impression cytology and flow cytometry in patients with sjögren's syndrome  
TOMLINS PJ, BOWMAN S, BRON A, RAUZ S, CURNOW SJ—Birmingham, Oxford, Birmingham
- T049 Lacrymal secretion in the non-affected fellow eye of patients with recurrent unilateral herpetic keratitis  
MGARRECH M, ROUSSEAU A, SAUER A, KASWIN G, BARREAU E, BOURCIER T, LABETOULLE M—Kremlin-Bicetre, Strasbourg
- T050 Wetability and deposits accumulation on anterior surface of blue light-filtering contact lens  
CHAMORRO E, BONNIN-ARIAS C, RAMIREZ-MERCADO G, URBANO-RODRIGUEZ R, RIOS-SANTOS R, SANCHEZ-RAMOS C—Madrid
- T051 Observation of dendritic cells in subclinical corneal graft disease using confocal microscopy imaging  
WOJCIK L, WYLEGALA E, SMEDOWSKI A, ORSKI M—Katowice
- T052 Risk factors for contact lenses related microbial keratitis: a prospective multicenter case control study  
BOURCIER T, SAUER A—Strasbourg
- T053 Observation of dendritic cells in corneal graft disease in keratoconus patient after deep anterior lamellar keratoplasty using confocal microscopy imaging  
WOJCIK L, WYLEGALA E, SMEDOWSKI A, ORSKI M—Katowice
- T054 Role of human corneal stroma-derived mesenchymal-like stem cells in immunity and wound healing  
VEREB Z, ALBERT R, MOE MC, RAJNAVÖLGYI E, FESUS L, BERTA A, PETROVSKI G—Debrecen, Oslo
- T055 Tear film proteins attached to soft contact lenses  
NIELSEN K, VORUM H, EHLERS N, HUORTDAL J, HONORÉ B—Aarhus C
- T056 Epidemiology of microbial keratitis: A review of 508 cases  
HOFFART L, DORNADIN A, DRANCOURT M—Marseille
- T057 The contribution of tear osmolarity measurement to ocular surface assessment in soft contact lens wearers  
MUSELIER A, MATHIEU B, BRIGNOLE-BAUDOUIN F, NIAZI A, BRETILLON L, BRON A, CREUZOT-GARCHER C—Dijon, Paris

- T058 Quality of vision in patients with herpetic keratitis  
ROUSSEAU A, KASWIN G, BARREAU E, M'GARRECH M, LABETOUILLE M—Le Kremlin-Bicêtre
- T059 Assessment of the improvement of the quality of vision after Meibopatch® treatment, with OQAS and Hartmann-Shack aberrometry in patients with meibomian gland dysfunction  
DUPONT L, NOCHEZ Y, PISELLA PJ, COCHENER B, GICQUEL JJ—Poitiers, Tours, Brest
- T060 Whole exome sequencing identifies a mutation for a novel form of hereditary benign intraepithelial dyskeratosis  
SOLER V, TRAN-VIET KN, ST.GERMAIN E, FOURNIE P, KLEMM T, HAWTHORNE F, AFSHARI NA, CALVAS P, MALECAZE F, YOUNG T—Toulouse, Durham, Singapore
- T061 Prospective study of a new matrix therapy agent (RGTA) for the treatment of neurotrophic ulcers  
GUEUDRY J, AIFA A, PORTMANN A, DELCAMPE A, MURAIN E—Rouen
- T062 Polymeric membranes for corneal epithelium engineering based on chitosan and structural proteins  
WOWRA B, WYLEGALA E, GROLIK M, DOBROWOLSKI D, SCZUBIALKA K, NOWAKOWSKA M, ORSKI M, SMEDOWSKI A, WOJCIK L—Katowice, Cracow
- T063 Ocular granulomatosis associated with brimonidine treatment. Does brimonidine have an effect on human macrophages and dendritic cells in vitro?  
BOUABANE I, MAURAGE CA, LABALETTE M, ROULAND JF, LABALETTE P—Lille, France
- T064 Quantification of tear film thickness in healthy subjects using ultrahigh resolution OCT imaging  
KAYA S, WERKMEISTER R, LEITGEB R, ALEX A, GARHOEFER G, SCHMETTERER L—Vienna
- T065 The role of Confocal Microscopy in evaluation and treatment of infectious keratitis  
ORSKI M, WYLEGALA E, TARNAWSKA D, WOJCIK L, SMEDOWSKI A, WOWRA B—Katowice
- T066 Corneal cross-linking and Ferrara® intracorneal rings for the treatment of progressive keratoconus: About 23 cases  
LUSSATO M, DELBARRE M, BLAVIER B, LEDUC C, CREPY P, FROUSSAERT-MAILLE F, RIGAL-SASTOURNE JC—Clamart
- T067 Severe corticoreistant Mooren Ulcers: management with Rituximab and peripheral lamellar graft  
BEN MHAMED M, PEREIRA D, DOAN S, COCHEREAU I, GABISON E—Paris
- T068 Surgical approach in corneal perforations and deep ulcers  
DOBROWOLSKI D, JANISZEWSKA D, TARNAWSKA D, KRYSIK K, WYLEGALA E—Katowice, Sosnowiec
- T069 Postoperative astigmatism induction - femtosecondlaser-assisted penetrating keratoplasty vs penetrating keratoplasty  
DOBROWOLSKI D, MILKA M, WYLEGALA E—Sosnowiec
- T070 Assessment of angle and anterior chamber changes after keratoplasty  
SICARD F, JANY B, BENNAI D, BREMOND-GIGNAC D—Amiens
- T071 Identification of label-retaining endothelial cells in adult human corneas: a new clue for the existence of endothelial stem cells  
HA THI BM, HE Z, CAMPOLMI N, PISELLI S, GAIN P, PEOC'H M, DUMOLLARD JM, ACQUART S, GARRAUD O, THURET G—Saint-Etienne
- T072 Ex vivo test bench for preclinical assessment of intra corneal new medical devices is needed more than ever  
BERNARD A, CAMPOLMI N, NEFZAOUI C, THURET G, GAIN P—Saint-Etienne
- T073 Improving DSAEK donor grafts cut using microkeratome motorization and pressure monitoring  
BERNARD A, NEFZAOUI C, GRIOT O, CAMPOLMI N, ACQUART S, PEREIRA S, THEILLIERE C, PISELLI S, THURET G, GAIN P—Saint-Etienne
- T074 One year stored corneas: is it possible?  
HE Z, CAMPOLMI N, NEFZAOUI C, PISELLI S, PEOC'H M, DUMOLLARD JM, GAIN P, THURET G—Saint-Etienne
- T075 Rabbit, rat and pig corneas: main characteristics and storage in organ culture  
HE Z, CROUZET E, PISELLI S, CAMPOLMI C, FOREST F, PEOC'H M, DUMOLLARD JM, GAIN P, THURET G—Saint-Etienne
- T076 Big bubble technique dissection plane: histological and ultrastructural comparative analysis on both white and clear margin dissected corneas  
IRION L, MCKEE H, BRAHMA A, CARLEY F—Manchester
- T077 Impact of photodynamic inactivation (PDI) on bFGF, HGF, KGF, TGFβ1 and VEGF secretion of keratocytes in vitro  
SZENTMARY N, STACHON T, WANG J, EPPIG T, LANGENBUCHER A, BISCHOFF M, FOTH HJ, SEITZ B—Homburg/Saar, Kaiserslautern
- T078 Expression of stromelysins 2 and 3 in rabbit corneal epithelium upon UV radiation  
ARDAN T—Prague
- T079 Corneal biomechanics after corneal cross-linking for keratoconus  
CELLINI M, STROBBE E, GIZZI C, BALDUCCI N, CAMPOS EC—Bologna
- T080 Gelatinous drop like dystrophy (GDLD) in a Sudanese patient  
AKHTAR S, GUGGENHEIM J, ALKATAN H, KIRAT O, ALMUBRAD T—Riyadh, Cardiff
- T081 The correlation between central corneal thickness and endothelial cells in healthy patients and in patients with cataract or primary open angle glaucoma  
JURKUTE N, PAJAUJIS M, GALGAUSKAS S, KRASAUSKAITE D, ASOKLIS R—Vilnius
- T082 Three year visual outcomes and correlation with graft thickness in eyes following descemet stripping automated endothelial keratoplasty (dsaek)  
LIM FPM, ANG M, HTOON H, TAN D, MEHTA J—Singapore
- T083 Distribution of the central corneal thickness in adult residents of Lithuania  
GALGAUSKAS S, LIUTVINAITE R, JUODKAITE G, TUTKUVIENE J, ASOKLIS R—Vilnius
- T084 Efficacy of amniotic membrane transplantation (AMT) on corneal surface in bullous keratopathy eyes  
KOEV K—Sofia
- T085 Keratoconus screening based on data of the high resolution anterior segment OCT Casia 1000  
LANGENBUCHER A, GILLNER M, KANNENGIESSER M, EPPIG T—Homburg, Erlangen
- T086 Efficacy of gas permeable scleral lenses in refractory severe dry eye syndrome  
DOAN S, ELLUARD M, GABISON E, COCHEREAU I, DELCAMPE A—Paris

## THURSDAY

- T087 Boston Keratoprosthesis (Type I): visual prognosis and complications  
DE LA PAZ M, STOIBER J, MICHAEL R—Barcelona, Salzburg
- T088 Ukraine implantation results of collagen-based bioengineered substitutes of donor corneal allografts in rabbits  
BOYCHUK IRYNA, PASECHNIKOVA NV, LEUS M, BUZNYK OI, GRIFFITH M—Odessa, Linköping
- T089 Laser subepithelial keratomileusis ( LASEK ) versus femtosecond sub-Bowman keratomileusis ( FSBK ) to correct myopic astigmatism  
CANADAS SUAREZ PILAR, IGLESIAS MLUZ, GARCIA-GONZALEZ M, TEUS MA—Madrid
- T090 Causes of intracorneal ring segments explantation  
CANADAS SUAREZ P, ARRUBARRENA C, HERNANDEZ-VERDEJO JL, GARCIA-GONZALEZ M, TEUS MA—Madrid
- T091 Ability of keratoconus match index and keratoconus match probability in the differentiation of forme fruste keratoconus and healthy corneas  
DELBARRE M, LUSSATO M, RIGAL-SASTOURNE JC—Clamart
- T092 Influence of intraocular pressure on the photorefractive keratectomy for myopia correction. a numerical analysis  
DEL BUEY MA, LANCHARES E, CALVO B, LAVILLA L, CRISTOBAL JA, CASAS P, ASCASO F, CRUZ N, JIMENEZ B, DOBLARE M, PALOMINO C—Zaragoza, Madrid
- T093 Combined treatments for keratoconus: a numerical approach  
DEL BUEY MA, LANCHARES E, CRISTOBAL JA, CALVO B, CASAS P, ASCASO F, CRUZ N, LAVILLA L, JIMENEZ B, PEIRO C, PALOMINO C—Zaragoza, Madrid
- T094 Usefulness of the optical coherence tomography Spectralis® anterior segment module in the diagnosis and monitoring of corneal pathology  
JIMENEZ DEL RIO B, DEL BUEY MA, CRISTOBAL JA, CRUZ N, RAMIRO P, MATEO J, CASAS P, PADGETT E—Zaragoza
- T095 Adapting a dermatological multi-laser fluorescent confocal microscope for ophthalmology applications  
GRIOT O, GRIVET D, ESPINASSE M, PERROT JL, LABELLE B, CAMBAZARD F, CAMPOLMI N, GAIN P, THURET G—Saint-Etienne
- T096 Revisiting corneal storage using a bioreactor: proof of concept  
GAIN P, BERNARD A, NEFZAOU I, CAMPOLMI N, GRIOT O, ACQUART S, PISELLI S, THURET G—Saint-Etienne
- T097 Sub Bowman's keratomileusis for the correction of anisometropia after penetrating and lamellar corneal surgery  
MENICACCI F, MENICACCI FL, MENICACCI C, BATISTI C, ESPOSTI G, FRUSCHELLI M—Siena
- T098 Corneal hystomorphology and myopic regression in patients after LASIK in the long follow-up period  
NIKULIN SERGE, KACHANOV ANDRE, CHURAKOV TIMUR, BAUER SVETA, ZIMIN BORIS—St.-Petersburg
- T099 Corneal ectasia after excimer surgery and the mandelbrot B. fractal theory in ophthalmology  
KACHANOV ANDRE, NIKULIN SERGE, BAUER SVETA, ZIMIN BORIS—St.-Petersburg
- T100 Graft thickness and visual acuity after automated endothelial keratoplasty  
RABOT A, SOLER V, FOURNIE P—Nice, Toulouse
- T101 Functional and biomechanical changes in keratoconic corneas after implantation of intracorneal ring segments 5 and 6mm in diameter  
PERIS-MARTINEZ C, ARGUDO M, ESPANA-GREGORI E—Valencia
- T102 Interest of endosaver® using on endothelial graft  
GUENOUN S, PROUST H, CONRATH J, RIDINGS B, HOFFART L—Marseille
- T103 The current practice and researches of orthokeratology in China  
LU F—Wenzhou, Zhejiang
- T104 ★ Cis-urocanic acid eye drops are safe and well tolerated in healthy adults – results from a randomised phase 1 clinical study  
LEINO L, JAUHONEN HM, KARI E, PYLKKÄNEN L, POUTANEN J, LAIHIA JK, KAARNIRANTA K—Turku, Kuopio
- T105 Monochromatic aberrations in children and youth in different cycloplegic conditions  
MOCKO L, WYLEGALA E, ZAJAC M—Katowice, Wrocław
- T106 Clinical and therapeutic aspects of vernal keratoconjunctivitis in Algeria  
LAZREG S—Blida
- T107 Comparison of decellularization methods for human corneal lenticules  
HE Z, PERRIER E, CARA G, CAMPOLMI N, FOREST F, PEOC'H M, DUMOLLARD JM, GAIN P, THURET G—Saint-Etienne
- T108 We don't graft as many endothelial cells as we think (Part 1): what early post-operative endothelial cell counts tell us  
NEFZAOU I, TRONE M, CAMPOLMI N, ACQUART S, THEILLIERE C, THURET G, GAIN P—Saint-Etienne
- T109 We don't graft as many endothelial cells as we think (part 2): comparison of cell loss after autograft and organ cultured allograft in the same patient  
TRONE M, NEFZAOU I, ALDOSSARY M, CAMPOLMI N, ACQUART S, GARRAUD O, THURET G, GAIN P—Saint-Etienne
- T110 ★ Cornea innervation: from physiologic to drug-induced recovery  
ZURRIA M—Casoria - Naples
- T111 Influence of culture time on maintenance of limbal epithelial progenitors in the explant culture system  
GHOUBAY D, SANDALI O, GOLDSCHMIDT P, BULLETT J, LAROCHE L, BORDERIE V—Paris
- T112 Targeting host kinases for the treatment of herpes keratitis  
ALEKSEEV O, JENNINGS S, AZIZKHAN-CLIFFORD J—Philadelphia
- T113 Biocompatible of human acellular cornea matrix  
NASINNYK I, PASYECHNIKOVA N, LEUS M—Odessa
- T114 Epithelial thickness and structure in patients with congenital aniridia after COMET procedure  
WOWRA B, WYLEGALA E, DOBROWOLSKI D, ORZECZOWSKA-WYLEGALA B, ORSKI M, SMEDOWSKI A, WOJCIK L—Katowice
- T115 Treatment of ligneous conjunctivitis with subconjunctival fresh frozen plasma (ffp): about three severe cases  
GABISON E, DOAN S, AJZENBERG N, COCHEREAU I—Paris
- T116 Cultivating oral mucosa epithelial transplantation (COMET) followed by penetrating keratoplasty (PK) in ocular surface reconstruction  
DOBROWOLSKI D, WOWRA B, ORZECZOWSKA-WYLEGALA B, WYLEGALA E—Katowice

**Neuro-ophthalmology / Strabismology / Paediatric / History**

**Moderators:**

**Dominique BREMOND-GIGNAC, Marko HAWLINA, Andrzej GRZYBOWSKI**

- T117 Comparative study of three exophthalmometers and computed tomographic biometry  
DELMAS J, MARTIN S, LOUSTAU JM, BOURMAULT L, ADENIS JP, ROBERT PY—Limoges, Brive
- T118 Use of wide field digital retinal imaging (RET CAM II) in paediatric retinal diseases  
PINELLO L, MAZZAROLO M—Padua
- T119 Lyme borreiosis with ocular manifestations during childhood period  
SAUER A, HANSMANN Y, JAULHAC B, BOURCIER T, SPEEG-SCHATZ C—Strasbourg
- T120 Vincristine-induced unilateral ptosis  
BATA B, TRECHOT F, GEORGE JL, ANGIOI K—Nancy
- T121 Bilateral non-arteritic ischemic optic neuropathy due to excessive use of transdermal estrogen by transgender patient  
DE ZAEYTIJD J, DE POTTER R, MONSTREY S, LEROY BP, HEYLENS G, WIERICKX K, T'SJOEN G—Ghent
- T122 Jugular venous thrombosis secondary to idiopathic myelofibrosis: a rare cause of bilateral papilledema  
MATEO J, JIMENEZ B, ASCASO F, LAVILLA L, PEIRO C, IBANEZ J—Zaragoza
- T123 Optical coherence tomography: a window into the brain of schizophrenic patients  
CABEZON L, ASCASO F, RAMIRO P, QUINTANILLA MA, GUTIERREZ L, LOBO A, CRISTOBAL JA—Zaragoza
- T124 Contribution of MRI in cases of isolated mydriasis: description of neurovascular conflicts.  
TRECHOT F, BRAUN M, CLOCHE V, ANGIOI K—Nancy
- T125 Relationship between retinal nerve fiber layer thickness and the duration and severity of parkinson disease  
JIMENEZ DEL RIO B, ASCASO F, CRISTOBAL JA, PÉREZ D, CABEZÓN L, IBANEZ J, DEL BUEY MA, LÓPEZ DEL VAL J—Zaragoza
- T126 Three-dimensional geometries representing the retinal nerve fiber layer in multiple sclerosis, optic neuritis, and healthy eyes  
GARCIA MARTIN E, DE LA MATA G, SATUE M, BAMBO M, ARA M, EGEA MC, FERNANDEZ-PEREZ S, HERRERO R, IDOIBE M, OTIN S, LARROSA JM, POLO V, GONZALEZ-GARCIA C, GARCIA-FEIJOO J, PABLO L—Zaragoza, Madrid
- T127 Retina thickness measurements provide a sensitive and specific diagnostic tool in Parkinson's disease  
GARCIA MARTIN E, BAMBO M, PRIETO E, DE LA MATA G, FERNANDEZ-PEREZ S, SATUE M, IDOIBE M, FUERTES I, OTIN S, ALARCIA R, ROCHE JC, SERAL M, POLO V, LARROSA JM, PABLO L—Zaragoza
- T128 Axonal loss in multiple sclerosis: a morphological and functional analysis of retinal nerve fibers  
FAVARD A, MAJZOUB S, NOCHEZ Y, PISELLA PJ—Tours
- T129 Extraocular blood flow in multiple sclerosis (MS) patients  
JANKOWSKA-LECH I—Warsaw
- T130 Retinal circulation and intracranial pressure in idiopathic intracranial hypertension  
PIERRU A, VIGNAL C, GENEVOIS O, PAQUES M—NICE, Paris, Rouen

- T131 A new technique of noninvasive evaluation of the intracranial pressure with retinal vessel analyzer  
GENEVOIS O, MURAIN M, PAQUES M—Rouen, Paris
- T132 Persistence of treatment effect of idebenone in Leber's Hereditary Optic Neuropathy  
★  
FSADNI MG, KLOPSTOCK T, METZ G, YU-WAI-MAN P, BÜCHNER B, GALLENMÜLLER C, BAILIE M, NWALI N, GRIFFITHS PG, RUDOLPH G, KORTÜM K, ROULEAU J, COPPARD N, MEIER T, CHINNERY PF—Harpending, Munich, Liestal, Newcastle upon Tyne, Montreal
- T133 An interesting case of Mohr-Tranebjærg Syndrome  
HALFELD FURTADO DE MENDONCA R, ABBRUZZESE S, FERREIRA EL—Rome, Juiz de Fora
- T134 Dyslexia and eye movements  
VAGGE A, CAVANNA M, IESTER M, PARISIO A, BURTOLO C, TRAVERSO CE—Genoa
- T135 Aicardi syndrome with macrocrania  
DEGOUMOIS A, LUX AL, RYSANEK B, PONTE K, EMERY E, DENION E—Caen
- T136 Postural control in children with early strabismus without amblyopia  
ORSSAUD C, GAERTNER C, CREUX C, ESPINASSE-BERROD MA, ROCHE O, DUFIER JL, KAPOULA Z—Paris
- T137 Visual function improvement after idebenone therapy in Leber hereditary optic neuropathy  
ORSSAUD C, ROBERT M, ROCHE O, DUFIER JL—Paris
- T138 Analysis of changes in the macula and retinal nerve fiber layer by optical coherence tomography in patients with Alzheimer's disease (AD)  
CRUZ N, CASAS P, ASCASO F, CRISTOBAL JA, DEL BUEY MA, MINGUEZ E—Zaragoza
- T139 Neurotrophic keratopathy associated with congenital agenesis of the corpus callosum  
HERRERO LATORRE R, GARCIA-MARTIN E, DE LA MATA G, SATUE M, BAMBO MP, ARA M, EGEA MC, FERNANDEZ-PEREZ S, PUEYO V—Zaragoza
- T140 Altered functional connectivity of primary visual cortex in adult comitant strabismus using resting-functional mri  
YAN X, LIN X, ZHOU Y, LIU Y, JIANG T—Guangzhou, Beijing
- T141 Comparison of latency of P100 wave in children demonstrating some pathological disorders  
PILECKI W, RUSIECKI L, KALKA D, SZAWROWICZ T—Wrocław
- T142 The use of propranolol in the treatment of periocular infantile hemangiomas  
rf  
BUIJSROGGE M, CLAERHOUT I, DELBEKE P, WALRAEDT S, DECOCK C—Ghent
- T143 Generating human retinal ganglion cells from human induced pluripotent cells in feeder and feeder-free conditions  
rf  
ALSHAMEKH S, HERTZ J, DEROSA B, UDDIN S, PATEL R, SALERO E, DYKXHOORN D, GOLDBERG JL—Miami



THURSDAY

**SIS RV**      **Retinal oximetry - challenges, possibilities and future outlook**      **Uranie**  
Rebekka HEITMAR, Einar STEFANSSON

|       |   |      |  |
|-------|---|------|--|
| 18:00 | ★ | 2811 | Retinal oxygen saturation in health and disease<br>HARDARSON S—Reykjavik   |
| 18:12 | ★ | 2812 | Light flicker and oxygen saturation in diabetes<br>HAMMER M, HELLER T, JENTSCH S, MANDECA A, SCHWEITZER D, MÜLLER UA—Jena    |
| 18:24 |   | 2813 | Diabetic retinopathy and oximetry<br>BEK T—Denmark   |
| 18:36 | ★ | 2814 | Oxygen metabolism in age related macular degeneration<br>STEFANSSON E, GEIRSDOTTIR A, HARDARSON S—Reykjavik                  |
| 18:48 | ★ | 2815 | Extraneous factors affecting retinal oximetry<br>HUDSON C, PATEL SR, SHAHIDI AM, KULASEKARA S, FLANAGAN JG—Waterloo, Toronto |
| 19:00 |   | 2816 | Clinical aspects of retinal oximetry<br>GIBSON J—Birmingham  |
| 19:12 |   | 2817 | Oxygen distribution in the retina<br>POURNARAS CJ—Geneva   |

**JM**      **EVICR.net: Clinical trials in diabetic retinopathy and retinal vascular disease**

Jose CUNHA-VAZ

Euterpe



|       |  |      |   |
|-------|--|------|---|
| 18:00 |  | 2821 | Novel therapeutic targets in diabetic retinopathy<br>SCHLINGEMANN RO—Amsterdam  |
| 18:10 |  | 2822 | Investigator-initiated trials: a corporate perspective<br>LAMBROU G—Strasbourg  |
| 18:20 |  | 2823 | Perspectives for new treatments at Allergan<br>MALTMAN J—Buckinghamshire  |
| 18:30 |  | 2824 | Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures. Protocol n° ECR-RET-2010-02. ClinicalTrials.gov Identifier: NCT01145599<br>CUNHA-VAZ J—Coimbra   |
| 18:40 |  | 2825 | Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomised controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest Diabetic Retinopathy. EUROCONDOR – EU FP7 Project<br>CUNHA-VAZ J—Coimbra          |
| 18:50 |  | 2826 | Prospective, randomized, multicenter, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus and PRP in monotherapy in the treatment of patients with high risk proliferative diabetic retinopathy. PROTEUS<br>FIGUEIRA J—Coimbra |
| 19:00 |  |      | Open discussion   |



**SIS** **As lamellar as possible: an update on pros and cons of corneal lamellar surgery** **Erato**

**COS** Jean-Jacques GICQUEL, Mario NUBILE

|       |      |  |
|-------|------|--|
| 18:00 | 2831 | Interface quality of endothelial keratoplasty buttons obtained with optimised femtosecond laser settings<br>BOURGES JL–Paris |
| 18:18 | 2832 | Microkeratome vs femtosecond laser assisted endothelial transplant cut<br>TOUBOUL D–Bordeaux                                 |
| 18:36 | 2833 | The interest of imaging for corneal lamellar grafting<br>NUBILE M–Chieti   |
| 18:54 | 2834 | New trends in endothelial transplantation: DSAEK vs DMEK<br>SCORCIA V–Catanzaro  |
| 19:12 | 2835 | Is there still room for penetrating keratoplasty in 2012<br>GICQUEL JJ–Poitiers  |

**FP** **Ocular immunology for 360° from basic science to clinical practice** **Thalie**

**IM** Talin BARISANI-ASENBAUER, Uwe PLEYER

|       |                   |  |
|-------|-------------------|--|
| 18:00 | 2841              | New therapeutic approaches in uveitis<br>FERAOUN N, HESBERT A, MONNET D, BREZIN A, BATTEUX F–Paris   |
| 18:12 | 2842              | Inflammasome activation by oxidative stress in ARPE-19 cells<br>KAUPPINEN A, LAAKSO N, KINNUNEN K, SALMINEN A, KAARNIRANTA K–Kuopio  |
| 18:24 | 2843              | IL-17A as a possible target of anti-inflammatory and anti-parasitic treatment in toxoplasmic uveitis<br>SAUER A, PFAFF A, CREUZOT-GARCHER C, DALLE F, CHIQUET C, PELLOUX H, SPEEG-SCHATZ C, CANDOLFI E, BOURCIER T–Strasbourg, Dijon, Grenoble       |
| 18:36 | 2844              | Immune responses to model antigen elicited by immunization via conjunctiva associated lymphoid tissue<br>BARISANI-ASENBAUER T, BELIJ S, STOJANOVIC M, MARINKOVIC E, STOJICEVIC I, MONTANARO J, STEIN E, BINTNER NORA, INIC-KANADA A–Vienna, Belgrade |
| 18:48 | 2845              | Secondary choriocapillaritis in infectious choroiretinitis<br>KNECHT P, MOKRIM R, HERBORT CP–Lausanne  |
| 19:00 | 2846              | Central serous chorioretinopathy misdiagnosed as posterior uveitis: frequency and consequences<br>PAPADIA M, HERBPRT CP–Lausanne   |
| 19:12 | 2847<br><i>rf</i> | Atypical panuveitis parasitic and Herpes virus co-infection in immunocompetent adults: real co-infection or false positive?<br>NGUYEN AM, DENIS P, GRANGE JD, KODJIKIAN L–Lyon   |

**SIS** **Eye and brain in glaucoma** **Clio**

**G** Georg MICHELSON, Doina GHERGHEL

|       |      |  |
|-------|------|--|
| 18:00 | 2851 | Intracranial pressure and glaucoma<br>JONAS JB–Erlangen  |
| 18:18 | 2852 | Quantitative assessment of the visual pathway by DTI-MRI in Glaucoma<br>MICHELSON G, WAERNTGES S, ENGELHORN T, HORNEGGER J, DÖRFLER A–Erlangen |
| 18:36 | 2853 | Autonomic nervous system dysfunction in glaucoma<br>GHERGHEL DOINA–Birmingham  |
| 18:54 | 2854 | Neurodegeneration of the visual pathway in glaucoma<br>CORDEIRO MF–London  |
| 19:12 | 2855 | Neuroprotective therapy of the visual pathway in glaucoma<br>ARAI E M–Tokyo  |



**SIS** **Retinal vessel analysis - biomarkers and new developments** **Gallieni 1&2**  
**PBP** Leopold SCHMETTERER

|         |      |  |
|---------|------|--|
| 18:00   | 2861 | Retinal vessels as biomarkers<br>SCHMETTERER L—Vienna  |
| 18:22   | 2862 | Combining vessel analysis with Doppler OCT<br>GARHOFER G—Vienna                                      |
| 18:44 ★ | 2863 | Retinal vessel analysis and oximetry - technical advances and clinical applications<br>HAMMER M—Jena |
| 19:06   | 2864 | Retinal vessel analysis in animal models<br>SCHMETTERER L—Vienna                                     |

**SIS** **Metastatic disease from uveal melanoma: prediction, detection and treatment** **Gallieni 4**  
**PO** Sarah COUPLAND, Bertil DAMATO

|       |      |   |
|-------|------|---|
| 18:00 | 2871 | Biology of metastatic disease<br>COUPLAND SE, KALIRAI H, DODSON A, DAMATO B—Liverpool   |
| 18:12 | 2872 | Genetic analyses of uveal melanoma metastases<br>SAULE S, COUTURIER J, STERN MH, MARIANI P, DESJARDINS L, ROMAN-ROMAN S, BARILLOT E, PIPERNO-NEUMANN S, LAURENT C—Paris |
| 18:24 | 2873 | Prediction of metastasis<br>DAMATO B, COUPLAND SE—Liverpool   |
| 18:36 | 2874 | Serum biomarkers of metastatic disease: current practice and future perspectives<br>ANGI M, KALIRAI H, DAMATO B, COUPLAND SE—Liverpool                                  |
| 18:48 | 2875 | Staging of uveal melanoma metastases<br>KIVELÄ T, ESKELIN S—Helsinki  |
| 19:00 | 2876 | Metastatic uveal melanoma: A liver disease or a systemic disease?<br>KEILHOLZ U—Berlin  |
| 19:12 | 2877 | Therapeutic options in metastatic uveal melanoma<br>PIPERNO-NEUMANN S—Paris   |

**SIS** **Educational case presentations in ophthalmic genetics** **Gallieni 3**  
**MBGE** Bart LEROY, Graeme CM BLACK

|       |      |   |
|-------|------|---|
| 18:00 | 2881 | Difficult counselling issues<br>HALL G—Manchester     |
| 18:22 | 2882 | Syndromic ophthalmic genetics<br>BLACK GCM—Manchester |
| 18:44 | 2883 | Mitochondrial optic neuropathies<br>VOTRUBA M—Cardiff |
| 19:06 | 2884 | Inherited retinal disease<br>LEROY BP—Ghent           |



The background is a light green gradient with a complex pattern of thin, white, overlapping lines that create a sense of motion and depth. A white rectangular box is positioned in the upper right quadrant, containing the date information in a bold, green, sans-serif font.

**FRIDAY  
OCT 12  
2012**





# BREAKFAST CIS

Uranie

The Alcon logo is displayed in a white box on the left side of a purple banner. The logo consists of the word "Alcon" in a bold, blue, sans-serif font.

An innovative new approach to treating  
vitreomacular traction and macular hole

Moderator: Albert J. AUGUSTIN

|       |   |
|-------|---|
| 07:15 | Welcome and introductions                                     |
| 07:20 | Vitreomacular adhesion: pathology and implications            |
| 07:30 | Vitreomacular traction: resolution with enzymatic vitreolysis |
| 07:45 | Macular holes: an option for pharmacologic management         |
| 08:00 | Panel discussion  |

FRIDAY

**SIS RV** **Central serous chorioretinopathy: what's new?** **Uranie**  
Francine BEHAR-COHEN, Alain GAUDRIC

|         |      |   |
|---------|------|---|
| 08:15   | 3211 | CSCR/ DRPE : a same disease?<br>GAUDRIC A-Paris   |
| 08:33 ★ | 3212 | Correlation between spectral-domain OCT features and fundus auto-fluorescence patterns in CSCR<br>BANDELLO F-Milano |
| 08:51   | 3213 | Role of corticosteroids in CSCR<br>POURNARAS CJ-Geneva  |
| 09:09   | 3214 | Photodynamic therapy in the treatment of CSCR<br>RUIZ MORENO JM-Alicante  |
| 09:27   | 3215 | Other therapeutic options<br>BEHAR-COHEN F-Paris  |

**JM** **EVICR.net: Clinical trials in AMD and rare diseases** **Euterpe**  
Jose SAHEL



|       |      |  |
|-------|------|--|
| 08:15 | 3221 | Markers of disease progression in atrophic AMD<br>HOLZ F, FLECKENSTEIN M, SCHMITZ-VALCKENBERG S-Bonn |
| 08:25 | 3222 | Gene therapy in rare diseases<br>SAHEL JA-Paris  |
| 08:35 | 3223 | Perspectives for new treatments at Novartis<br>BURIAN G-Basel  |
| 08:45 | 3224 | Perspectives for new treatments at Alcon - part 2<br>RICH C-Fort Worth                               |
| 08:55 | 3225 | Study Assessing Double-masKed Uveitis tReAtment (SAKURA)<br>NAOR J-Emeryville                        |
| 09:05 | 3226 | Stargardt macular dystrophy<br>HOLZ F, SCHMITZ-VALCKENBERG S, CHARBEL ISSA P-Bonn                    |
| 09:15 | 3227 | Sparing of the fovea in geographic atrophy<br>HOLZ F, SCHMITZ-VALCKENBERG S, FLECKENSTEIN M-Bonn     |
| 09:25 |      | Open discussion  |

**SIS PBP** **Neuronal death processes in retinal disease** **Erato**  
Neville OSBORNE

|         |      |  |
|---------|------|--|
| 08:15   | 3231 | Autophagy: a new way to retinal neuroprotection<br>RUSSO R, BAGETTA G, CORASANITI MT-Cosenza, Catanzaro  |
| 08:33   | 3232 | Neuroprotective factors against retinal injury in response to hypoxia: new perspectives<br>BAGNOLI P, DAL MONTE M-Pisa   |
| 08:51   | 3233 | Retinal neuronal death caused by ocular hypertension<br>VIDAL-SANZ M, SALINAS-NAVARRO M, VALIENTE-SORIANO FJ, ORTIN-MARTÍNEZ A, NADAL-NICOLÁS FM, ALARCÓN-MARTÍNEZ L, AVILÉS-TRIGUEROS M, AGUDO-BARRIUSO M, VILLEGAS-PÉREZ MP-Murcia |
| 09:09 ★ | 3234 | RIP Kinases, necroptosis and redundancy in neuronal cell death<br>VAVVAS D, MURAKAMI Y, KAYAMA M, MILLER JW-Boston   |
| 09:27   | 3235 | Neuroprotection and autoimmunity in glaucoma<br>GRUS F-Mainz   |

**SIS** **Beyond age related macular degeneration** **Thalie**  
**IM** Piergiorgio NERI, Andrew DICK

|       |      |  |
|-------|------|--|
| 08:15 | 3241 | Molecular pathology of inflammation in age-related macular degeneration<br>CHAN C—Bethesda |
| 08:37 | 3242 | Parainflammation and the ageing retina<br>XU H—Belfast                                     |
| 08:59 | 3243 | Imaging and the ageing retina<br>KEANE PA—London   |
| 09:21 | 3244 | Macrophages and the ageing and diseased retina<br>LUHMANN U—London                         |

**SIS** **Structure and function in glaucoma management** **Clio**  
**G** Ingeborg STALMANS, Luca ROSSETTI



|       |      |   |
|-------|------|---|
| 08:15 | 3251 | Why should we care about rate of progression in glaucoma management?<br>STALMANS I—Leuven |
| 08:33 | 3252 | Detecting progression using visual fields<br>ROSSETTI L—Milano                            |
| 08:51 | 3253 | Detecting progression using structural measurements<br>BRON A—Dijon                       |
| 09:09 | 3254 | Linking it together: structure-function correlation<br>SUNARIC MEGEVAND G—Geneva          |
| 09:27 | 3255 | Into practice: clinical examples<br>STALMANS I—Leuven                                     |

**SIS** **Controversies in neuro-ophthalmology and paediatrics** **Gallieni 1&2**  
**NSPH** Andrzej GRZYBOWSKI, Francisco ASCASO

|       |      |  |
|-------|------|--|
| 08:15 | 3261 | GCA diagnosis controversies<br>HAWLINA M—Ljubljana   |
| 08:33 | 3262 | Strabismus surgery: minimally invasive or not?<br>MOJON D—Zurich   |
| 08:51 | 3263 | Atropine use in childhood myopia treatment<br>GRZYBOWSKI A—Poznan  |
| 09:09 | 3264 | Is the eye a window to the mind? RNFL thickness measurements by OCT as a biomarker for neurodegenerative diseases<br>ASCASO F—Zaragoza |
| 09:27 | 3265 | Controversies related to mfVEP use<br>CASTELO-BRANCO M, REIS A—Coimbra   |

FRIDAY

**SIS  
EOVS****Myopia – genesis, prevalence and control**

Franziska RAUSCHER

Gallieni 4




|         |      |   |
|---------|------|---|
| 08:15   | 3271 | Visual, ocular and refractive development in children<br>SCHAEFFEL F–Tübingen                               |
| 08:37 ★ | 3272 | Myopia - Its etiology and prevalence<br>SANKARIDURG P–Sydney  |
| 08:54 ★ | 3273 | The influence of peripheral refractive errors on myopia development<br>OHLENDORF A–Aalen                    |
| 09:11   | 3274 | Correction of peripheral refractive errors and its impact on visual performance<br>ATCHISON DA–Kelvin Grove |
| 09:28 ★ | 3275 | (New) Approaches to reduce progression of myopia with spectacles from Carl Zeiss Vision<br>KRATZER T–Aalen  |

**FP  
PO****Uveal melanoma**

Martine J JAGER, Ann SCHALENBOURG

Gallieni 3

|   |      |  |
|---|------|--|
| 08:15   | 3281 | A comparison of HLA genotype with inflammation in uveal melanoma<br>JAGER MJ, VAN ESSEN TH, BRONKHORST IHG, VERDUYN W, ROELEN DL, MAAT W, LUYTEN GPM–Leiden  |
| 08:27  | 3282 | Proteomic analysis of uveal melanoma<br>RAMASAMY P, HENRY M, LINGE A, HORGAN N, MURPHY C, CLYNES M, KENNEDY S, MELEADY P–Dublin  |
| 08:39   | 3283 | Pre-clinical analysis of Crizotinib in uveal melanoma<br>DE LANGE MJ, VERSLUIS M, JAGER MJ, LUYTEN GPM, VAN DER VELDEN PA–Leiden   |
| 08:51   | 3284 | Temperature-dependent vascular endothelial growth factor (VEGF) induction in human retinal pigment epithelium – implications for transpupillary thermotherapy in uveal melanoma<br>KLETTNER A, FABY H, HILLENKAMP J, ROIDER J–Kiel |
| 09:03   | 3285 | Primary transpupillary thermotherapy for small suspicious choroidal nevi<br>TURCOTTE S, BERGERON D, ROUSSEAU A, MOURIAUX F–Quebec  |
| 09:15   | 3286 | Ultrasound features changing during uveal melanoma local treatment<br>AMIRYAN AG, SAAKYAN S– Moscow  |





## KEYNOTE LECTURE

Uranie

Genetics and treatment of Stargardt disease  
Rando ALLIKMETS

|       |      |   |
|-------|------|---|
| 09:50 |      | Introduction by Bart LEROY  |
| 10:00 | 3311 | Genetics and treatment of Stargardt disease<br>ALLIKMETS R–New York |
| 10:30 |      | Award of the EVER certificate of honour                             |

FRIDAY

**SIS** **Endophthalmitis from the ocular surface to the vitreous: prevention, diagnosis, treatment** **Uranie**

**RV** Christophe CHIQUET, Alain BRON

|       |      |   |
|-------|------|---|
| 11:00 | 3411 | Prevention of endophthalmitis in cataract surgery<br>MONTAN P—Stockholm   |
| 11:18 | 3412 | Is there a rationale for the use of topical antibiotics before and after intravitreal injections<br>LABETOULLE M—Le Kremlin Bicêtre |
| 11:36 | 3413 | Microbiological diagnosis of bacterial endophthalmitis<br>CHIQUET C—Grenoble  |
| 11:54 | 3414 | Management of postoperative endophthalmitis<br>BRON A—Dijon   |

**JM** **EVICR.net: Reading centres** **Euterpe**

Tunde PETO

|       |      |  |
|-------|------|--|
| 11:00 | 3421 | EVICR.net Reading Centre Network<br>PETO T, EVICR.NET READING CENTRE EXPERT COMMITTEE—London |
|-------|------|--|



**FP** **From banking to grafting** **Erato**

**COS** Vincent BORDERIE, Christopher LIU

|         |                   |   |
|---------|-------------------|---|
| 11:00   | 3431              | Risk factors for endothelial cell loss after corneal transplantation<br>BORDERIE V, BULLET J, TOUZEAU O, BASLI E, LAROCHE L—Paris   |
| 11:12   | 3432              | Delivery of molecules into corneal endothelium using nanoparticles activated by femtosecond laser pulses: proof of concept<br>JUMELLE C, CAMPOLMI N, BERNARD A, PISELLI S, AUDOUARD E, GRANIER J, SODER H, GAIN P, THURET G—Saint-Etienne |
| 11:24   | 3433              | Characterization of cell cycle modifications induced by electric pulses in human corneal endothelium<br>HA THI BM, HE Z, CAMPOLMI N, PISELLI S, GAIN P, PEOC'H M, DUMOLLARD JM, ACQUART S, GARRAUD O, THURET G—Saint-Etienne              |
| 11:36 ★ | 3434              | Inhibition of Apaf-1 as a potential therapeutic strategy to improve corneal quality<br>HERRERO C, MARCHAN S, TRAVER E, MONTAVA R, ORZAEZ M, SANCHO M, GUIMERÀ A, VILLA R, PEREZ-PAYÀ E, LAGUNAS C—Barcelona, Valencia, Bellaterra         |
| 11:48   | 3435              | Impact of corneal donor post-mortem time on the rate of culture medium contaminations<br>GRUENERT A, ROSENBAUM K, GEERLING G, FUCHSLUGER T—Duesseldorf  |
| 12:00   | 3436<br><i>rf</i> | Big bubble technique dissection plane: histological and ultrastructural comparative analysis on both white and clear margin dissected corneas<br>IRION L, MCKEE H, BRAHMA A, CARLEY F—Manchester  |
| 12:06   | 3437<br><i>rf</i> | Rabbit, rat and pig corneas: main characteristics and storage in organ culture<br>HE Z, CROUZET E, PISELLI S, CAMPOLMI C, FOREST F, PEOC'H M, DUMOLLARD JM, GAIN P, THURET G—Saint-Etienne  |

FRIDAY

**SIS** **Research challenges of anti-microbial ocular therapy** **Thalie**  
**IM** Regis KOWALSKI

- |         |      |   |
|---------|------|---|
| 11:00   | 3441 | Clinical challenges of ocular anti-microbial therapy<br>RAJU L–Pittsburgh           |
| 11:22 ★ | 3442 | Is there an anti-adenoviral drug on the horizon?<br>ROMANOWSKI E–Pittsburgh         |
| 11:44   | 3443 | Biofilms in ocular infection<br>SHANKS RM, ROMANOWSKI E, KOWALSKI R–Pittsburgh      |
| 12:06   | 3444 | Is antibiotic resistance a major problem in ophthalmology?<br>KOWALSKI R–Pittsburgh |

**SIS** **Controversies in current concepts of glaucoma** **Clio**  
**G** Sayeh POURJAVAN, Andrzej GRZYBOWSKI

- |       |      |  |
|-------|------|--|
| 11:00 | 3451 | Historical concepts of glaucoma<br>GRZYBOWSKI A–Poznan                               |
| 11:22 | 3452 | Pathogenesis of glaucoma: does light play a part in the process?<br>OSBORNE N–Oxford |
| 11:44 | 3453 | Non-IOP lowering treatment<br>MOZAFFARIEH M–Basel                                    |
| 12:06 | 3454 | Biomechanical concepts in Glaucoma<br>KOTECHA AACHA–London                           |

**SIS** **Vascular tumours of the retina and choroid** **Gallieni 1&2**  
**PO** Tero KIVELÄ, Ann SCHALENBOURG

- |       |      |  |
|-------|------|--|
| 11:00 | 3461 | Vascular tumours of the retina and choroid: classification, diagnosis and treatment<br>SCHALENBOURG A–Lausanne   |
| 11:12 | 3462 | Coats' disease: classification and current treatment<br>MUNIER F–Lausanne  |
| 11:24 | 3463 | Coats' reaction and angiomas of the retina from mutations affecting telomere maintenance<br>KIVELÄ T, LINDAHL P, POLVI A, MAJANDER A, MÄKITIE O, LEHESJOKI AE, LINNANKIVI T–Helsinki                 |
| 11:36 | 3464 | Von Hippel-Lindau's disease: general and ocular management<br>GAUDRIC A–Paris  |
| 11:48 | 3465 | Choroidal hemangioma: photodynamic vs. radiotherapy<br>ZOGRAFOS L–Lausanne   |
| 12:00 | 3466 | Debate: Epi- and peripapillary capillary hemangiomas and hemangioblastomas: in search of an optimal therapeutic approach<br>GAUDRIC A, DAMATO B, DESJARDINS L, ZOGRAFOS L–Paris, Liverpool, Lausanne |

FRIDAY

FP  
EOVS**Colour vision**

Werner SPILEERS, Miguel CASTELO-BRANCO


Gallieni 4

|         |      |   |
|---------|------|---|
| 11:00   | 3471 | Predicting chromatic sensitivity in normal trichromats and in subjects with congenital deficiency<br>BARBUR JL, RODRIGUEZ-CARMONA M—London                        |
| 11:12   | 3472 | The contribution of the rod/melanopsin driven ganglion cells to the dynamic pupil light reflex response<br>BIW, TSUJIMURA S, PLANT G, BARBUR JL—London, Kagoshima |
| 11:24   | 3473 | Colour vision as a screening tool for sub-clinical retinal disease<br>KONSTANTAKOPOULOU E, BARBUR JL—London   |
| 11:36 ★ | 3474 | Effects of viewing time of pseudoisochromatic plates<br>KRASTEL H, LEERS S, KALTAKJI F, KIRCHHUEBEL R, JONAS JB—Mannheim, Sulzbach, Wetzlar                       |
| 11:48   | 3475 | Age-corrected monocular limits of normal trichromacy<br>RODRIGUEZ - CARMONA M, KONSTANTAKOPOULOU E, KEUKEN A, BARBUR JL—London, Kestern                           |
| 12:00   | 3476 | Detection of colour vision changes in patients with systemic diseases that can affect the eye<br>KEUKEN A, RODRIGUEZ-CARMONA M, BARBUR JL—London                  |

FP  
LC**Cataract surgery**

Marie - José TASSIGNON, Rafael I. BARRAQUER

Gallieni 3

|   |      |   |
|---|------|---|
| 11:00   | 3481 | Evolution of cataract surgery: Barraquer experience<br>DE LA PAZ M, BARRAQUER J, ALVAREZ DE TOLEDO JP—Barcelona   |
| 11:12   | 3482 | Efficacy of surgical simulator training versus traditional wetlab training on the complication rate during capsulorrhexis portion of cataract surgery in trainees<br>DALY MK, SIRACUSE-LEE D, LEGUTKO PA—Boston, Novato |
| 11:24  | 3483 | Intracameral cefuroxime injection at the end of cataract surgery reduces the incidence of endophthalmitis, a French study<br>BARREAU G, MOUNIER M, MARIN B, ADENIS JP, ROBERT PY—Limoges                                |
| 11:36   | 3484 | Morphology of age-related cuneiform cortical cataracts: the case for mechanical stress.<br>MICHAEL R, VRENSSEN G, BARRAQUER RI—Barcelona, Leiden  |
| 11:48 ★   | 3485 | Contribution of 3D anterior segment reconstruction by rotative UBM to the sizing of phakic IOL<br>MAINDRON C, LE LOIR M, KOHANDANI TAFRESHI M, LAMARD M, COCHENER B—Brest   |
| 12:00   | 3486 | Influence of multifocal intraocular lenses on standard automated perimetry test results<br>AYCHOUA N, JUNOY MONTOLIO F, JANSONIUS NM—Groningen  |

## LUNCHTIME CIS

Uranie



Focus on Inflammation in retinal disease

Moderators: Gabriel COSCAS, Francesco BANDELLO

|       |      |   |
|-------|------|---|
| 12:35 | 3511 | Inflammation in retina disease<br>TADAYONI R-Paris          |
| 12:47 | 3512 | Early markers of inflammation<br>BEHAR-COHEN F-Paris        |
| 12:59 | 3513 | Clinical markers of inflammation<br>COSCAS G-Creteil        |
| 13:11 | 3514 | Inflammation in uveitis<br>DE SMET M-Lausanne               |
| 13:23 | 3515 | Management of inflammation in RVO<br>LOEWENSTEIN A-Tel Aviv |
| 13:35 |      | End of session  |



FRIDAY

**SIS** **Macular surgery** **Uranie**  
**RV** Efstratios MENDRINOS, Constantin POURNARAS

|       |      |   |
|-------|------|---|
| 13:35 | 3611 | Revisiting transconjunctival sutureless 25 gauge vitrectomy for macular surgery<br>GOTZARIDIS S, LIAZOS ST, MORPHIS G—Athens                            |
| 13:53 | 3612 | Myopic foveoschisis: OCT findings, surgical indications and results<br>GAUDRIC A—Paris  |
| 14:11 | 3613 | Clinical and OCT outcomes for full-thickness and lamellar macular hole surgery<br>STAPPLER T—Liverpool  |
| 14:29 | 3614 | Morphology of surgical ILM-specimens in epiretinal membranes, macular holes, and diabetic retinopathy<br>POURNARAS CJ—Geneva                            |
| 14:47 | 3615 | Vitrectomy with subretinal t-PA, gas tamponade and intravitreal ranibizumab for the treatment of submacular hemorrhage due to AMD<br>MENDRINOS E—Geneva |

**JM** **EVICR.net: General Assembly (members only)**

**Euterpe**

**SIS** **Therapeutics in the pipeline for unmet needs in ophthalmology** **Erato**  
**COS** Thomas FUCHSLUGER, Einar STEFANSSON

|         |      |  |
|---------|------|--|
| 13:35   | 3631 | Gene therapy approaches in corneal pathologies<br>FUCHSLUGER T—Düsseldorf  |
| 13:53 ★ | 3632 | Nanoparticles for drug delivery<br>STEFANSSON E, GUDMUNSDOTTIR B, ASGRIMSDOTTIR G, LOFTSSON T—Reykjavik  |
| 14:11   | 3633 | Recombinant NFG for treatment of ocular surface diseases<br>BONINI S—Rome  |
| 14:29   | 3634 | SEGRAs a new therapeutic option on the horizon?<br>PLEYER U—Berlin   |
| 14:47   | 3635 | Synthetic eye prosthesis<br>STORSBERG J, SCHMIDT C, REHFELDT S, KOBUCH K, MESSNER A, RÖTHGEN H, DUNCKER GIW, KNAK M, CORDES A, SCHRAGE N, NASS N, SEL S—Potsdam, München, Sankt Augustin, Halle, Cologne, Aachen, Erlangen-Nuremberg |

**JM** **ARVO@EVER: Translating ocular immunology from the laboratory to the clinic** **Thalie**

**IM** Justine SMITH, Sally ATHERTON



|       |      |   |
|-------|------|---|
| 13:35 | 3641 | Translating ocular immunology from the laboratory to the clinic - keratoplasty - PLEYER U–Berlin      |
| 13:57 | 3642 | Exploiting the immune response to halt progression of ocular melanoma MCKENNA KC–Pittsburgh           |
| 14:19 | 3643 | Regulatory T cell therapy for uveitis BODAGHI B–Paris   |
| 14:41 | 3644 | Immunological aspects of age-related macular degeneration: implications for treatment CHAN C–Bethesda |

**SIS** **Recent developments in ocular blood flow and glaucoma** **Clio**

**G** Ingeborg STALMANS, Leopold SCHMETTERER

|       |      |  |
|-------|------|--|
| 13:35 | 3651 | Individual ONH blood flow patterns during changes in perfusion pressure SCHMETTERER L–Vienna |
| 13:57 | 3652 | Metabolism in glaucoma using retinal oximetry STALMANS I–Leuven                              |
| 14:19 | 3653 | Spontaneous venous pulsation revisited - relevance to glaucoma? PINTO LA–Lisboa              |
| 14:41 | 3654 | From retinal venous pressure to intra-cranial pressure in glaucoma JONAS JB–Mannheim         |

**FP** **AMD** **Gallieni 1&2**

**RV** Gisèle SOUBRANE, Anita LEYS

|         |      |   |
|---------|------|---|
| 13:35   | 3661 | The LDL receptor in the retina: the missing link in aging, the new target in dietary prevention BRETILLON L, SIMON E, ACAR N, BRON A, CREUZOT-GARCHER C–Dijon   |
| 13:47   | 3662 | Aflibercept in clinical practice: Evaluation of the first 50 patients treated with antiVEGF trap for age-related macular degeneration BARBAZETTO I, SORENSON J, ENGELBERT M–New York  |
| 13:59   | 3663 | Lutein decreases complement factor D in age-related macular degeneration BERENDSCHOT T, TIAN Y, VAN DER VEEN R, MAKRIDAKI M, MURRAY I, KIJLSTRA A–Maastricht, Manchester  |
| 14:11   | 3664 | Relevance of complement factor H polymorphisms in the response to intravitreal bevacizumab in exudative age-related macular degeneration BOLTZ A, JONAS JB, PALKOVITS S, TAO Y, RENSCH F, WEGER M, GARHÖFER G, FRANTAL S, EL-SHABRAWI Y, SCHMETTERER L–Vienna, Mannheim, Graz |
| 14:23   | 3665 | A randomized observer and subject masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration TOLD R, BINDER S, KREBS I, BOLTZ A, SCHMETTERER L–Vienna                            |
| 14:35 ★ | 3666 | Retrospective analysis of the real-world utilization of ranibizumab in wAMD TADAYONI R, HOLZ F, HEAH TGH, HELDNER S, THE AURA STEERING COMMITTEE FOR–Paris, Bonn, Montville, Berlin   |



**SIS  
NSPH****Ocular surface disorders in children****Gallieni 4**

Jean-Jacques GICQUEL, Dominique BREMOND-GIGNAC

|         |      |   |
|---------|------|---|
| 13:35 ★ | 3671 | Diagnosis and treatment of vernal conjunctivitis<br>BREMOND-GIGNAC D—Amiens   |
| 13:53   | 3672 | Cutaneous and ocular signs of childhood rosacea<br>MORTEMOSQUE B—Bordeaux   |
| 14:11   | 3673 | The indications of cyclosporine A in children 's ocular surface diseases<br>DOAN S—Paris  |
| 14:29   | 3674 | Limbal stem cell deficiency in children<br>YEUNG A—Nottingham   |
| 14:47   | 3675 | Noninvasive assessment of the tear film stability in children<br>GICQUEL JJ, PISELLA PJ, BREMOND-GIGNAC D—Poitiers, Tours, Amiens |

**FP  
PO****Basic mechanisms in ocular pathology****Gallieni 3**

Steffen HEEGAARD, Karin LOEFFLER

|       |                   |  |
|-------|-------------------|--|
| 13:35 | 3681              | RUNX2 expression in conjunctival melanocytic proliferations<br>MOULIN A, NICOLAS M, HAMEDANI M, SCHALENBOURG A, ZOGRAFOS L—Lausanne  |
| 13:47 | 3682<br><i>rf</i> | Valproic acid (VPA), a class I and II histone deacetylase (HDAC) inhibitor and conjunctival melanoma<br>MADIGAN MC, MUNOZ-ERAZO L, CONWAY RM—Sydney  |
| 13:53 | 3683              | Macrophage markers and C3d in the central & peripheral choroid of young, aged and amd eyes<br>MADIGAN MC, VAN DEN BERG C, MORELAND A, LIANG J, LORD S, DEMIR A, JAISWAL S, JAGER MJ—Sydney, Leiden |
| 14:05 | 3684              | Ophthalmological manifestations of IgG4-related disease<br>PHILIPPAKIS E, TOUITOU V, CHARLOTTE F, RIGOLET A, LEHOANG P, BLOCH-QUEYRAT C, BODAGHI B—Paris   |
| 14:17 | 3685<br><i>rf</i> | Idiopathic orbital inflammation: a report of 18 cases<br>COFFIN-PICHONNET S, LANGLOIS B, JACOMET PV, PUTTERMAN M, BADELON I, MORAX S, GALATOIRE O—Caen, Paris                                      |
| 14:23 | 3686<br><i>rf</i> | A patient with eyelid and anterior orbital myeloproliferative hypereosinophilic syndrome<br>DE KEIZER RJW, AL SABAI N, BAL TA, DE GROOT V—Antwerp, Mechelen  |
| 14:29 | 3687<br><i>rf</i> | Congenital orbital teratoma<br>ROSNER M, FABIAN ID, PRIEL A, FRIDMAN E, GREENBERG G, ROSEN N—Tel Hashomer  |





### Business meetings of the scientific sections

- ACB - Anatomy / Cell Biology ..... Gallieni 4
- COS - Cornea / Ocular Surface ..... Erato
- EOVS - Electrophysiology, Physiological Optics, Vision Sciences ..... Gallieni 3
- G - Glaucoma ..... Clío
- IM - Immunology / Microbiology ..... Thalie
- LC - Lens and Cataract ..... Gallieni 3
- MBGE - Molecular Biology / Genetics / Epidemiology ..... Gallieni 1&2
- NSPH - Neuro-ophthalmology / Strabismology / Paediatric ophthalmology / History ..... Thalie
- PO - Pathology / Oncology ..... Gallieni 4
- PBP - Physiology / Biochemistry / Pharmacology ..... Gallieni 1&2
- RV - Retina / Vitreous ..... Uranie

### Agenda

1. Report of the chair of section
2. Report of the programme secretary
3. Next year's meeting:
  - nomination of the 2013 section programme secretary (different from the section chair)
  - proposals of 2013 Special Interest Symposia (SIS)
  - proposals of 2013 Courses
  - proposals for 2014 Keynote speakers
4. Comment on the EVER activities
5. Other business

**In addition to the agenda, the sections LC and RV will nominate at least 2 candidates for section chair.**



Ophthalmic  
Research  
Journal for Research in Experimental and Clinical Ophthalmology



# OPHTHALMIC RESEARCH LECTURE

Uranie

Priorities of Ophthalmic Research  
George L. SPAETH

|       |      |  |
|-------|------|--|
| 15:55 |      | Introduction by Uwe PLEYER                                 |
| 16:05 | 3711 | Priorities of Ophthalmic Research<br>SPAETH G—Philadelphia |
| 16:30 |      | Ophthalmic Research Award                                  |



**Glaucoma**

**Moderators:**

**Aachal KOTECHA, Michèle DETRY-MOREL,  
Anna-Maria STEVENS**

- F001 Comparison of three different methods of intraocular pressure (IOP) measurements including properties of the cornea  
SMEDOWSKI A, WYLEGALA E, WEGLARZ B, ORSKI M, WOJCIK L—Katowice
- F002 Comparison of intraocular pressure measurements with the reichert pt100, the keeler pulsair intellipuff portable non-contact tonometers and goldmann applanation tonometry  
APTEL F, HUBANOVA R, ZHOU T, ARNOL N, CHIQUET C, ROMANET JP—Grenoble
- F003 24-hour intraocular pressure of healthy humans in supine position: rhythm and reproducibility  
MOTTET B, CHIQUET C, APTEL F, NOEL C, ROMANET JP—Grenoble
- F004 Relationship between IOP and biomechanical corneal values obtained by ORA  
LOPEZ DE LA FUENTE C, SANCHEZ-CANO A, PINILLA I, FUENTES BROTO L, SEGURA CLAVO F—Zaragoza
- F005 Comparison between Keeler and ORA IOP measurements  
LOPEZ DE LA FUENTE C, SANCHEZ-CANO A, PINILLA I, FUENTES BROTO L, SEGURA CLAVO F—Zaragoza
- F006 To assess the difference in the corneal biomechanical properties in healthy subjects with and without their contact lenses  
DE FAYS A, POURJAVAN S—Brussels
- F007 IOP management in glaucoma/OHT following intravitreal anti-VEGF injections  
ANSARI E—Maidstone
- F008 Persistent ocular hypertension following intravitreal injections of anti-VEGF agents or dexamethasone intravitreal implant  
AGARD E, ELCHEHAB H, RUSSO A, RACT MADOUX G, SWALDUZ B, DUSSART C, DOT C—Lyon, Paris
- F009 Optic disc torsion direction predicts the location of glaucomatous damage in normal tension glaucoma patients with myopia  
LEE K—Seoul
- F010 Structure–function relationship: assessment of macular ganglion cell complex with FD-OCT and standard automated perimetry  
EL CHEHAB H, GIRAUD JM, FENOLLAND J, FRANCOZ M, SENDON D, EL ASRI F, MESSAOUDI R, DOT C, MAY F, RENARD JP—Paris, Lyon
- F011 Retinal pigmentepithelium (rpe) alterations correspond to retinal nerve fiber layer (rnfl) degeneration in glaucoma  
KERNT M, HUEBERT I, MANN T, NEUBAUER A, HIRNEISS C—Munich
- F012 Correlation of various optic nerve head parameters obtained by 3D non-mydiatic retinal camera and optical coherence tomography (OCT)  
KANG KD, JUNG SH—Incheon, Gangneung
- F013 To assess circumpapillary retinal arteries and veins thickness (cRAT and cRVT) at optic disc (OD) border and correlate them with circumpapillary retinal nerve fiber layer (cRNFL)  
PEREIRA I, WEBER S, HOLZER S, RESCH H, KISS B, FISCHER G, VASS C—Wien

- F014 Asymmetry in hemifield macular thickness as an indicator of early glaucomatous structural or functional progression  
CHEN Y, KOBAYASHI N, KOBAYASHI K—Koriyama, Fukushima
- F015 *rf* Biomechanical response of lamina cribrosa and prelaminar tissue to an acute induced IOP elevati  
GIZZI C, CELLINI M, CAMPOS EC—Bologna
- F016 Macular ganglion cell-Inner plexiform layer thickness measurement and reproducibility with SD-OCT  
FRANCOZ M, FENOLLAND J, GIRAUD JM, EL CHEHAB H, SENDON D, MESSAOUDI R, MAY F, RENARD JP—Paris
- F017 Average nerve width measurement obtained by optical coherence tomography and glaucoma  
SHENG-YAO HSU—Hualien
- F018 Glaucoma diagnostic accuracy : comparison of RTVue-100 and Cirrus HD  
FENOLLAND J, GIRAUD JM, EL CHEHAB H, FRANCOZ M, SENDON D, MAY F, RENARD JP—Paris
- F019 Scanning laser polarimetry in glaucoma suspects: influence of the lens  
MILANO G, VERTICCHIO VERCELLIN AC, LOMBARDO S, BOSSOLESI L, RAIMONDI M, LANTERI S, ROSSI GCM—Pavia
- F020 Reproducibility of retinal nerve fiber layer parameters measured with scanning laser polarimetry in healthy eyes  
BAMBO M, PRIETO E, DE LA MATA G, FERNANDEZ-PEREZ S, SATUE M, GARCIA-MARTIN E, FERRERAS A—Zaragoza
- F021 The influence of TSD (topographic standard deviation) and RH (reference height) test/retest variability upon the test/retest variability of the HRT stereometric parameters  
POPA CHERECHEANU A, DASCALU AM, SERBAN D, STANA D—Bucharest
- F022 Stereometric parameters change vs. HRT Topographic Change Analysis (TCA) agreement in early detection of glaucoma progression  
POPA CHERECHEANU A, DASCALU AM, SERBAN D, STANA D—Bucharest
- F023 *rf* Defects in macular-retinal layer analysis of glaucoma patients compared to normative database  
HOLZER S, PEREIRA I, KISS B, VASS C—Wien
- F024 *rf* Manual placement of SD-OCT peripapillary circle scan: possible influence on RNFLT classification and profile shape  
★ SCHULZ S, ZINSER G—Heidelberg
- F025 ★ Combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension  
PFENNIGSDORF S, DE JONG L, MAKK S, FOURNICHOT Y, MORGAN-WARREN RJ, MALTMAN J—Polch, Amsterdam, Graz, Schlieren, Marlow
- F026 The impact of brimonidine on the loss of retinal nerve fiber layer (RNFL) thickness in glaucoma diabetic patients  
SMEDOWSKI A, WYLEGALA E, ORSKI M, WOJCIK L—Katowice
- F027 Effectiveness of brimonidin and dorsolamid as additional therapy to beta-blockers-comparable analysis  
RADUNOVIC M, RADUNOVIC M, RADUNOVIC A, KUJUNDZIC H—Podgorica
- F028 *rf* Clinical trial for the evaluation of neuroprotective effects of palmitoylethanolamide: Visual Field and Pattern-ERG  
GAGLIANO C, LONGO A, UVA MG, REIBALDI M, AMATO R, RUSSO V, BIONDI P, AVITABILE T—Catania, Foggia



## FRIDAY

- F029 ★ Multiple topical administrations of Ramipril enhance retinal ganglion cell survival after transient retinal ischemia-reperfusion in rats  
ELENA P, VIAUD-QUENTRIC K, CHARFEDDINE R, REKIK R—La Gaude, Sousse, Tunis
- F030 Efficacy and safety assessment of preservative-free latanoprost (T2345) versus Xalatan™ in ocular hypertensive or glaucomatous patients  
ROULAND JF—Lille
- F031 ★ Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension. An adjusted indirect comparison meta-analysis  
CUCHERAT M, ROULAND JF—Lyon, Lille
- F032 ★ Prostaglandin drug partitioning into contact lens material  
FLEITMAN J, KENLEY R—Irvine, San Diego
- F033 Angle closure glaucoma associated with venlafaxine treatment  
TURCOTTE S, FREDETTE MJ—Quebec
- F034 Safety and efficacy of phacoemulsification and intraocular lens implantation in eyes with end-stage chronic angle-closure glaucoma  
KIM S, CHOI HJ—Seoul
- F035 Case from hell in narrow angle glaucoma patient  
*rf* VAN DE VEIRE S, WEBERS C, BECKERS H—Maastricht
- F036 Valuation of surgery in combination chamber angle lens  
RAMIRO P, CABEZON L, IBAÑEZ J, PINILLA I, PEREZ D, CRISTOBAL JA, DEL BUEY MA—Zaragoza
- F037 Marginally controlled open angle glaucoma and cataract: sequential (1st phacoemulsification, 2nd trabeculectomy) versus combined (phacotrabeculectomy) surgery  
*rf* LIASKA A, ANDRIANOPOULOU K—Lamia
- F038 Ex-press glaucoma shunt for the treatment of complex glaucoma  
ANSARI E—Maidstone
- F039 Non penetrating deep sclerectomy versus trabeculectomy in bilateral primary open-angle glaucoma  
IBANEZ J, PEREZ D, MATEO OROBIA A, ASCASO F, PEIRO C, CRISTOBAL JA—Zaragoza
- F040 Glaucoma surgery in a patient with prominent episcleral vessels  
PRIETO CALVO E, DE LA MATA G, FERNANDEZ-PEREZ S, SATUE M, GARCÍA-MARTÍN E, BAMBO MP, PEREZ-OLIVAN S—Zaragoza
- F041 The morphological changes in the eye tissues during implantation drainages for glaucoma surgery  
GAVRILOVA I, CHUPROV A—Kirov
- F042 Changes in anterior segment after-iridotomy with nd: yag laser for narrow angle measured with spectral domain OCT  
IBANEZ J, PEREZ GARCIA D, JIMENEZ DEL RIO B, RAMIRO P, MATEO J, ASCASO F, CRISTOBAL JA—Zaragoza
- F043 Experimental application of high-frequency electric welding of biological tissues for iridoplasty and trabeculectomy  
ZADOROZHNYI O, PASYECHNIKOVA N, NAUMENKO V, LAZAR Y—Odessa
- F044 ★ Ultrasonic circular cyclo coagulation in patients with primary open-angle glaucoma: preliminary results of a multicenter clinical trial  
APTEL F, DENIS P, ROULAND JF, NORDMANN JP, LACHKAR Y, RENARD JP, SELLEM E, BAUDOUIN C, BRON A—Grenoble, Lyon, Lille, Paris, Dijon
- F045 Efficacy of pneumatic trabeculectomy in patients with primary open angle glaucoma and ocular hypertension in combination with prostaglandin monotherapy  
MARTY A, BECCAT S, AMARI E, NORDMANN JP, DENIS P—Lyon, Paris
- F046 Epidemiology of primary congenital glaucoma: a study lasting 11 years  
AZIZ A, DENIS D, MATONTI F—Marseille
- F047 Megalocornea, iris desinsertion and crystalline luxation in congenital glaucoma  
ARA GABARRE M, EGEA ESTOPINAN, FERNANDEZ-PEREZ S, HERRERO LATORRE R, GARCIA-MARTIN E, DE LA MATA PEREZ G, SATUE PALACIAN M, BAMBO M—Zaragoza
- F048 Glaucomatous optic neuropathy complicated by pituitary adenoma: case report  
PESCE G, MONTRONE F, VELLA G, GARRIBBA AP—Bari
- F049 Experimental glaucoma model using polyurethane microbeads in rats  
KIM C, RHO S, LEE N, LEE C, KIM N, PARK S, CHOI B—Seoul, Incheon
- F050 *rf* Retinal MMP expression is upregulated in an excitotoxic mouse model of glaucoma  
DE GROEF L, GAUBLomme D, JANSSENS E, DEKEYSTER E, MOONS L—Leuven
- F051 Experimental glaucoma model in two lines of rats using polystyren microspheres (Bead Model)  
SMEDOWSKI A, PIETRUCHA-DUTCZAK M, WYLEGALA E, LEWIN-KOWALIK J—Katowice
- F052 IOP lowering effect of low intensity ultrasound on experimental glaucoma model using microbeads in rats  
KIM C, RHO S, LEE N, LEE C, KIM N, PARK S, CHOI B, CHOI M—Seoul, Incheon, Jeju



**Electrophysiology, Physiological Optics, Vision Sciences**

**Moderators:**

**Miguel CASTELO-BRANCO, Werner SPILEERS**

- F053 Controlled pupilar miosis to improve mesopic visual function in drivers over 40 years old  
 NAVARRO VALLS J, RAMIREZ-MERCADO G, PÉREZ-CARRASCO MJ, LOBATO RINCON LL, CHAMORRO E, SANCHEZ-RAMOS C—Madrid
- F054 Changes in contrast sensitivity perception due to protector screens for welding tasks: conventional protective optical filter vs novel protective optical filter of selective absorbance  
 BONNIN ARIAS C, AGUIRRE-VILACORO V, CHAMORRO E, LOBATO RINCON LL, LANGA-MORAGA A, NAVARRO-VALLS J, SANCHEZ-RAMOS C—Madrid
- F055 Vision quality in population research of children and adolescents in Siemianowice Slaskie (southern Poland)  
 MOCKO L, WYLEGALA E, ZAJAC M, JOZWIK A, LEWANDOWSKA M—Katowice, Wrocław
- F056 Morphometrical indices in acquired myopia  
 BOYCHUK IRYNA, GORBATUK TL—Odessa
- F057 Mesopic pupil amplitude depending on the age and the wavelenght of the stimuli  
 LOBATO RINCON LL, NAVARRO VALLS J, NAVARRO BLANCO C, BONNIN ARIAS C, RAMIREZ-MERCADO G, SÁNCHEZ-RAMOS RODA C—Madrid
- F058 Undercorrection of refractive error and cognitive function. The Beijing Eye Study 2011  
 SCHMIDBAUER M—Mannheim
- F059 Eye refraction: a comparative study between autorefractometer, aberrometer and subjective test  
 SEGURA CALVO F, SANCHEZ-CANO A, LOPEZ DE LA FUENTE C, FUENTES BROTO L, PINILLA I—Zaragoza
- F060 Fish-eye disease with retinal involvement associated with mutation in the LCAT gene  
 BOUTBOUL S, BORDERIE V, LAROCHE L—Paris
- F061 Relationship between visual acuity and other optical parameters in no presbyopic eyes  
 SEGURA CALVO F, SANCHEZ-CANO A, LOPEZ DE LA FUENTE C, FUENTES BROTO L, PINILLA I—Zaragoza
- F062 The effect of simplified and traditional chinese character on accommodative reponses in myopes and emmtropes  
 XU D, XIN W—Wenzhou
- F063 Evaluation of magnitude and phase of sweep-visual evoked potentials  
 ★ CHARLIER J, CABON M, ZANLONGHI X, DEFOORT-DHELLEMMES S—Perenchies, Nantes, Lille
- F064 Spatial tuning affects diagnostic efficacy of pseudoisochromatic plates  
 ★ KRASTEL H, KALTAKJI F, LEERS S, JERCHEL N, JONAS JB—Mannheim, Sulzbach, Wetzlar
- F065 Visual capacity in albino mice. Are albino mice good for every neuroscience's experiment?  
 VICENTE TEJEDOR J, RAMÍREZ L, TORETS C, CARRALERO S, DE LA VILLA P, SANCHEZ-RAMOS C—Madrid
- F066 Vision in subjects with hyperawareness of afterimages and "visual snow"  
 ALISSA R, BI W, BESSERO AC, PLANT G, BARBUR JL—London
- F067 Comparison of visual evoked potentials between premature and full-term childrens  
 HAN SJ, JEON SY—Seoul
- F068 Functional activity of retinal neurons and Muller cells in idiopathic full-thickness macular holes  
 ZUEVA M, NEROEV V, TSAPENKO I, BYCHKOV P, SARYGINA O—Moscow
- F069 New clinical measure to assess the visual awareness in peripheral field loss (PFL)  
 ALSHAGHTHRAH A, DICKINSON C, MURRAY I—Manchester
- F070 Detection of colour signals in objects defined by luminance contrast  
 HICKEY J, RODRIGUEZ-CARMONA M, BARBUR JL—London
- F071 Normal range of Cambridge low contrast grating test: a population based study  
 OSTADIMOGHADDAM H, YEKTA AA, HERAVIAN J, AZIMI A, KHABAZKHOOB M, MOHAMMADIAN M—Mashhad, Tehran
- F072 Normal aging: capturing changes in contrast acuity at low light levels  
 GILLESPIE-GALLERY H, KONSTANTAKOPOULOU E, BARBUR JL—London
- F073 Colour vision losses in diabetes in the absence of proliferative retinopathy  
 BARBUR JL, ANSARI I, CANNING C—London, Dubai
- F074 Evidence of neuroplasticity in the human visual cortex following beneficial anti-VEGF treatment in exudative age-related macular degeneration  
 VOTTONEN P, PÄÄKKÖNEN A, TARKKA I, KAARNIRANTA K—Kuopio, Jyväskylä
- F075 Adjuvant stem cell-based therapy in acute retinal injury after sodium iodate administration in mice  
 rf MACHALINSKA A—Szczecin
- F076 Fructose diet induced short-term impairment of cone sensitivity and gene expression in rat retina  
 rf THIERRY M, BUTEAU B, PASQUIS B, ACAR N, BRON A, CREUZOT-GARCHER C, BRETILLON L—Dijon

## FRIDAY

**Immunology / Microbiology****Moderators:****Piergiorgio NERI, François WILLERMAIN**

- F077 Adhesion molecules in experimental autoimmune uveitis  
DEWISPELAERE R, LIPSKI D, MAKHOUL M, JUDICE L, CASPERS L, BRUYNS C, WILLERMAIN F—Brussels
- F078 Cytokines in patients with HLA-B27 + acute anterior uveitis  
JAKOB E, UMANSKY L, BECKHOVE P, MACKENSEN F—Heidelberg
- F079 Polyphenolic compounds reduce inflammation in ARPE-19 cells  
HÄNLER M, SUURONEN T, SALMINEN A, KAARNIRANTA K, KAUPPINEN A—Kuopio
- F080 Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells  
LAAKSO N, KINNUNEN K, SALMINEN A, KAARNIRANTA K, KAUPPINEN A—Kuopio
- F081 The dynamics of molecular markers expression of blood lymphocytes activating at patients with an uveal melanoma at the different types of treatment  
VELICHKO LN, MALETSKIY AP, VIT VV, CHEBOTARYOV YEP—Odessa
- F082 *★* An antimicrobial peptide can enhance the activity of a fluoroquinolone in reducing the colony counts of fluoroquinolone-resistant MRSA in the NZW rabbit keratitis model  
ROMANOWSKI E, YATES K, MAH F, GORDON Y, KOWALSKI R—Pittsburgh
- F083 Diagnosis of Herpetic Uveitis is Aided by Confocal Microscopy with the HRT RCM  
KNOLL A, POSTOLE S, MACKENSEN F—Heidelberg
- F084 *★* HSV1-specific meganuclease may reduce ocular infection in a mouse model of herpes keratitis  
LABETOULLE M, GABISON E, ROUSSEAU A, HUOT N, CHAPPELLIER B, GAILLED RAT M, ERGANI A—Le Kremlin Bicêtre, Paris, Gif sur Yvette
- F085 Regulation of immune response in post-operative endophthalmitis  
SAUER A, CREUZOT-GARCHER C, CHIQUET C, BERROD JP, SALEH M, GAUCHER D, CANDOLFI E, PREVOST G, BOURCIER T—Strasbourg, Dijon, Grenoble, Nancy, Besançon
- F086 *rf* Miltefosine and polyhexamethylene biguanide, a new drug combination for the treatment of Acanthamoeba keratitis. Results from in-vivo toxicological and efficacy studies  
OBWALLER A, POLAT ZA, WALOCHNIK J, VURAL A, DURSUM A, ARICI MK—Vienna, Sivas
- F087 Lattice dystrophy complicated by Cryptococcus curvatus infection  
IRION L, MORGAN S, KOERNER R, JOHNSON E—Manchester, Sunderland, Bristol
- F088 Syphilitic uveitis: Vilnius region perspective: 6 case reports  
STECH S, STRUPAITE R, KARALIUTE Z, CIMBALAS A, SVEIKATIENE J, ASOKLIS R—Vilnius
- F089 *rf* Tocilizumab for anterior uveitis and juvenile idiopathic arthritis — a case report  
KNOLL A, LUTZ T, GRULICH-HENN J, MACKENSEN F—Heidelberg
- F090 Use of tuf PCR for staphylococcal and streptococcal genus detection in endophthalmitis  
CORNUT PL, BOISSET S, BENITO Y, BURILLON C, ETIENNE J, MAURIN M, CHIQUET C, VANDENESCH F—Lyon, Grenoble
- F091 Baseline predictive factors of visual prognosis in acute bacterial postcataract endophthalmitis  
CHIQUET C, CREUZOT-GARCHER C, COMBEY A, CORNUT PL, CAMPOLMI N, ROMANET JP, BRON A, GAIN P, MAURIN M—Grenoble, CHU de DIJON, Lyon, Saint-Etienne, Dijon
- F092 *rf* Time profile of viral DNA in aqueous humor of patients treated for VZV acute retinal necrosis using quantitative real-time PCR  
CHIQUET C, LABETOULLE M, GERMI R, BERNHEIM D, MORAND P, ROMANET JP—Grenoble, Paris
- F093 Evaluation of the early diagnosis of uveitis toxoplasma using only western blot  
BECCAT S, WALLON M, SEVE P, PEYRON F, KODJIKIAN L—LYON, Lyon
- F094 Serratamolide as a novel hemolytic factor produced by Serratia marcescens  
SHANKS RM, STELLA N, LAHR R, WANG S, KOWALSKI R, LIU X—Pittsburgh
- F095 Successful management of recurrent Acanthamoeba keratitis using topical and systemic miltefosine  
BARISANI-ASENBAUER T, WALOCHNIK J, MEJDOUBI L, BINDER S—Vienna
- F096 *rf* Atypical panuveitis parasitic and Herpes virus co-infection in immunocompetent adults: real co-infection or false positive?  
NGUYEN AM, DENIS P, GRANGE JD, KODJIKIAN L—Lyon
- F097 Effect of tocilizumab for uveitis accompanied with Castleman disease  
TOBE A, OSHITARI T, YAMAMOTO S—Chiba
- F098 Efficacy and safety of TNF alpha blockers in patients with Behçet's disease uveitis  
GUINDOLET D, SAADOUN D, CASSOUX N, FARDEAU C, TOUITOU V, LEHOANG P, BODAGHI B—Paris
- F099 Ocular granuloma, uveitis and X-linked chronic granulomatous disease  
KURUN S, ANGIOI K, LOCATELLI A, TERRADA C, BODAGHI B—Nancy, Paris
- F100 Iritis and angle closure glaucoma caused by caterpillar hairs  
BLASETTI F, TARALLO S, DORE S, PINNA A—sassari, Sassari
- F101 *rf* Paediatric rheumatology clinic outcome at Leeds Teaching Hospitals, UK  
JEEVA I, HARDISTY A, KOLB S, HOOLE J, LONG V, WOOD M—Leeds
- F102 Uveitis and ocular wall granulomas associated with brimonidine treatment  
LABALETTE P, MAURAGE CA—Lille

**Physiology / Biochemistry / Pharmacology**

**Moderators:**

**Neville OSBORNE, Gerhard GARHOFER**

F103 Protective effects of *Crepidiastrum denticulatum* on oxidative stress-induced retinal degeneration  
JUNG SH, AHN HR, LEE HJ, KIM CY, KANG KD, NHO CW—Gangneung, Gyeonggi, Incheon

F104 ★ Supplement enriched in antioxidants protects the retina from light-induced damage  
RANCHON-COLE I, RAMCHANI BEN OTMAN K, CERCY C, REBIKA H, DOLY M—Clermont Ferrand

F105 Effects of low intensity ultrasound (LIUS) on the macular degeneration model in vitro  
KIM NK, KIM CY, CHOI MJ, RHO S, PARK S, CHOI BH—Incheon, Seoul, Jeju

F106 Hypoxia stimulates the synthesis and release of Brain Natriuretic Peptide (BNP) in RPE cells  
ARJAMAA O, AALTONEN V—Turku

F107 ★ Augmentation of the ocular penetration of dexamethasone with  $\beta$ -blocker and  $\alpha$ -agonist co-administration  
ELENA P, SENSEBY F, BERMON F, CHARFEDDINE R, REKIK R—La Gaude, Sousse, Tunis

F108 Effects of intravitreal injection of anti-TNF $\alpha$  and anti-VEGF in experimental branch retinal vein occlusion in rats  
ANDRIANAKI A, GILODI N, CONTI A, POURNARAS CJ—Geneva

F109 Examination of between eye retinal oxygenation saturation in the peri-papillary region  
CUBBIDGE R, VEKRIA P, KALITZEOS A, HEITMAR R—Birmingham

F110 Flicker-induced retinal vasodilatation is not dependent on complement factor H polymorphism in healthy young subjects  
NAPORA KJ, TOLD R, PALKOVITS S, KAYA S, BOLTZ A, SCHMIDL D, WERKMEISTER R, GARHÖFER G, SCHMETTERER L—Vienna

F111 How much flicker is enough?  
HEITMAR R, SUMMERS RJ—Birmingham

F112 The influence of age on retinal vessel oxygenation  
HEITMAR R, CUBBIDGE R—Birmingham

F113 Retinal vessel reactivity after cigarette smoking  
CUBBIDGE R, SUMMERS RJ, HEITMAR R—Birmingham

F114 Correcting influence of arsenic mineral water on structural characteristic of the retina of rat eyes in model chronic immobilization-emotional stress  
GUSHCHA S, NASIBULLIN BA, YAROSHENKO NA, ZOLOTARYOVA TA—Odessa

F115 Blindness due to mistake of antituberculosis treatment  
ROBERT PY, YAYA G, YASSAMINA S, MGBALI J, GINOUX J—Limoges, Bangui

F116 Galenic and analytic development of Tacrolimus 0.06% eye drops  
GAUTHIER AS, RIVAL B, SAHLER J, FAGNONI-LEGAT C, GUILLAUME YVES, LIMAT S, DELBOSC B—Besançon

F117 Damage of tolerance to glucose (TG) is the predecessor of insular diabetes (ID) and is accompanied by different metabolic changes, which need all-round research  
GUSHCHA S, BABOV KD, YAROSHENKO NA—Odessa

F118 Effects of Irifrin 2,5% on the disturbances pupillary-accommodative system in patients  
BUSHUYEVA N, MALIEVA O—Odessa

F119 Sunglasses with wide temples and thick frame severely constrict temporal visual field extent  
DENION E, DUGUE AE, AUGY S, COFFIN-PICHONNET S, MOURIAUX F—Caen

F120 *rf* Role of nitric oxide in optic nerve head blood flow regulation during experimental increase of intraocular pressure in healthy humans  
SCHMIDL D, BOLTZ A, KAYA S, PALKOVITS S, TOLD R, FUCHSJAEGER-MAYRL G, WERKMEISTER R, GARHOFER G, SCHMETTERER L—Vienna

F121 *rf* Eye motion increases temporal visual field extent  
DENION E, DUGUE AE, COFFIN-PICHONNET S, AUGY S, MOURIAUX F—Caen

F122 *rf* Oxidative stress in retinal pigment epithelial cells: protective effect of wood-derived phenolic compounds  
REINISALO M, PAIMELA T, RYHÄNEN T, KAUPPINEN A, KOSKELA A, SOININEN T, KAARNIRANTA K, KARJALAINEN RO—Kuopio

F123 Aqueous erythropoietin level in retinal vein occlusion  
SHIN HJ, LEE SH—Seoul

FRIDAY

**SIS** **New trends in the treatment of diabetic macular oedema** **Uranie**  
**RV** Pascale MASSIN, Jean - Antoine C POURNARAS

|         |      |  |
|---------|------|--|
| 17:30   | 3811 | Role of laser<br>CONRATH J—Marseille           |
| 17:48 ★ | 3812 | Role of corticosteroids<br>BANDELLO F—Milano   |
| 18:06   | 3813 | Role of anti-VEGF<br>POURNARAS JA—Lausanne     |
| 18:24   | 3814 | Role of vitrectomy<br>WOLFENSBERGER T—Lausanne |
| 18:42   | 3815 | Case presentation<br>MASSIN P—Paris            |

**FP** **Surgery** **Euterpe**  
**RV** Jean-Paul BERROD, Jost B JONAS

|       |      |  |
|-------|------|--|
| 17:30 | 3821 | Incidence of tears and retinal detachments after macular surgery according to the depression of the vitrectomy cutter<br>BERROD JP, SELTON J, CONART JB, HUBERT I—Vandoeuvre-les-Nancy     |
| 17:42 | 3822 | Outcomes of macular hole surgery in highly myopic eyes : a case-control study<br>CONART JB, HUBERT I, BERROD JP—Nancy  |
| 17:54 | 3823 | Macular sensitivity and structure in epiretinal membranes 6 months after surgical treatment<br>CREUZOT C, ISAICO R, NICOT F, BRON A—Dijon  |
| 18:06 | 3824 | Implication of functional and anatomical preoperative characteristics in the outcomes of epiretinal membrane (ERM) surgery<br>CASTRO NAVARRO J, GARCÍA FERNÁNDEZ M—Lugo de Ilanera, Oviedo |
| 18:18 | 3825 | Content-based MPEG-4 video stream retrieval for video-guided eye surgery<br>DROUECHE Z, LAMARD M, QUELLEC G, CAZUGUEL G, ROUX C, COCHENER B—Brest  |
| 18:30 | 3826 | Cytopathological findings in the vitreous of patients with retinal detachment<br>ARNDT C, BONNAY G, RAMONT L, DIEBOLD MD, DUCASSE A, BOULAGNON C—Reims                                     |

**SIS** **From ocular surface to ganglion cells** **Erato**  
**ACB** Hannu UUSITALO, Giedrius KALESNYKAS



|         |      |  |
|---------|------|--|
| 17:30   | 3831 | Ocular surfaces in the treatment of glaucoma<br>UUSITALO H—Tampere   |
| 17:52   | 3832 | Post-surgical intra-ocular inflammation in a mouse model and high mobility group box protein 1<br>BEUERMAN R, YUAN ZH—Singapore              |
| 18:14 ★ | 3833 | Retinal neuroprotection: the path from cell-based high content screening, to animal models, and hopefully to the clinic<br>ZACK DJ—Baltimore |
| 18:36   | 3834 | Changes in retinal ganglion cell morphology after optic nerve crush and experimental glaucoma<br>KALESNYKAS G—Kuopio                         |

**SIS** **Killer cases in uveitis: challenges and controversies** **Thalie**  
**IM** Piergiorgio NERI, Carl P HERBORT

|       |      |  |
|-------|------|--|
| 17:30 | 3841 | Progressive serpiginous choroidopathy – what to do?<br>PAVESIO C–London                                  |
| 17:45 | 3842 | Primum non nocere et non occidere<br>HERBORT CP–Lausanne   |
| 18:00 | 3843 | Killer cases due to occult choroidal inflammation: how to prevent them<br>PAPADIA M, HERBORT CP–Lausanne |
| 18:15 | 3844 | How a benign granulomatous uveitis can become a killer case<br>BOUCHENAKI N, HERBORT CP–Lausanne         |
| 18:30 | 3845 | TB or not TB...or what else?!<br>NERI P, ARAPI I, PIRANI V, CAPUANO V–Torrette-Ancona, Ancona            |
| 18:45 | 3846 | Infectious driven autoimmunity - how to treat?<br>DICK A–Bristol   |

**SIS** **Myopia and glaucoma** **Clio**  
**G** Sayeh POURJAVAN, K. Sheng LIM

|       |      |  |
|-------|------|--|
| 17:30 | 3851 | The association between myopia and glaucoma - causality or classification?<br>KHAWAJA A–London |
| 17:55 | 3852 | Refractive surgery in myopic, glaucomatous patient<br>CHAVES A–Brussels                        |
| 18:20 | 3853 | Glaucoma surgery in high myopia<br>LIM K–London  |
| 18:45 | 3854 | Interesting case-reports<br>POURJAVAN S–Brussels   |

**SIS** **The blue light photoreceptor and ipRGCs:** **Gallieni 1&2**  
**NSPH** **Review and update of their role in human health**  
 Aki KAWASAKI

|         |      |  |
|---------|------|--|
| 17:30   | 3861 | Anatomic and physiologic considerations of the intrinsically-photosensitive retinal ganglion cells<br>LUCAS R–Manchester     |
| 17:48   | 3862 | Rod, cone and melanopsin contributions to the pupil light reflex<br>KARDON RANDY–Iowa  |
| 18:06 ★ | 3863 | Chromatic pupillometry as a novel means to assess outer retinal function in health and disease states<br>KAWASAKI A–Lausanne |
| 18:24   | 3864 | The importance of blue light exposure to circadian integrity and general health<br>LUCAS R–Manchester                        |
| 18:42   | 3865 | Melanopsin and its role in photophobia<br>KARDON RANDY–Iowa  |





A series of horizontal lines for writing, spanning the width of the page. There are 20 lines in total, evenly spaced.



**FP  
COS**      **From refractive surgery to corneal grafting**      **Gallieni 4**  
Harminder S DUA, Frederic CHIAMBARETTA

|       |                   |   |
|-------|-------------------|---|
| 17:30 | 3871              | Study of stromal femtosecond laser ablation for deep corneal cut optimization<br>BERNARD A, AUDOUARD E, THURET G, PEOC'H M, DUMOLLARD JM, GRANIER J, SODER H, MOINE B, GAIN P—Saint-Etienne           |
| 17:42 | 3872              | Large optico-reconstructive corneal grafts in complicated cases<br>BARRAQUER J—Barcelona  |
| 17:54 | 3873              | Spectral domain OCT-assisted "big bubble" deep anterior lamellar keratoplasty in keratoconus patients<br>WYLEGALA E, TARNAWSKA D, WROBLEWSKA CZAJKA E, JANISZEWSKA D, WOWRO B, DOBROWOLSKI D—Katowice |
| 18:06 | 3874              | New improvements in Boston Keratoprosthesis (KPro): titanium surface modifications<br>SALVADOR CULLA B, JEONG KJ, PASCHALIS EI, CHIANG HH, GIPSON IK, DOHLMAN CH, KOHANE DS—Boston                    |
| 18:18 | 3875              | Stromal alteration in post-lasik ectasia cornea<br>AKHTAR S, KIRAT O, ALKATAN H, ALMUBRAD T—Riyadh  |
| 18:30 | 3876<br><i>rf</i> | Investigation of bacterial contamination of corneal donors using molecular biology<br>ROBERT PY, DUBOIS A, CHAIGNIER D, GARNIER F, PLOY MC—Limoges  |
| 18:36 | 3877<br><i>rf</i> | Surgical approach in corneal perforations and deep ulcers<br>DOBROWOLSKI D, JANISZEWSKA D, TARNAWSKA D, KRYSIK K, WYLEGALA E—Katowice, Sosnowiec  |

**WS**      **Patients as stakeholders in European ophthalmology**      **Gallieni 3**  
Nadja KNOP, Erich KNOP

|       |      |  |
|-------|------|--|
| 17:30 | 3881 | EBU - European Blind Union - The voice of blind and partially sighted people in Europe<br>ANGERMANN W—Hannover                     |
| 17:48 | 3882 | DBSV – A success story in forming a patient organization for blind and partially sighted people<br>HOLZAPFEL S, OSTROWSKI A—Berlin |
| 18:06 | 3883 | Deutsche Uveitis Arbeitsgemeinschaft (DUAG) - How patients can support research<br>ZIERHUT M—Tübingen                              |
| 18:24 | 3884 | Initiating a glaucoma interest group in Belgium<br>STALMANS I—Leuven   |
| 18:42 | 3885 | Visual impairment, blindness in an aging society<br>SUTTIE A—Kirkcaldy   |



The background is a light green gradient with a complex pattern of thin, white, overlapping lines that create a sense of motion and depth. A white rectangular box is positioned in the upper right quadrant, containing the date information in a bold, green, sans-serif font.

**SATURDAY  
OCT 13  
2012**

# Yellox...putting a stop to ocular inflammation†

fewer drops. less time.\*

## SYMPOSIUM

"New aspects of managing post-surgical inflammation"  
Saturday 13<sup>th</sup> October 2012

7:15 – 8:15 a.m.

Room: Uranie

# YELLOX

Bromfenac sodium sesquihydrate

The only twice daily NSAID

#### Yellox® (bromfenac sodium sesquihydrate) 0.9 mg/ml eye drops, solution.

**Prescribing Information.** Please refer to the Summary of Product Characteristics before prescribing Yellox®. **Pharmaceutical form:** Eye drops containing 0.9 mg/ml bromfenac (as sodium sesquihydrate) in clear yellow solution; one drop contains approximately 33 micrograms bromfenac. **Indication:** Treatment of postoperative ocular inflammation following cataract extraction in adults. **Dosage and administration:** For ocular use. Use in adults, including the elderly. The dose is one drop of Yellox in the affected eye(s) twice daily, beginning the day after cataract surgery and continuing through the first 2 postoperative weeks. The treatment should not exceed 2 weeks as safety data beyond this is not available. **Paediatric population:** Safety and efficacy in paediatric patients have not been established. **Hepatic or renal impairment:** Safety and efficacy have not been established in patients with hepatic disease or renal impairment. **Contraindications:** Known hypersensitivity to bromfenac, any of the excipients, or other non-steroidal anti-inflammatory medicinal products (NSAIDs). History of asthma, urticaria or acute rhinitis precipitated by acetylsalicylic acid or by other medicinal products with prostaglandin synthetase inhibiting activity. **Special warnings and precautions:** Topical NSAIDs and corticosteroids may both slow or delay healing; their concomitant use may increase this potential. Yellox contains sodium sulphite, which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible patients. **Cross-sensitivity:** There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, so caution is required among patients with a history of sensitivities to these medicinal products. **Susceptible persons:** In susceptible patients, continued use of topical NSAIDs, including Yellox, may result in potentially sight-threatening complications (epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation). Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and be closely monitored. In at-risk patients, concomitant use of ophthalmic corticosteroids with NSAIDs may increase risk of corneal adverse events. **Postmarketing experience with NSAIDs:** Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus and ocular surface diseases (e.g. dry eye syndrome), rheumatoid arthritis or repeat ocular surgeries within a short period of time, may be at increased risk for corneal adverse reactions. Topical NSAIDs should

be used with caution in these patients. There have been reports that ophthalmic NSAIDs may cause increased bleeding of ocular tissues (including hyphaema) in conjunction with ocular surgery. Yellox should therefore be used with caution in patients with known bleeding tendencies or who are receiving other medicinal products that may prolong bleeding time. **Ocular infection:** An acute ocular infection may be masked by the topical use of anti-inflammatory medicinal products. **Excipients:** Since Yellox contains benzalkonium chloride, close monitoring is required with frequent or prolonged use. Benzalkonium chloride is known to discolour soft contact lenses, and has been reported to cause eye irritation, punctate keratopathy and/or toxic ulcerative keratopathy. **Special instructions regarding drop instillation:** Multiple topical ophthalmic medicinal products should be administered at least 5 minutes apart. Avoid contaminating the dropper-tip and solution, and tightly close the bottle when not in use. Contact lenses should not be worn during treatment with Yellox. **Interactions:** Formal interaction studies have not been performed, but no interactions with antibiotic eye drops used in conjunction with surgery have been reported. **Fertility, pregnancy and lactation:** **Pregnancy:** There are no adequate data from the use of bromfenac in pregnant women, and the potential risk for humans is unknown. In general, the use of Yellox is not recommended during pregnancy unless the benefit outweighs the potential risk. **Breast-feeding:** It is unknown whether bromfenac or its metabolites are excreted in human milk. The use of Yellox is in general not recommended during breastfeeding unless the benefit outweighs the potential risk. **Fertility:** No pregnancy testing or contraceptive measures are required. **Effects on ability to drive and use machinery:** Transient blurring of vision may occur on instillation. If blurred vision occurs at instillation refrain from driving or using machines until vision is clear. **Undesirable effects:** In clinical trials (n=973), a total of 3.4% of patients had  $\geq 1$  adverse reactions. The most common or most important reactions were abnormal sensation in eye (0.5%), corneal erosion (mild or moderate, 0.4%), eye pruritus (0.4%), eye pain (0.3%) and eye redness (0.3%). **Summary of adverse reactions:** **Uncommon ( $\geq 0.1\%$  to  $<1\%$ ):** reduced visual acuity, haemorrhagic retinopathy, corneal epithelium defect (reported with QID use, off-label use, QID), corneal erosion (mild or moderate), corneal epithelium disorder, corneal oedema, retinal exudates, eye pain, eyelid bleeding, vision blurred, photophobia, eyelid oedema, eye discharge, eye pruritus, eye irritation, eye redness, conjunctival hyperaemia, abnormal sensation

in eye, ocular discomfort, epistaxis, cough, nasal sinus drainage and face swelling. **Rare ( $\geq 0.01\%$  to  $<0.1\%$ ; isolated reports from post-marketing experience of more than 20 million patients):** corneal perforation, corneal ulcer, corneal erosion – serious, scleromalacia, corneal infiltrates, corneal disorder, corneal scar and asthma. Please consult the Summary of Product Characteristics for a full list of side effects. **Overdose:** If Yellox is accidentally ingested, fluids should be taken to dilute the medicinal product. **Pharmaceutical precautions:** Do not store above 25°C. **Legal Category:** POM. **Marketing Authorisation Number:** EU/1/11/692/001. **Marketing Authorisation Holder:** Cromax Pharma GmbH, Industriezeile 6, A-2100 Leobendorf, Austria. **Date of preparation:** April 2011.

Adverse events should be reported. Reporting forms and information can be found at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk). Adverse events should also be reported to Bausch & Lomb UK Ltd on 01748 828864.

#### References

1. Yellox, Summary of Product Characteristics
2. Donnenfeld ED *et al.* Ophthalmology 2007; 114(9):1653-62
3. Donnenfeld ED, Donnenfeld A. Int Ophthalmol Clin. 2006; 46(4):21-40
4. Baklayan GA *et al.* J Ocul Pharmacol Ther. 2008; 24(4):392-8
5. Nevanac, Summary of Product Characteristics. 2009
6. Acular, Summary of Product Characteristics. 16 Feb 2010
7. Voltarol, Summary of Product Characteristics. 04 May 2010

035-2011-04-BMF

Date of preparation: June 2011

Yellox is a registered trademark used by Bausch & Lomb Incorporated by permission of Cromax Pharma GmbH.

Bausch + Lomb is a registered trademark of Bausch & Lomb Incorporated.

Yellox is licensed in all EEA member states, not in Switzerland

©Bausch & Lomb Incorporated.

## BAUSCH + LOMB

**CROMA**  
HEALTH • CARE • INNOVATION

† Yellox is the first and only twice-daily topical ocular NSAID indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. † In a large phase III trial, BID Yellox for 14 days controlled ocular inflammation (SOIS=0) in 59.3% of patients vs 26.9% with placebo (p<0.0001).<sup>2</sup>

\*Yellox has demonstrated clinical efficacy in two weeks with BID dosing. Treatment duration & dosing is relative to current clinical standards across Europe as well as older available NSAIDs.<sup>3,7</sup>



# BREAKFAST CIS

Uranie



SATURDAY

**SIS** **Unmet needs in treatment of retinal diseases** **Uranie**  
**RV** Gisèle SOUBRANE

|         |      |   |
|---------|------|---|
| 08:15   | 4211 | Prevention of AMD<br>CREUZOT C—Dijon            |
| 08:30   | 4212 | Geographic atrophy<br>STAURENGHI G—Ponte Lambro |
| 08:45   | 4213 | Genetic retinal diseases<br>LEROY BP—Ghent      |
| 09:00   | 4214 | Recurrence of vasculitis<br>BODAGHI B—Paris     |
| 09:15 ★ | 4215 | Non diabetic CME<br>LOEWENSTEIN A—Tel Aviv      |
| 09:30   | 4216 | Targeted delivery<br>BEHAR-COHEN F—Paris        |

**FP** **Dystrophy, Inflammation, Miscellaneous** **Euterpe**  
**RV** Isabelle AUDO, Eberhart ZRENNER, Pierre BITOUN

|         |                   |   |
|---------|-------------------|---|
| 08:15 ★ | 4221              | Clinical study results with new wireless electronic subretinal implant alpha-ims<br>ZRENNER E, BARTZ-SCHMIDT KU, GEKELER F, GREPPMAIER U, HEKMAT A, HOERTDOERFER G, KERNSTOCK C, KITIRATSCHKY V, SACHS H, STINGL K, WILHELM B—Tübingen, Reutlingen, Dresden |
| 08:27   | 4222              | ARHGEF26/SGEF controls fovea formation, immunity, neurodevelopment and arteriosclerosis<br>BITOUN P, PIPIRAS E, BENZACKEN B, DELAHAYE A—Bondy   |
| 08:39   | 4223              | Efficacy and safety of gene therapy with AAV4 in childhood blindness due to rpe65 mutations<br>LE MEUR G, LEBRANCHU P, PEREON Y, BILLAUD F, IVAN C, CHAUVEAU C, ROLLING F, WEBER M—Nantes   |
| 08:51   | 4224              | Etiologic distribution of necrotizing retinopathies : a nine-year experience at a university referral centre<br>JOUFFROY T, BODAGHI B, ROZENBERG F, LEHOANG P—Paris   |
| 09:03   | 4225<br><i>rf</i> | Ocular prognosis of congenital toxoplasmosis (genotypes II and III)<br>DELMAS J, DARDE ML, AJZENBERG D, ADENIS JP, ROBERT PY—Limoges  |
| 09:09   | 4226<br><i>rf</i> | Circadien cycle and chronic central serous chorioretinopathy<br>HUBAULT B, SETROUK E, ZAMBROWSKI O, DUCASSE A, ARNDT C—Reims  |
| 09:15   | 4227<br><i>rf</i> | Comparative study of post-natal retinal vascular development in mice models of iPLA2 inhibition and plasmalogen deficiency<br>SAAB S, BUTEAU B, LECLERE L, CREUZOT-GARCHER C, BRON A, BRETILLON L, ACAR N—Dijon   |

**SIS** **Update on keratoconus pathophysiology** **Erato**  
**COS** François MALECAZE, Joseph COLIN

|       |      |   |
|-------|------|---|
| 08:15 | 4231 | Genetics of keratoconus<br>SOLER V, CASSAGNE M, FOURNIE P, MALECAZE F—Toulouse  |
| 08:33 | 4232 | Biomechanics in keratoconus<br>TOUBOUL D—Bordeaux                               |
| 08:51 | 4233 | Inflammation in the pathogenesis of keratoconus<br>JUN A—Baltimore              |
| 09:09 | 4234 | Oxidative stress in keratoconus<br>MENEZO ROZALEN JL, PERIS-MARTINEZ C—Valencia |
| 09:27 | 4235 | Endocrinology and keratoconus<br>GATZIOUFAS Z—Homburg/Saar                      |



FP  
NSPH**Neuro-ophthalmology 1**

Aki KAWASAKI, Antonella BOSCHI

Thalie

|       |      |  |
|-------|------|--|
| 08:15 | 4241 | Chromatic pupillometry as highly sensitive testing method of photoreceptor function in retinal dystrophies<br>LORENZ B—Giessen   |
| 08:27 | 4242 | Boleslaw Wicherkiewicz: interesting contributor to European ophthalmology<br>GRZYBOWSKI A, SCHMIDT D—Poznan, Freiburg  |
| 08:39 | 4243 | Apoplexy in pituitary tumors, clinical and MRI analyses<br>DE KEIZER RJW, SCHUTTE P—Edegem, Leiden   |
| 08:51 | 4244 | Four-year-old child with optic nerve glioma revealed by a proptosis<br>BENNAI D, CRETU I, FICHTEN A, SEVESTRE H, COPIN H, BREMOND-GIGNAC D—Amiens  |
| 09:03 | 4245 | Strabismus and visual acuity in children with ocular coloboma<br>ARNAUD M, NADEAU S, AZIZ A, HAMDAN J, DENIS D—Marseille   |
| 09:15 | 4246 | Evaluation of the retinal fiber layer thickness as a biomarker for sleep apnea syndrome<br>FERRANDEZ ARENAS B, GIL-ARRIBAS L, FERRERAS AMEZ A, ARA GABARRE M, SATUÉ PALACIÁN M, BAMBO MP, CALVO PÉREZ P—Zaragoza |

SIS  
G**Cataract and glaucoma surgery, combined or staged?**

Thierry ZEYEN


Clio

|       |      |  |
|-------|------|--|
| 08:15 | 4251 | Cataract and glaucoma surgery, combined or staged: where do we stand?<br>SUNARIC MEGEVAND G—Geneva |
| 08:37 | 4252 | Combined approach, the yield of microincisions for cataract surgery<br>BRON A—Dijon                |
| 08:59 | 4253 | Staging the surgeries: glaucoma first or cataract first?<br>ZEYEN T—Leuven                         |
| 09:21 | 4254 | Combined approach: practical tips<br>MCNAUGHT A—Cheltenham   |

FP  
PBP**Retinal physiology and pharmacology**

Leopold SCHMETTERER, Amandio ROCHA DE SOUSA

Gallieni 1&amp;2

|       |  |   |
|-------|--|---|
| 08:15 | 4261   | An ex vivo assay to measure the intravitreal mobility of nanomedicines for retinal gene therapy<br>MARTENS TF, VERCAUTEREN D, FORIER K, DESCHOUT H, REMAUT K, DEMEESTER J, DE SMEDT SC, BRAECKMANS K—Ghent                |
| 08:27 | 4262   | Drug delivery by ionic hydrogel contact lenses in preoperative prophylaxis of intraocular infections<br>FOKINA DV, BOIKO EV, REITUZOV VA—St. Petersburg   |
| 08:39 | ★  4263 | Ghrelin's expression in the eye and its implication in the reduction of intraocular pressure<br>ROCHA DE SOUSA A, PEREIRA-SILVA P, AZEVEDO-PINTO S, RODRIGUES-ARAÚJO J, TAVARES-SILVA M, PINHO S—Porto                    |
| 08:51 | 4264   | Polyunsaturated fatty acids and Plasmalogens in diabetics<br>KOEHRER P, SAAB S, BRON A, ACAR N—Dijon  |
| 09:03 | 4265   | Circulating markers of retinal and optic nerve lipids<br>ACAR N, BERDEAUX O, HE Z, GREGOIRE S, CABARET S, MARTINE L, GAIN P, THURET G, CREUZOT-GARCHER C, BRON A, BRETILLON L—Dijon, Saint-Etienne                        |
| 09:15 | 4266<br><i>rf</i>  | Oxidative stress in retinal pigment epithelial cells: protective effect of wood-derived phenolic compounds<br>REINISALO M, PAIMELA T, RYHÄNEN T, KAUPPINEN A, KOSKELA A, SOININEN T, KAARNIRANTA K, KARJALAINEN RO—Kuopio |

SATURDAY

**Course 14 MGD - Pathophysiology, diagnosis and clinical treatment**  
**ACB**

Erich KNOP, Nadja KNOP

Gallieni 4

Intermediate

Meibomian Gland Disease (MGD) has come into the focus of ocular surface disease with the MGD report of the Tear Film and Ocular Surface Society (TFOS). This chronic diffuse dysfunction of the Meibomian glands appears to represent the most frequent underlying cause of dry eye disease. Chronic obstruction of the Meibomian glands results not only in a lipid deficiency with evaporative dry eye disease but also in a subsequent destruction of the gland tissue.

Since obstructive MGD has few symptoms in initial stages, and its asymptomatic form is even more wide-spread, increasing clinical knowledge on MGD is desirable in order to allow a timely diagnosis and effective therapy. State of the art concepts of MGD pathophysiology as well as of its practical clinical and differential diagnosis by newly developed techniques and practical treatment options are explained in a hands-on approach.

|         |      |   |
|---------|------|---|
| 08:15   | 4271 | Anatomy, physiology and pathophysiology of the meibomian gland<br>KNOP E, KNOP N, SULLIVAN DA—Berlin, Boston  |
| 08:30   | 4272 | Obvious, non-obvious MGD and new therapy options & the German perspective on MGD<br>KNOP N, KORB DR, BLACKIE CA, KNOP E—Berlin, Boston  |
| 08:45   | 4273 | Physical therapy in MGD as a cornerstone for improvement of signs and symptoms & The British perspective on MGD<br>PURSLOW C—Plymouth   |
| 09:00   | 4274 | Identification of MGD in dry eye patients and its treatment in the practical clinical setting & The Austrian perspective on MGD<br>HORWATH-WINTER J, RABENSTEINER DF, BOLDIN I—Graz |
| 09:15 ★ | 4275 | Special features of MGD in children: how to diagnose how to treat and the French perspective on MGD<br>BREMONT-GIGNAC D, CHIAMBARETTA F—Amiens, Clermont-Ferrand                    |
| 09:30   |      | European Perspectives on the Practical Clinical Situation for MGD, Round table  |

**FP**  
**EOVS**
**Physiological optics and visual function**

John L. BARBUR, Graham HOLDER

Gallieni 3

|       |      |  |
|-------|------|--|
| 08:15 | 4281 | Can scattered light improve visual performance?<br>PATTERSON EJ, BARGARY G, BARBUR JL—London   |
| 08:27 | 4282 | Effect of light source size on discomfort glare thresholds<br>JIA Y, BARGARY G, BARBUR JL—London   |
| 08:39 | 4283 | The effect of discomfort glare on parallel processing of visual information<br>BARGARY G, BARBUR JL—London   |
| 08:51 | 4284 | Characterization of human corneal grafts' transparency by optical coherence tomography and scattering measurements<br>HOFFART L, CASADESSUS O, GEORGES G, SIOZADE L, DEUMIÉ C—Marseille                |
| 09:03 | 4285 | Characterization of visual impairment in a Wfs1 mouse model of Wolfram syndrome<br>DELETTRE C, BONNET WERSINGER D, LENAERS G, TANIZAWA Y, HAMEL C—Montpellier, Ube                                     |
| 09:15 | 4286 | Adjuvant stem cell-based therapy in acute retinal injury after sodium iodate administration in mice<br><i>rf</i><br>MACHALINSKA A—Szczecin   |
| 09:21 | 4287 | Fructose diet induced short-term impairment of cone sensitivity and gene expression in rat retina<br><i>rf</i><br>THIERRY M, BUTEAU B, PASQUIS B, ACAR N, BRON A, CREUZOT-GARCHER C, BRETILLON L—Dijon |



## KEYNOTE LECTURE

Uranie

Diced Alu: Canning the blinding inflammasome  
Jayakrishna AMBATI

|       |        |  |
|-------|--------|--|
| 09:50 |        | Introduction by Bahram BODAGHI                                     |
| 10:00 | ★ 4311 | Diced Alu: Canning the blinding inflammasome<br>AMBATI J—Lexington |
| 10:30 |        | Award of the EVER certificate of honour                            |

SATURDAY

**SIS** **Pathogenesis of macular oedema and neurodegeneration in vascular retinal diseases** **Uranie**

**RV** Matus REHAK, Peter WIEDEMANN

|       |      |  |
|-------|------|--|
| 11:00 | 4411 | In vitro studies on the mechanism of action of VEGF and its inhibitors on blood-retina barrier<br>DEISSLER H, LANG G—Ulm   |
| 11:15 | 4412 | Role of retinal glial cells in pathogenesis of macular oedema<br>YANDIEV Y, BRINGMANN A, WIEDEMANN P—Leipzig   |
| 11:30 | 4413 | Combination of ranibizumab and laser photocoagulation in CRVO<br>WIEDEMANN P, REHAK M—Leipzig  |
| 11:45 | 4414 | Vasomotor reaction of retinal arterioles in hypoxic and ischemic conditions<br>POURNARAS CJ—Geneva   |
| 12:00 | 4415 | Treatment of macular oedema due to branch retinal vein occlusion with laser induced arterial constriction. Twenty years results of retrospective interventional study<br>REHAK J—Olomouc |
| 12:15 | 4416 | Neurodegeneration in retinal diseases and new strategies in its inhibition<br>REHAK M, WIEDEMANN P, RAO NA—Leipzig, Los Angeles  |

**JM** **SOIE/CAC - Indocyanine green angiography (ICGA): is it still relevant today?** **Euterpe**

**RV** Carl P HERBERT, Piergiorgio NERI



|       |      |   |
|-------|------|---|
| 11:00 | 4421 | ICGA: why I think that it is still relevant today<br>NERI P, ARAPI I, CAPUANO V, PIRANI V—Ancona  |
| 11:15 | 4422 | ICGA in inflammatory diseases<br>HERBERT CP—Lausanne  |
| 11:30 | 4423 | Advances in central serous chorioretinopathy: from diagnosis to treatment<br>NICOLO M—Genova  |
| 11:45 | 4424 | Anatomical location of polypoidal choroidal vasculopathy lesions inferred from simultaneous ICGA-OCT<br>KANG SW, JH KIM, HA HS—Seoul                                |
| 12:00 | 4425 | Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab: a study by indocyanine green angiography<br>TRAN THC, QUERQUES G—Lille, Paris |
| 12:10 | 4426 | Integrated imaging approach in RAP diagnosis<br>PARRAVANO M, VARANO M, VIRGILI G—Rome, Firenze  |
| 12:20 |      | Discussion  |

**SIS** **Current management of keratoconus** **Erato**  
**COS** Rafael I. BARRAQUER, Ralph MICHAEL


|         |      |   |
|---------|------|---|
| 11:00   | 4431 | Keratoconus and keratectasia<br>COLIN J—Bordeaux  |
| 11:18   | 4432 | Long-term results of deep anterior lamellar keratoplasty in patients with keratoconus<br>FOURNIE P, TOUBOUL D, ARNE JL, COLIN J, MALECAZE F—Toulouse, Bordeaux                                      |
| 11:36 ★ | 4433 | Keratoconus patterns and intrastromal segments<br>BARRAQUER RI, ALFONSO J, MURTA J—Barcelona, Oviedo, Coimbra   |
| 11:54   | 4434 | Visual and refractive outcomes of intracorneal ring segments in the treatment of keratoconus: the RETICS multicentric study<br>VEGA-ESTRADA A, ALIO JL, MICHAEL R, BARRAQUER RI—Alicante, Barcelona |
| 12:12   | 4435 | Cross linking for keratoconus - clinical results comparing epithelium removal versus no removal<br>CAPOROSSI ALDO, MAZZOTTA C, PARADISO AL—Siena  |

**FP** **Ocular surface and dry eye** **Thalie**  
**COS** Dominique BREMOND-GIGNAC, Thomas FUCHSLUGER

|         |                   |   |
|---------|-------------------|---|
| 11:00   | 4441              | Assessment of dry eye after LASIK by real-time measurement of higher order aberrations variation<br>GICQUEL JJ, DJABAROUTI M, ZAKARI W, BREMOND-GIGNAC D, PISELLA PJ—Poitiers, Amiens, Tours            |
| 11:12   | 4442              | Pathogenetic evaluation of the ocular surface drug correction in patients before LASIK<br>SERGEEVA M, KOVALEVSKAYA M, CHERNIKOVA I—Voronezh   |
| 11:24   | 4443              | Keratocyte density after microkeratome LASIK versus femtosecond laser-assisted LASIK<br>CANADAS SUAREZ PILAR, HERNANDEZ-VERDEJO JL, DE BENITO LLOPIS L, DRAKE P, TEUS MA—Madrid                         |
| 11:36   | 4444              | Evaluation of intraocular pressure according to corneal thickness before and after Excimer laser corneal ablation for myopia<br>HAMED AZZAM S, BRISCOE D, TOMKINS O, SHEHADEH M, GARZOZI H—Afula, Haifa |
| 11:48   | 4445              | Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study<br>BENAYOUN Y, ADENIS JP, CASSE G, FORTE R, ROBERT PY—Limoges, Naples                              |
| 12:00 ★ | 4446<br><i>rf</i> | Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping<br>DAULL P, FERAILLE L, ELENA P, BAUDOUIN C, GARRIGUE JS—Evry, La Gaude, Paris                       |
| 12:06   | 4447<br><i>rf</i> | Secreted frizzled proteins in control and keratoconus (KC) tears and corneas<br>MADIGAN MC, YOU JJ, WEN L, HODGES C, ROUFAS A, MCAVOY JW, SUTTON G—Sydney   |

SATURDAY

| FP<br>G | Imaging 2 / Treatment in glaucoma            |  | Clio |
|---------|--|--|------|
|         | Gordana SUNARIC MEGEVAND, Anna-Maria STEVENS |  |      |
| 11:00   | 4451   | Diagnostic ability for glaucoma of imaging technologies based on optic nerve head parameters<br>GIL ARRIBAS L, ARA M, FERRERAS A, SATUE M, BAMBO M, FERRANDEZ B—Zaragoza   |      |
| 11:12   | 4452   | Parapapillary atrophy: histological gamma zone and delta zone<br>JONAS JB, JONAS S, JONAS R, HOLBACH L, DAI Y, SUN X, PANDA-JONAS S—Mannheim, Erlangen, Shanghai   |      |
| 11:24   | 4453<br><i>rf</i>                            | Biomechanical response of lamina cribrosa and prelaminar tissue to an acute induced IOP elevati<br>GIZZI C, CELLINI M, CAMPOS EC—Bologna   |      |
| 11:30   | 4454   | Advanced open angle glaucoma with controlled intraocular pressure and cataract: one-year predictive model of glaucoma progression after surgical treatment.<br>LIASKA A, PAPA-KONSTANTINOPOULOU D, THEODOSIADIS P, CHATZISTEPHANOU K—Lamia, Athens |      |
| 11:42   | 4455   | Therapeutic options for narrow angle glaucoma<br>VAN DE VEIRE S—Maastricht   |      |
| 11:54 ★ | 4456   | STARflo™, a new suprachoroidal drainage implant for glaucoma: 3 months clinical results<br>POURJAVAN S, COLLIGNON N, DE GROOT V, GEENS P, MAGINNESS M, MARSHALL A, ROY C, ALVAREZ M—Bruxelles, Liège, Antwerpen, Isnes, Seattle                    |      |
| 12:06   | 4457<br><i>rf</i>                            | Marginally controlled open angle glaucoma and cataract: sequential (1st phacoemulsification, 2nd trabeculectomy) versus combined (phacotrabeculectomy) surgery<br>LIASKA A, ANDRIANOPOULOU K—Lamia   |      |


| JM    | OOG session 1 - Uveal melanoma  |   | Gallieni 1&2  |
|-------|---------------------------------|---|---|
|       | Bertil DAMATO, Nathalie CASSOUX |   |   |
|       |                                 |   |  |
| 11:00 | 4461                            | Local recurrence after uveal melanoma protontherapy: prognostic consequences<br>CAUJOLLE JP, PAOLI V, CHAMOREY E, MASCHI C, HANNOUN-LEVI JM—Nice  |   |
| 11:10 | 4462                            | When should we retreat choroidal melanomas?<br>MASCHI C, GASTAUD P, GAL J, CAUJOLLE JP—Nice   |   |
| 11:20 | 4463                            | Second course of proton beam therapy for recurrent uveal melanoma<br>PAOLI V, DELAS J, CAUJOLLE JP—Nice   |   |
| 11:30 | 4464                            | Pediatric uveal melanoma<br>CASSOUX N, COUTURIER J, PLANCHER C, LUMBROSO-LE ROUIC L, LEVY C, ASSELAIN B, DENDALE R, AERTS I, DESJARDINS L—Paris, Orsay                                    |   |
| 11:40 | 4465                            | Uveal melanoma among Finnish children and adolescents<br>ALJAMAL R, KIVELÄ T—Helsinki   |   |
| 11:50 | 4466                            | Lethal metastatic ciliary body melanoma without hepatic disease in a young girl<br>GRANGE JD, MONTEIRO S, BENTALEB Z—Lyon   |   |
| 11:58 | 4467                            | Fine needle aspiration biopsy in uveal melanoma : the Curie experience<br>DESJARDINS L, LEVY C, LUMBROSO-LEROUIC L, CASSOUX N, SASTRE X, ASSELAIN B, PLANCHER C, COUTURIER J—Paris, paris |   |
| 12:08 | 4468                            | A randomized multicentric phase III ongoing study of adjuvant fotemustine versus observation in high risk uveal melanoma patients (FOTEADJ)<br>PIPERNO-NEUMANN S—Paris                    |   |



FP  
NSPH**Neuro-ophthalmology 2**

Andrzej GRZYBOWSKI, Francisco ASCASO


Gallieni 4

|   |                   |   |
|---|-------------------|---|
| 11:00   | 4471              | Importance of visual evoked potential in amblyopic children<br>HALFELD FURTADO DE MENDONCA R, ABBRUZZESE S, BAGOLINI B, NOFRONI I, FERREIRA EL—Rome, Juiz de Fora - MG  |
| 11:12 ★   | 4472              | Evaluation of a new technique to evaluate the visual pursuit in infants<br>MONTEIRO K, CHARLIER J, DEFOORT-DHELLEMMES S—Compiègne, Pérenchies, Lille  |
| 11:24   | 4473              | Quantification of axonal loss in pseudotumor cerebri syndrome using macular thickness measurements with frequency domain-OCT<br>MONTEIRO M, AFONSO C—São Paulo  |
| 11:36   | 4474              | Correlation between function and structure of retinal nerve fiber layer in Parkinson disease<br>SATUE M, BAMBO M, GARCIA-MARTIN E, FERRANDEZ B, GIL-ARRIBAS LM, ARA M—Zaragoza                                  |
| 11:48  | 4475              | Neuroprotective and regenerative effect of neurotrophin-4 on neuronal degeneration induced by advanced glycation end-products in adult rat retinas<br>BIKBOVA G, OSHITARI T, YAMAMOTO S—Chiba                   |
| 12:00   | 4476<br><i>rf</i> | Generating human retinal ganglion cells from human induced pluripotent cells in feeder and feeder-free conditions<br>ALSHAMEKH S, HERTZ J, DEROSA B, UDDIN S, PATEL R, SALERO E, DYKXHOORN D, GOLDBERG JL—Miami |
| 12:06   | 4477<br><i>rf</i> | The use of propranolol in the treatment of periocular infantile hemangiomas<br>BUJISROGGE M, CLAERHOUT I, DELBEKE P, WALRAEDT S, DECOCK C—Ghent   |

FP  
ACB**Functional studies of retinal cells**

Heli SKOTTMAN, Goran PETROVSKI

Gallieni 3

|   |                   |   |
|---|-------------------|---|
| 11:00  | 4481              | AICAR induces effectively autophagy clearance in ARPE-19 cells<br>KAARNIRANTA K, VIIRI J, HYTTINEN J, SALMINEN A—Kuopio   |
| 11:12   | 4482              | The p62/sequestosome 1 binds irreversibly to protein aggregates prior to autophagy clearance in ARPE-19 cells<br>VIIRI J, HYTTINEN J, SALMINEN A, KAARNIRANTA K—Kuopio  |
| 11:24   | 4483              | Triamcinolone regulated apopto-phagocytic gene expression patterns in the clearance of dying cells in the retina<br>PETROVSKI G, ALBERT R, KRISTÓF E, ZAHUCZKY G, BERTA A, FESUS L—Debrecen                               |
| 11:36   | 4484              | Human pluripotent stem cell derived retinal pigment epithelium fulfills requirements of the in vitro functionality<br>SKOTTMAN H, VAAJASAARI H, NYMARK S, JUUTI-UUSITALO K, HYTTINEN J, UUSITALO H, ILMARINEN T—Tampere   |
| 11:48   | 4485              | Assessment of the retinal pigment epithelial functions- modelling approach<br>HYTTINEN J, VAINIO I, KHAMIDAKH A, JUUTI-UUSITALO K, LUUKKANEN H, SKOTTMAN H, NYMARK S—Tampere  |
| 12:00   | 4486<br><i>rf</i> | CD34 marks angiogenic tip cells in human vascular endothelial cell cultures: a new model to study mechanisms of ocular angiogenesis<br>SCHLINGEMANN RO, SIEMERINK MJ, GRIFFIOEN AW, KLAASSEN I, VAN NOORDEN CJF—Amsterdam |



# LUNCHTIME CIS

Uranie



## The management of neovascular AMD in 2012 and beyond

Moderator: Ramin TADAYONI

|       |      |  |
|-------|------|--|
| 12:35 |      | Introduction   |
| 12:40 | 4511 | VEGF Trap-Eye: features of the molecule<br>TADAYONI R-Paris                |
| 12:50 | 4512 | The VIEW Studies: clinical results in wet AMD<br>WEBER M-Vertou            |
| 13:10 | 4513 | VEGF Trap-Eye: update on ongoing clinical trials<br>LOEWENSTEIN A-Tel Aviv |
| 13:30 |      | Summary  |



**FP  
RV**

**Vascular Diseases**

Constantin POURNARAS, Albert J. AUGUSTIN

**Uranie**

|       |                   |   |
|-------|-------------------|---|
| 13:35 | 4611              | Response of retinal blood flow to systemic hyperoxia as measured with dual-beam bidirectional Doppler Fourier-domain optical coherence tomography<br>PALKOVITS S, WERKMEISTER R, TOLD R, GRÖSCHEL M, LEITGEB R, GARHÖFER G, SCHMETTERER L—Vienna  |
| 13:47 | 4612              | The influence of retinal oxygenation on the clinical outcomes in eyes with epiretinal membrane after successful vitrectomy<br>WEIGERT G, SACU S, GEORGOPOULOS M, PALKOVITS S, BLUM R, REZAR S, EIBENBERGER K, SCHMIDT-ERFURTH U, SCHMETTERER L—Vienna   |
| 13:59 | 4613              | Prevention of ocular hypertension in patients receiving intra-vitreous steroids<br>RADOI C, AFRIAT M, DUCASSE A, ARNDT C—Reims  |
| 14:11 | 4614              | Clinical and SD-OCT pattern of retinal venous occlusion with cystoid macular oedema treated with Ozurdex®<br>FORTOUL V, DENIS P, KODJIKIAN L—Lyon   |
| 14:23 | 4615<br><i>rf</i> | A retrospective data collection study in patients receiving two or more OZURDEX® injections for macular oedema secondary to retinal vein occlusion<br>AUGUSTIN A, HOLZ F, HARITOGLOU C, MEYER W, LOMMATZSCH A, BOPP S, SCHEUERLE A, MAIER M, SEKUNDO W, SANDNER D, MALTMAN J, SHIRLAW A, HATTENBACH L—Karlsruhe, Bonn, München, Munster, Bremen, Heidelberg, Giessen and Marburg, Dresden, Marlow, Ludwigshafen |
| 14:29 | 4616<br><i>rf</i> | Dexamethasone drug delivery system (Ozurdex) for the treatment of refractory diabetic macular oedema: retrospective case series analysis<br>AKNIN I, MELKI L—Golfe Juan, Cannes   |
| 14:35 | 4617<br><i>rf</i> | Pars plana vitrectomy for valsalva retinopathy: a case series<br>GARCIA FERNÁNDEZ M, CASTRO NAVARRO J, GONZÁLEZ CASTAÑO C—Oviedo  |
| 14:41 | 4618<br><i>rf</i> | Retinal vascular reactivity over extended vessel segments<br>KALITZEOS A, SUMMERS RJ, HEITMAR R—Birmingham  |

**JM  
RV**

**FAN Club**

Anita LEYS

**Euterpe**



International Fluorescein Angiography Club - [www.fan-int.org](http://www.fan-int.org)

Cases with retinal imaging are presented and discussed with a panel.

Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates.

In addition en face OCT cases will be presented.

Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

**SIS  
COS**

**Keratoprostheses 1**

Christopher LIU, Thomas FUCHSLUGER

**Erato**



|       |      |  |
|-------|------|--|
| 13:35 | 4631 | Infection and inflammation in Boston Type 1 KPro<br>ETXEBARRIA J, ORIVE A, SANTAMARIA A, FEIJOO R—Bilbao                                 |
| 13:50 | 4632 | Boston Keratoprosthesis in 2012: preventing complications and optimizing outcomes<br>COLBY K—Boston                                      |
| 14:05 | 4633 | Advances in imaging of the OOKP lamina<br>LIU C, NORRIS J, FRANCIS I, AVADHANAM V, THORP S, HEROLD J—Brighton                            |
| 14:20 | 4634 | Oculoplastic complications of OOKP surgery<br>AVADHANAM V, HAWKES G, BRITTAIN P, HEROLD J, THORP S, LIU C—Brighton                       |
| 14:35 | 4635 | A study of the real life performance of OOKP optical cylinders<br>LEE R, ONG G, LAM F, WHITE J, HEROLD J, LIU C, HULL C—Brighton, London |
| 14:50 | 4636 | Psychological factors and complications in OOKP assessment and surgery<br>BUSUTTIL A, HEROLD J, LIU C—Hastings, Brighton                 |

SATURDAY

**FP** **Imaging** **Thalie**  
**COS** Leopold SCHMETTERER, Pierre Jean PISELLA

- |       |                   |  |
|-------|-------------------|--|
| 13:35 | 4641              | Evaluation of lower tear meniscus shape with OCT<br>BANDLITZ S, PURSLOW C, MURPHY PJ, PULT H—Cardiff   |
| 13:47 | 4642              | In vivo laser scanning microscopy of cornea, conjunctiva and ocular adnexa with a handheld dermatological laser-scanning microscope: new perspectives<br>GRIVET D, ESPINASSE M, CINOTTI E, LABELLE B, CAMBAZARD F, PERROT JL, CAMPOLMI N, PEOC'H M, DUMOLLARD JM, FOREST F, GAIN P, THURET G—Saint-Etienne |
| 13:59 | 4643              | Fluorescence multi-laser scanning microscopy of the cornea and ocular adnexa: a new era for functional confocal microscopy in ophthalmology<br>THURET G, ESPINASSE M, GRIVET D, HE Z, CAMPOLMI N, PERROT JL, LABELLE B, CAMBAZARD F, GAIN P—Saint Etienne, Saint-Etienne                                   |
| 14:11 | 4644              | Spatial arrangement of collagen fibrils in normal and keratoconus human cornea studied by low-frequency dielectric spectroscopy<br>TARNAWSKA D, KOCOT A, JASTRZEBSKA M, WYLEGALA E, RATUSZNA A—Katowice  |
| 14:23 | 4645<br><i>rf</i> | Tear film break-up time evaluation by real-time wavefront aberrometry in normal subjects<br>DJABAROUTI M, ZAKARI W, NOCHEZ Y, PISELLA PJ, GICQUEL JJ—Poitiers, Tours   |
| 14:29 | 4646<br><i>rf</i> | Tear film break-up time evaluation by real-time wavefront aberrometry in adult patients with meibomian gland<br>GICQUEL JJ, DJABAROUTI M, DUPONT L, ZAKARI W, PISELLA PJ, BREMOND-GIGNAC D—Poitiers, Tours, Amiens   |
| 14:35 | 4647<br><i>rf</i> | Corneal respiratory function by FAD autofluorescence lifetime<br>BATISTA A, LOUREIRO C, DOMINGUES JP, SILVA JS, MORGADO AM—Coimbra   |
| 14:41 | 4648<br><i>rf</i> | Assessment of angle and anterior chamber changes after keratoplasty<br>SICARD F, JANY B, BENNAI D, BREMOND-GIGNAC D—Amiens   |

**FP** **Translational research in glaucoma** **Clio**  
**G** Neville OSBORNE, Alain BRON

- |       |                   |   |
|-------|-------------------|---|
| 13:35 | 4651              | Oximetry in glaucoma: correlation of metabolic changes with structural and functional<br>VANDEWALLE E, PINTO LA, OLAFSDOTTIR OB, STALMANS P, VAN CALSTER J, ZEYEN T, STEFANSSON E, STALMANS I—Leuven, Lisbon, Reykjavik   |
| 13:47 | 4652              | Blockade of the chemokine receptor CXCR3 lowers intraocular pressure and prevents retinal degeneration in an animal model of glaucoma<br>DENOYER A, FRUGIER J, GODEFROY D, DEGARDIN J, BRIGNOLE-BAUDOUIN F, HARRISON JK, ROSTENE W, BAUDOUIN C—Paris, Gainesville |
| 13:59 | 4653              | The effect of Benzalkonium chloride on the intraocular pressure lowering efficacy of a local ROCK-inhibitor (AMA0076)<br>HOLLANDERS K, SIJNAVE D, VAN BERGEN T, VAN DE VELDE S, MOONS L, STALMANS I—Leuven  |
| 14:11 | 4654              | Outcome improvement of glaucoma filtration surgery through the effect of local rock-inhibition on wound healing<br>SIJNAVE D, HOLLANDERS K, VAN BERGEN T, VAN DE VELDE S, VANDEWALLE E, MOONS L, STALMANS I—Leuven  |
| 14:23 | 4655              | Inhibition of placental growth factor improves surgical outcome of glaucoma surgery<br>VAN BERGEN T, JONCKX B, HOLLANDERS K, SIJNAVE D, VAN DE VELDE S, VANDEWALLE E, MOONS L, STASSEN JM, STALMANS I—Leuven  |
| 14:35 | 4656              | Topical application of AMA0076, a locally acting rho kinase (ROCK) inhibitor, results in a robust IOP control in Dutch Belted Rabbits<br>VAN DE VELDE S, VAN BERGEN T, SIJNAVE D, HOLLANDERS K, MOONS L, STALMANS I—Leuven  |
| 14:47 | 4657<br><i>rf</i> | Retinal MMP expression is upregulated in an excitotoxic mouse model of glaucoma<br>DE GROEF L, GAUBLomme D, JANSSENS E, DEKEYSTER E, MOONS L—Leuven   |



JM

**OOG session 2: Retinoblastoma and other tumours**

Gallieni 1&amp;2

Theodora HADJISTILIANOU, Steffen HEEGAARD



|       |                   |   |
|-------|-------------------|---|
| 13:35 | 4661              | Successful treatment of macular retinoblastoma with superselective ophthalmic artery infusion<br>HADJISTILIANOU T, CORIOLANI G, BRACCO S, GENNARI P, CAINI M, CERASE A, GALIMBERTI D, DE FRANCESCO S—Siena                            |
| 13:45 | 4662              | Indications for intraarterial chemotherapy in patients with advanced retinoblastoma<br>SAAKYAN S, JARWAH A, YAKOVLEV S, KOBYAKOV G—Moscow   |
| 13:53 | 4663              | Natural history of an early diagnosed retinocytoma: case report and literature review<br>DE FRANCESCO S, GALLUZZI P, RENIERI A, BORRI M, MAZZERA L, MENICACCI C, HADJISTILIANOU T—Siena   |
| 14:01 | 4664              | Bilateral primary iris pigment epithelial cysts<br>MAMUNUR R, KIVELÄ T—Helsinki   |
| 14:09 | 4665              | Combined topical 5-Fluoruracil and extensive surgery in the management of corneo-conjunctival squamous cell carcinoma.<br>PARROZZANI R, PILOTTO E, DARIO A, MIGLIONICO G, MIDENA E—Roma, Padova                                       |
| 14:19 | 4666              | MicroRNA profiling in ocular adnexal extranodal marginal zone lymphoma and diffuse large B-cell lymphoma<br>RASMUSSEN P, HOTHER C, JOSHI T, REKER D, RALFKAER U, WORKMAN C, RALFKAER E, GRØNBÆK K, HEEGAARD S—Copenhagen, Kgs. Lyngby |
| 14:29 | 4667              | Acute lymphoblastic leukemia in the eye region<br>LARSEN A, STENMAN L, RASMUSSEN P, PRAUSE JU, RALFKAER E, HEEGAARD S—Copenhagen  |
| 14:37 | 4668<br><i>rf</i> | Pink pseudohypopyon as a presenting feature of large B-cell lymphoma<br>MESQUIDA M, SOLE M, LLORENS V, ADAN A—Barcelona   |
| 14:45 | 4669              | Diagnosis of choroidal lymphoma, difficulties and possibilities<br>VAN GINDERDEUREN R, MISSOTTEN G, VAN CALLSTER J—Leuven   |
| 14:53 | 466a              | Schwannoma of the ciliar body (clinical case)<br>SAAKYAN S, AMIRYAN AG, ZAHAROVA G, TSYGANKOV A—Moscow  |

SIS  
LC**Ocular straylight: new developments**

Gallieni 4

Ralph MICHAEL, Thomas JTP VAN DEN BERG

|       |   |      |   |
|-------|---|------|---|
| 13:35 | ★ | 4671 | New straylight issues in treatment of the eye<br>VAN DEN BERG TJTP—Amsterdam  |
| 13:53 |   | 4672 | A statistical eye model that incorporates straylight<br>ROZEMA J—Antwerp  |
| 14:11 |   | 4673 | Straylight as indication for cataract surgery<br>COCHENER B—Brest   |
| 14:29 | ★ | 4674 | Straylight values in pseudophakes - standard IOL versus bag-in-the-lens IOL<br>TASSIGNON MJ, ROZEMA J—Antwerp                                   |
| 14:47 |   | 4675 | Clinical relevance of straylight in patients with retinitis pigmentosa<br>VAN BREE MCJ, VAN DEN BORN LI, VAN DEN BERG TJTP—Rotterdam, Amsterdam |



**Pathology / Oncology**

**Moderators:**

**Alexandre MOULIN, Rita VAN GINDERDEUREN**

- S001 Structural changes of the cornea in a patient with mucopolysaccharidosis (Hurler- Scheie) in confocal microscopy images  
WYLEGALA E, SMEDOWSKI A, TARNAWSKA D, WOJCIK L, JANISZEWSKA D, PUZOLLO D—Katowice, Messyna
- S002 Digital analysis of the changes in carcinomatous conjunctiva using Aperio nuclear v9 algorithm  
ASOKLIS R, PAULAVICIENE R, PETROSKA D—Vilnius
- S003 Sebaceous carcinoma: diagnosis and therapeutic difficulties  
GAVARD-PERRET A, LAGIER J, CAUJOLLE JP—Nice
- S004 Amelanotic conjunctival melanoma: diagnosis and therapeutic management  
SATUE M, BAMBO M, ARA M, EGEA MC, FERNANDEZ-PEREZ S, HERRERO R, GARCIA-MARTIN E, DE LA MATA G—Zaragoza
- S005 Valproic acid (VPA), a class I and II histone deacetylase (HDAC) inhibitor and conjunctival melanoma  
*rf* MADIGAN MC, MUNOZ-ERAZO L, CONWAY RM—Sydney
- S006 Iris tuberculous granuloma simulating medulloepithelioma  
HADJISTILIANOU T, TOTI P, CORIOLANI G, CERASE A, DE FRANCESCO S, MICHELI L, MENICACCI F, DELUCA A—Siena
- S007 Pink pseudohypopyon as a presenting feature of large B-cell lymphoma  
*rf* MESQUIDA M, SOLE M, LLORENS V, ADAN A—Barcelona
- S008 Never miss uveal lymphoma  
LAVILLE MA, CASSOUX N, MOURIAUX F—CAEN, PARIS
- S009 A new and standardised method to sample and analyse vitreous biopsies  
VAN GINDERDEUREN R, VAN CALSTER J—Leuven
- S010 A case of spontaneously regressed uveal melanoma  
AMIRYAN AG, SAAKYAN S, TATSKOV RA—Moscow
- S011 The mitotic index in secondary enucleated eyes of previously treated uveal melanoma patients  
BAKALIAN S, CASSOUX N, LEVY C, LUMBROSO-LE ROUIC L, DESJARDINS L—Paris
- S012 Treatment of macular oedema following proton beam therapy for choroidal melanoma with dexamethasone 700µg intravitreal implant  
BAILLIF S, GASTAUD P, CAUJOLLE JP—Nice
- S013 Identification of mRNAs and proteins specifically associated with transformation in ocular malignant melanoma cells  
COSTAGLIOLA C, SEMERARO F, ROMANO MR, CAPUTO M, DE ROSA MC, TECCE MF—Campobasso, Brescia, Fisciano
- S014 Antitumor evaluation of the new Bcl-2/Bcl-xl inhibitor S44563 in primary human uveal melanoma xenografts  
NEMATI F, DE MONTRION C, SASTRE X, KRAUS BERTHIER L, BESNIARD A, DE PLATER L, LOCKHART BP, DESJARDINS L, MARIANI P, PIPERNO-NEUMANN S, DEPIL S, DECAUDIN D—Paris, Courbevoie
- S015 Bilateral choroidal metastases as presentation of dissemination of cutaneous malignant melanoma  
FERNANDEZ-PEREZ S, SATUE M, GARCIA-MARTIN E, BAMBO M, PRIETO E, DE LA MATA G, PUEYO V, RUIZ-MORENO O—Zaragoza

- S016 Retinoblastoma – risk factors and quality of life  
BOGDANICI T, ROMEEN A, COSTIN D, BOGDANICI C—Iasi
- S017 Massive anterior chamber involvement in advanced retinoblastoma following intra-arterial chemotherapy  
DE FRANCESCO S, MASTRANGELO D, DE LUCA MC, MENICACCI F, TOTI P, MICHELI L, HADJISTILIANOU T—Siena
- S018 Acute dacryoadenitis as atypical presentation in Sjögren Syndrome  
SATUE M, GARCIA-MARTIN E, BAMBO M, PRIETO E, DE LA MATA G, FERNANDEZ-PEREZ S—Zaragoza
- S019 Posttraumatic periorbital necrotizing fasciitis  
FERNANDEZ-PEREZ S, HERRERO R, GARCIA-MARTIN E, DE LA MATA G, SATUE M, BAMBO M, ARA M, EGEA MC, FERNANDEZ-TIRADO FJ—Zaragoza
- S020 Idiopathic orbital inflammation: a report of 18 cases  
*rf* COFFIN-PICHONNET S, LANGLOIS B, JACOMET PV, PUTTERMAN M, BADELON I, MORAX S, GALATOIRE O—Caen, Paris
- S021 A patient with eyelid and anterior orbital myeloproliferative hypereosinophilic syndrome  
*rf* DE KEIZER RJW, AL SABAI N, BAL TA, DE GROOT V—Antwerp, Mechelen
- S022 Congenital orbital teratoma  
*rf* ROSNER M, FABIAN ID, PRIEL A, FRIDMAN E, GREENBERG G, ROSEN N—Tel Hashomer
- S023 Ophthalmological symptoms in carotid-cavernous sinus fistulas  
DO TN, BOIVIN FAURE L, HOUDART E, CHAPOT R, ADENIS JP, ROBERT PY—Limoges

## SATURDAY

**Retina / Vitreous****Moderators:**

**Karine ANGIOI, Antoine BREZIN, Constantin POURNARAS, Christophe CHIQUET**

- S024 Topography of the human Henle Fiber Layer (HFL) as revealed by imaging and histology  
SJÖSTRAND J, POPOVIC Z—Göteborg
- S025 The human fovea revisited—a proposed new strategy based on neural connectivity for analysis of retinal images  
SJÖSTRAND J, POPOVIC Z—Göteborg
- S026 Peripapillary changes detected by SD OCT in eyes with high myopia  
CHEBIL A, BEN ACHOUR B, BOULADI M, KORT F, MGHAIETH F, EL MATRI L—Tunis
- S027 Stage 1 macular holes of Gass classification illustrated by Optical Coherence Tomography scans: a review of 4 cases  
BENTALEB Z, DENIS P, KODJIKIAN L—Lyon
- S028 Repeatability of retinal thickness and volume metrics in neovascular age-related macular degeneration using the Heidelberg spectralis optical coherence tomography  
DEGLI ESPOSTI S, COMYN O, KEANE PA, TUFAL A, PATEL P—London
- S029 Diabetic macular oedema and choroidal thickness measured by EDI SD-OCT  
ASCASO F, ZABADANI K, VILLÉN L, MATEO J, CASAS P, JIMENEZ B, DEL BUEY MA, CRISTOBAL JA—Zaragoza
- S030 Ratio of foveal thickness to choroidal thickness in caucasians  
SCHMIDBAUER M—Mannheim
- S031 Subfoveal choroidal thickness in Caucasians  
STEINMETZ P—Mannheim
- S032 Dexamethasone intravitreal implant in patients with macular oedema related to branch or central retinal vein occlusion, a retrospective study  
BENZERROUG M, SERRERO M, BREMOND-GIGNAC D, MILAZZO S—Amiens
- S033 Subfoveal choroidal thickness. The Beijing eye study  
STEINMETZ P—Mannheim
- S034 Changes in macular thickness measurements repeatability with age using Cirrus Fourier-domain optical coherence  
PINILLA I, GARCIA-MARTIN E, IDOPE M, FUENTES L, SANCHEZ-CANO A, LOPEZ DE LA FUENTE C, FUERTES MI—Zaragoza
- S035 Improving diabetic retinal clinics in a district general hospital to conform to UK national screening committee guidelines  
MALIK A, MOORE SJ, PAUL B, ISLAM N—London
- S036 Visual acuity and central macular thickness comparison between posterior sub-Tenon's capsule triamcinolone injection and vitrectomy for diffuse diabetic macular oedema  
NONOMURA S, OSHITARI T, YAMAMOTO S—Chiba City
- S037 Multimarkers for diabetic retinopathy screening  
CSUTAK A, TOROK ZS, TUKACS E, MAROS-SZABO ZS, CSOSZ E, BERTA A, MOLNAR AM, TOZSER J, NAGY V, DOMOKOS B, HAJDU A—Debrecen
- S038 Automated measurement of retinal vascular caliber and arteriovenous ratio in type 2 diabetic patients without retinopathy  
LEE DW, BAE JH, JANG HJ, KIM JM, CHOI CY—Seoul
- S039 Preoperative vitrectomy treatment preventing vitreous haemorrhage  
HALFELD FURTADO DE MENDONCA R, FERREIRA EL, ARAÚJO FERRAZ D, DE OLIVEIRA MAIA JUNIOR O, YUKIHIKO TAKAHASHI W—Juiz de Fora, Salvador, São Paulo
- S040 Role of Sp1 transcription factor in the pathogenesis of diabetic retinopathy  
DONOVAN K, ALEKSEEV O, CHO W, AZIZKHAN-CLIFFORD J—Philadelphia
- S041 Intravitreal bevacizumab injection with grid laser photocoagulation for macular oedema in branch retinal vein occlusion  
KIM HS—Seoul
- S042 RE-MI-DO Study: results of a multicenter study of dexamethasone implantation in eyes with macular oedema in retinal vein occlusion  
POMMIER S, MEYER F—L'Île sur la Sorgue, Aix en Provence
- S043 Cataract surgery and the dexamethasone drug delivery system for the treatment of retinal venous occlusion  
EGEA ESTOPINAN C, FERNANDEZ-PEREZ S, HERRERO R, GARCIA-MARTIN E, DE LA MATA G, SATUE M, BAMBO MP, ARA M, FERNANDEZ-LARRIPA S, FERRERAS A, ABECIA E—Zaragoza
- S044 The effects of exercise on peripapillary retinal oxygenation  
VEKRIA P, CUBBIDGE R, HEITMAR R—Birmingham
- S045 Effects of arteriolar constriction on retinal gene expression and müller cells in an experimental retinal vein occlusion  
KOEFERL P, BRINGMANN A, WIEDEMANN P, REHAK M—Leipzig
- S046 SD-OCT study of vitreoretinal traction at the obstruction site in patients diagnosed with branch retinal vein occlusion  
ASCASO F, PADGETT E, VILLÉN L, NÚÑEZ E, PEIRO C, CRUZ N, DEL BUEY MA, CRISTOBAL JA—Zaragoza
- S047 Ozurdex implant in retinal vein occlusions. 3-months clinical outcomes in the first 17 patients  
VARDARINOS A, EMPESLIDIS T, BANERJEE S—Leicester
- S048 Plasma taurine levels in age-related macular degeneration  
PINNA A, ZINELLU A, TENDAS D, CARRU C—Sassari
- S049 Prognostic implication of choroidal thickness in ranibizumab-treated eyes with neovascular age-related macular degeneration (nvAMD)  
YI JH, KWON HJ, LEE CS, LEE SC—Seoul
- S050 The ring like distribution profile of macular pigment appears highly heritable: a twin study  
VAN KUIJK E, LIEW M, BEATTY S, GILBERT C, HAMMOND C—Minneapolis, Minnesota, London, Waterford
- S051 AMD atrophic areas. Characteristics, evolution study, and its interest. 3 years follow-up  
GONZALEZ C—Toulouse
- S052 Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy  
KANG HM, KOH HJ—Seoul
- S053 Two year follow-up of low-level laser therapy (LLLT) in patients with age-related macular degeneration (AMD)  
KOEV K, AVRAMOV L, BORISSOVA K—Sofia
- S054 The in vitro anti-inflammatory and anti-angiogenic potential of a new resveratrol-based formula (Resvega)  
LANCON A, LIZARD G, LATRUFFE N—Dijon

- S055 Docosahexaenoic acid protects human RPE cells against oxidative stress via PI3K/Akt m-TOR/p70-p85S6K pathways  
BABCHIA N, DE ARAUJO A, LECLERE L, BUTEAU B, GREGOIRE S, MARTINE L, BRETILLON L—Dijon
- S056 Incidence of retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration  
CHEBIL A, KORT F, BOURAOUI R, CHAKER N, LIMAIE M, EL MATRI L—Tunis
- S057 Prognostic factors for visual outcome after intravitreal bevacizumab injection for pigment epithelial detachment in AMD  
BOULADI M, CHEBIL A, KORT F, BOURAOUI R, MGHAIETH F, EL MATRI L—Tunis
- S058 Subfoveal perfluorocarbon liquid (SFCL) extraction: a report of three cases  
CASTRO NAVARRO J, GARCÍA FERNÁNDEZ M, BAJO FUENTE A—Oviedo
- S059 Age related macular degeneration in the algerian population and comparison with the italian one  
LAZREG S, DELCOURT C, NOURI MT—Blida, Bordeaux, Algiers
- S060 Effects of bevacizumab on newborn rat retinal proteoglycans gene expression and on cell proliferation, death and differentiation, in vitro  
MONTEIRO M, KREMPEL P, PORTES A, MATSUDA M, ALLODI S, SHOLL-FRANCO A, MARQUEZINI M, PUNTAR T, MENDEZ-OTERO R, MIGUEL N—São Paulo, Rio de Janeiro
- S061 Isolated juxtapapillary haemangioma  
PEFKIANAKI M, MICHAELIDES M—London
- S062 Intraocular pressure response to acetazolamide in patients with retinal detachment  
ARNDT C, DUCASSE A, GHOUALI W—Reims
- S063 Protection of blue light induced retinal degeneration by the free radical scavenger Phenyl-N-tert-butyl nitron and a serotonin receptor 5-HT<sub>1a</sub> agonist in rats  
★  
GRILLO-ANTONELLI S, CIMBOLINI N, DUBOS H, FERAILLE L, MARGARON P, ELENA P—La Gaude
- S064 Effect of Resvega in a model of choroidal neovascularization in mice  
RECALDE S, GARCIA-GARCIA L, FERNANDEZ-ROBREDO P, IVANESCU A, REDONDO-EXPOSITO A, MORENO-ORDUÑA M, FERNANDEZ-GARCIA V, GARCIA-LAYANA A—Pamplona
- S065 Cytomegalovirus retinitis (CMVR) with and without extra-ocular CMV (EO-CMV) Infection – a comparative analysis of outcomes in HIV patients  
GAN N, AGRAWAL R, TEOH S—Singapore
- S066 Aqueous flare and choroidal thickness in patients with chronic hepatitis C virus infection  
STROBBE E, CELLINI M, BALDUCCI N, LATERZA L, BRILLANTI S, CAMPOS EC—Bologna
- S067 Macular involvement in non infectious intermediate, posterior and panuveitis  
BOULADI M, CHEBIL A, LARGUECHE L, KORT F, BROUR J, TURKI F, MGHAIETH F, EL MATRI L—Tunis
- S068 Ocular manifestations of Takayasu arteritis  
BUTEL N, NOEL N, BODAGHI B—Paris
- S069 Acute worsening of retinal lesions during oral steroid treatment in a case of intracular lymphoma  
BAZEWICZ M, PION B, LAHDA R, BRON D, MAKHOUL D, DE SAINT HAUBAIN N, DEHOU MF, CASPERS L, WILLERMAIN F—Brussels
- S070 Ocular effects of combined therapy with pegylated interferon (PegINF) and ribavirin (RBV) in hepatitis C  
ORSKI M, WYLEGALA E, MANKOWSKI W, TARNAWSKA D, WOJCIK L, SMEDOWSKI A, WOWRA B, BLONSKA - FAJFROWSKA B, MUSIALIK J—Katowice, Sosnowiec
- S071 Diagnosis of tuberculosis uveitis  
NGUYEN E, BAILLIF GOSTOLI S—Nice
- S072 Werner syndrome accompanied with refractory CME and WRN proteins expression in human retinas  
OSHITARI T, KITAHASHI M, MIZUNO S, BABA T, KUBOTA-TANAI M, ROY S, YAMAMOTO S—Chiba, Boston
- S073 Effect of hemodialysis on the ophthalmologic findings in chronic renal failure patients  
CHIN H, JUNG J—INCHEON, Incheon
- S074 Danger of research in lasers: about two examples of retinal impacts in senior researchers  
CAMPOLMI N, GRIVET D, THURET G, BERNARD A, GAIN P—Saint-Etienne
- S075 Pathologic findings for patients with acute and symptomatic floater  
CHOI MJ—Seoul
- S076 Value of fundus autofluorescence imaging in a rare case of clonazepam associated retinopathy  
MATEO J, JIMENEZ B, ASCASO F, MATEO A, PÉREZ D, CASAS P—Zaragoza
- S077 Dramatic effect of bolus cyclophosphamide in a severe case of lupus retinopathy  
KURUN S, BAUDOT A, MAALOUF T, ANGIOI K—Nancy
- S078 High-altitude retinopathy  
RUSSO A, AGARD E, BLEIN JP, EL CHEHAB H, RACT-MADOUX G, SWALDUZ B, DOT C—Lyon, Chamonix, Paris
- S079 Experimental study of the effect of femtosecond laser radiation on eye fundus and sclera morphology  
ZADOROZHNYI O, PASYECHNIKOVA N, KOROL A—Odessa
- S080 Unilateral Terson syndrome. Outcome after early vitrectomy  
DE LA MATA G, SATUE M, BAMBO M, ARA M, EGEE MC, FERNANDEZ-PEREZ S, HERRERO R, GARCIA-MARTIN E—Zaragoza
- S081 An unusual case of visual disturbance in a young boy  
PEFKIANAKI M, MICHAELIDES M—London
- S082 Peripheral exudative haemorrhagic chorioretinopathy complicated with acute onset of visual loss  
KABANAROU SA, FOTIOU P, ROUVAS AA, GEORGIADIS OP, XIROU T—Athens
- S083 Subretinal injection of recombinant tissue of plasminogen activator and intravitreal injection in the management of subretinal hemorrhages secondary to age-related macular degeneration. A report of eight cases  
DJABAROUTI M, FRISER L, GOBERT F, DE BEKETCH C, YANI N, GICQUEL JJ—Poitiers, La Rochelle
- S084 20 versus 23 Gauge sclerotomies for silicone oil extraction in vitreoretinal surgery  
RADOI C, HAYATE F, DUCASSE A, ARNDT C—Reims
- S085 Early reactionary hyperplasia and neuronal differentiation of the ciliary epithelium (CE) in experimental retinal detachment (RD) with proliferative vitreoretinopathy (PVR) in the porcine eye  
BOSCHER C, DUCOURNAU Y, GUILLAUBEY C, BOSSARD C, SCHMIDT MORAND D, GAUTHIER O, LAVAL A, HOLOPHERNE D, DUCOURNAU D, PACELLA E—Paris, Nantes, Saint-Etienne, Roma



## SATURDAY

- S086 Traumatic macular hole revealing a retinitis pigmentosa: a case report  
BAUDOT A, KURUN S, MAALOUF T, ANGIOI K—Nancy Brabois
- S087 Age macular degeneration-Alzheimer disease: relevance and interest of ophthalmologic exam in detection and follow-up of Alzheimer disease  
GONZALEZ C—Toulouse
- S088 Long term evolution of combined hamartoma of the retina and retinal pigment epithelium: a report of two cases  
CASTRO NAVARRO J, GARCÍA FERNÁNDEZ M—Oviedo
- S089 Intraretinal brilliant blue infiltration during membrane limiting intern peeling: a case report  
SAVARY P, LEAL C, MACHKOUR-BENTALEB Z, CHAISE F, FORTOUL V, DENIS P, KODJIKIAN L—Lyon
- S090 Bilateral macular coloboma in a patient with retinitis pigmentosa like changes  
KABANAROU SA, KOUROUPAKI A, PORTALIOU DM, FERETIS E, XIROU T—Athens
- S091 Primary observations of the effects of ACE inhibitor ramipril in patients with Stargardt's disease  
★ REKIK R, CHARFEDDINE R—Tunis, Sousse
- S092 Recurrent retinal detachment secondary to hereditary congenital collagen disease  
BAMBO M, ARA M, EGEA MC, FERNANDEZ-PEREZ S, HERRERO R, GARCIA-MARTIN E, DE LA MATA G, SATUE M—Zaragoza
- S093 Changes in chronobiological function related to retina degeneration P23H line 1 transgenic rats  
PINILLA I, LAX P, FUENTES L, FERNANDEZ-SANCHEZ L, ESQUIVA GEMA, PEREZ-GARCIA D, RAMIRO P, SANCHEZ-CANO A, SEGURA F, CUENCA N—Zaragoza, Alicante
- S094 Bilateral intermediate uveitis associated with retinitis pigmentosa  
HERRERO LATORRE R, FERNANDEZ-PEREZ S, GARCIA-MARTIN E, SATUE M, IDOIBE M, DE LA MATA G, TORRÓN C—Zaragoza
- S095 Ischemic maculopathy with temporal macular thinning on spectral-domain optical coherence tomography in sickle cell retinopathy: about three cases  
MEZIANI L, BONNEL S, LAROCHE L, HAMARD P, MONIN C—Paris
- S096 Ocular sarcoidosis: when should labial salivary gland biopsy be performed?  
RAHMI A, BERNARD C, SEVE P, BANCEL B, ISAAC S, BROUSSOLLE C, DENIS P, KODJIKIAN L—Lyon
- S097 Atrophic areas and/or with neovascular AMD. Characteristics, evolution of atrophic lesions associated to neovascular AMD treated by series of 3 Ranibizumab IVT protocol, 4 years follow-up  
*rf* GONZALEZ C—Toulouse
- S098 Assessment of different methods for inter-individual registration of OCT topography for statistical analysis  
*rf* HALDAR S, DAVIES N—London
- S099 Influence of cataract in reproducibility of Optical Coherence Tomography measurements  
*rf* BAMBO M, FERRANDEZ B, GARCIA-MARTIN E, GIL-ARRIBAS L, ARA M, SATUE M—Zaragoza
- S100 Subfoveal choroidal thickness: the Beijing Eye Study  
*rf* JONAS JB, WEI W, XU L, SHAO L, DU K, WANG S, CHEN C, XU J, WANG Y, ZHOU J, YOU Q—Mannheim, Beijing
- S101 Ocular prognosis of congenital toxoplasmosis (genotypes II and III)  
*rf* DELMAS J, DARDE ML, AJZENBERG D, ADENIS JP, ROBERT PY—Limoges
- S102 Circadian cycle and chronic central serous chorioretinopathy  
*rf* HUBAULT B, SETROUK E, ZAMBROWSKI O, DUCASSE A, ARNDT C—Reims
- S103 Comparative study of post-natal retinal vascular development in mice models of iPLA2 inhibition and plasmalogen deficiency  
*rf* SAAB S, BUTEAU B, LECLERE L, CREUZOT-GARCHER C, BRON A, BRETILLON L, ACAR N—Dijon
- S104 A retrospective data collection study in patients receiving two or more OZURDEX® injections for macular oedema secondary to retinal vein occlusion  
*rf* AUGUSTIN A, HOLZ F, HARITOGLOU C, MEYER W, LOMMATZSCH A, BOPP S, SCHEUERLE A, MAIER M, SEKUNDO W, SANDNER D, MALTMAN J, SHIRLAW A, HATTENBACH L—Karlsruhe, Bonn, München, Munster, Bremen, Heidelberg, Giessen and Marburg, Dresden, Marlow, Ludwigshafen
- S105 Dexamethasone drug delivery system (Ozurdex) for the treatment of refractory diabetic macular oedema: retrospective case series analysis  
*rf* AKNIN I, MELKI L—Golfe Juan, Cannes
- S106 Pars plana vitrectomy for valsalva retinopathy: a case series  
*rf* GARCIA FERNÁNDEZ M, CASTRO NAVARRO J, GONZÁLEZ CASTAÑO C—Oviedo
- S107 Retinal vascular reactivity over extended vessel segments  
*rf* KALITZEOS A, SUMMERS RJ, HEITMAR R—Birmingham
- S108 A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes  
*rf* SCHLINGEMANN RO, WISNIEWSKA-KRUK J, VOGELS IM, VAN NOORDEN CJF, KLAASSEN I—Amsterdam
- S109 Measurement of subfoveal choroidal thickness before and after cataract surgery using enhanced depth imaging optical coherence tomography  
*rf* PIERRU A, BAILLIF-GOSTOLI S, GASTAUD P—Nice
- S110 Subthreshold micropulse photocoagulation with true yellow 577nm diode laser for macular oedema  
*rf* FRUSCHELLI M, SPARAGNA MC, DENARO R, MENICACCI F, ESPOSTI G, ESPOSTI PL—Siena
- S111 Peripheral capillary network enlargement in diabetic maculopathy  
*rf* RADOI C, ZAMBROWSKI O, DUCASSE A, ARNDT C—Reims



**Lens and Cataract**

**Moderators:**

**Rafael BARRAQUER, Ralph MICHAEL**

- S112 Cationic amino acid transport activity and detection of B-defensin-1 in canine lens epithelial cells  
OCHIAI H—Sagamihara Kanagawa
- S113 The lipids of lens in the aging and in cataractogenesis  
KUDRYAVTSEVA Y, CHUPROV A, IVANOVA I—Kirov, Nizhny Novgorod
- S114 Age-related oxidation of lipids and proteins in rats' crystalline lens  
KUDRYAVTSEVA Y, CHUPROV A, IVANOVA I—Kirov, Nizhny Novgorod
- S115 Effect of Crocus sativus stigmas (saffron) extract on sodium selenite induced cataract formation  
MAKRI OE, FERLEMI AV, LAMARI FN, GEORGAKOPOULOS CD—Patras
- S116 Gaps between lens epithelial cells due to contractions  
ANDJELIC S, ZUPANCIC G, DRASLAR K, PEROVSEK D, HAWLINA M—Ljubljana
- S117 FYCO1 mutation hotspot in congenital cataract  
ABOUZEID H, HELMY G, EL SADA M, SHERIF M, YACOUB M, BOISSET G, FAVEZ T, SCHORDERET D—Lausanne, Cairo, Sion
- S118 Sunflower cataract in Wilson's disease : transmission electron microscopic study  
LEE DW, CHOI CY, BAE JH—Seoul
- S119 Corneal changes after a 3 incision cataract surgery by 2.2mm  
DOT C, ELCHEHAB H, AGARD E, RUSSO A, RACT-MADOUX G, SWALDUZ B, DUSSART C—Lyon, Paris
- S120 Safer posterior capsule polishing using the silicone sleeve from I/A cannula  
GIRAUD JM, FENOLLAND J, EL CHEHAB H, FRANCOZ M, SENDON D, MESSAOUDI R, DOT C, MAY F, RENARD JP—Paris, Lyon
- S121 Bilateral phacoemulsification in the day: a wise decision?  
RAMIRO P, CABEZON L, MINGUEZ E, CRISTOBAL JA, PADGETT E, JIMENEZ B, ASCASO J, PINILLA I—Zaragoza
- S122 Cataract surgery rationing in an age of austerity – Is a UK district general hospital compliant with regional cataract booking guidelines?  
HO J, MOORE S, PAUL B, ISLAM N—Romford
- S123 Clinical outcomes following cataract surgery in patients over 90 years old  
MICHALSKA-MALECKA K, SLOWINSKA-LOZYNSKA L, GOSCINIEWICZ P—Katowice, Zabrze
- S124 Improving effective lens position : comparison of femtosecond laser vs manual capsulotomy  
COLAS E, ABRIEU M, LAAYOUN J, MOUINGA ABAYI DA, LUSSATO M, BLAVIER B, FROUSSART F, RIGAL-SASTOURNE JC—Paris, Clamart
- S125 Manual rhexis vs femtosecond laser assisted rhexis in cataract surgery  
MOUINGA ABAYI DA, LAAYOUN J, COLAS E, ABRIEU M, LUSSATO M, RIGAL SASTOURNE JC—Clamart
- S126 Characteristics of the corneal endothelium and pseudoexfoliation syndrome in patients with senile cataract  
KOVALIUNAS E, STECH S, JURKUTE N, CIMBALAS A, ASOKLIS R—Vilnius

- S127 Long-term endothelial cell loss after iris-fixated phakic intraocular lens for high ametropia  
LECUEN N, SANDALI O, BASLI E, AMELINE B, BULLET J, PECHA F, BORDERIE V, LAROCHE L—Paris
- S128 Intraocular lens power adjustment calculator after myopic LASIK/PRK  
DÍAZ ALEMÁN VT, PAZOS M, LÓPEZ MJ,—Tenerife, Barcelona, Santiago de Compostela. Galicia
- S129 Visual acuity and contrast sensitivity function between spheric and aspheric intraocular lenses implanted in the same patient. A pilot study  
PERIS-MARTINEZ C, DíEZ-AJENJO, MA, GARCIA-DOMENE MC, MENEZO JL—Valencia
- S130 Customized intraocular lenses enhance binocular depth-of-focus and optimize stereoscopic vision  
TARFAOUI N, NOCHEZ Y, PISELLA PJ—Tours
- S131 Extraction of lens geometry in an optomechanical eye model during accommodation using automatic image processing  
GILLNER M, EPPIG T, KANNENGIESSER M, LANGENBUCHER A—Erlangen, Homburg/Saar
- S132 Single IOL surface measurements with UV-Shack-Hartmann-Sensors  
KANNENGIESSER M, GILLNER M, LANGENBUCHER A, JANUNTS E—Homburg
- S133 Moxifloxacin superior to cefuroxime in reducing early-phase adherence of staphylococcus epidermidis to hydrophobic intraocular lenses  
BENBOUZID F, BAILLIF S, RENAUD F, DENIS P, KODJIKIAN L—Lyon, Nice
- S134 Tele-ophthalmology research in post-phacoemulsification diagnostic outcomes (TORPEDO) study – preliminary results  
YANG FP, LIM TH—Singapore
- S135 Comparative analysis of changes in the macular region following cataract surgery by phacoemulsification with Ozil Intelligent Phaco technology according to different fluidics parameters  
DE LA MATA G, FERNANDEZ-PEREZ S, SATUE M, GARCIA-MARTIN E, BAMBO M, PRIETO E, LARROSA JM, POLO V, PABLO L—Zaragoza
- S136 Intraocular scattering, a useful tool for the indication of capsulotomy?  
CRUZ N, CASAS P, CRISTOBAL JA, DEL BUEY MA, ASCASO F, PEIRO C, MINGUEZ E—Zaragoza
- S137 Clear lens extraction in high myopic  
CABEZON L, RAMIRO P, PADGETT E, ZABADANI K, ITURBE F, MINGUEZ E, CRISTOBAL JA, JIMENEZ DEL RIO B—Zaragoza

SATURDAY

**SIS** **Conventional surgery for retinal detachment** **Uranie**  
**RV** Elias FERETIS

|       |      |  |
|-------|------|--|
| 16:20 | 4711 | Indications and contraindications<br>THEOCHARIS IP—Athens                                  |
| 16:35 | 4712 | General planning and thoughts for the operation<br>MOURTZOUKOS S—Athens                    |
| 16:50 | 4713 | Local v 360 degree plomb<br>TSERVAKIS I—Athens   |
| 17:05 | 4714 | To drain or not and how to drain<br>ANASTASAKIS A—Heraklion                                |
| 17:20 | 4715 | Cryo treatment and problems<br>PAPPAS G—Heraklion  |
| 17:35 | 4716 | Complications following conventional surgery for retinal detachment<br>KATSIMPRIS J—Patras |

**FP** **Clinical diabetic eye disease** **Euterpe**  
**RV** Pascale MASSIN, Catherine CREUZOT

|         |                   |   |
|---------|-------------------|---|
| 16:20   | 4721              | Determination of the optimal colour space for distinguishing small retinal haemorrhages from dust artefacts<br>SUZUKI N, YAMANE K—Higashi-Hiroshima, Hiroshima  |
| 16:32 ★ | 4722              | Matched pairs analysis of retinal navigated laser versus conventional laser<br>KERNT M, KOZAK I, FREEMAN W, KAMPIK A, ULBIG M, NEUBAUER A—Munich, La Jolla  |
| 16:44   | 4723              | A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy<br>SCHLINGEMANN RO, VAN GEEST RJ, LESNIK OBERSTEIN SY, VAN NOORDEN CJF, KLAASSEN I, GOLDSCHMEDING RG—Amsterdam, Utrecht |
| 16:56   | 4724              | Severity of colour vision loss in diabetes<br>ABDEL-HAY A, SIVAPRASAD S, KONSTANTAKOPOULOU E, EDGAR DF, BARBUR JL—London  |
| 17:08   | 4725<br><i>rf</i> | A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytes<br>SCHLINGEMANN RO, WISNIEWSKA-KRUK J, VOGELS IM, VAN NOORDEN CJF, KLAASSEN I—Amsterdam  |
| 17:14   | 4726<br><i>rf</i> | Measurement of subfoveal choroidal thickness before and after cataract surgery using enhanced depth imaging optical coherence tomography<br>PIERRU A, BAILLIF-GOSTOLI S, GASTAUD P—Nice   |
| 17:20   | 4727<br><i>rf</i> | Subthreshold micropulse photocoagulation with true yellow 577nm diode laser for macular oedema<br>FRUSCHELLI M, SPARAGNA MC, DENARO R, MENICACCI F, ESPOSTI G, ESPOSTI PL—Siena   |
| 17:26   | 4728<br><i>rf</i> | Peripheral capillary network enlargement in diabetic maculopathy<br>RADOI C, ZAMBROWSKI O, DUCASSE A, ARNDT C—Reims   |

SIS  
COS

**Keratoprotheses 2 – Biomaterials**

Thomas FUCHSLUGER, Christopher LIU

Erato



|       |      |  |
|-------|------|--|
| 16:20 | 4731 | Where are the limits of corneal transplantation - why is there a need for biomaterials?<br>FUCHSLUGER T–Düsseldorf   |
| 16:38 | 4732 | Is a synthetic lamina the ultimate goal for osteo-odonto-keratoprosthesis (OOKP) surgery?<br>Options for the edentulous patient who require OOKP surgery<br>LLOYD A, AVADHANAM V, SANDEMAN S, LIU C–Brighton |
| 16:56 | 4733 | Plastic compressed collagen as a biomimetic substrate for human limbal epithelial culture<br>DANIELS JT  |
| 17:14 | 4734 | Synthetic eye prosthesis – phase I results of a successfully developed biomaterial<br>STORSBERG J, KOBUCH K, DUNCKER GIW, KNAK M, REHFELDT S, SCHMIDT C, NASS N, SEL S–Potsdam, München, Halle               |
| 17:32 | 4735 | Biomimetic materials for regenerating the cornea<br>GRIFFITH M–Ottawa  |

FP  
PBP

**Bloodflow and pharmacology**

Gerhard GARHOFER, Sveinn HARDARSON

Thalie

|       |                   |  |
|-------|-------------------|--|
| 16:20 | 4741              | Choroidal blood flow in central serous chorioretinopathy (CSC)<br>FUCHSJAGER-MAYRL G, PALKOVITS S, BOLTZ A, WERKMEISTER R, TOLD R, SCHMETTERER L–Vienna  |
| 16:32 | 4742              | Volumetric flow rate of ophthalmic artery in healthy individuals using a new magnetic resonance imaging technique<br>JÓHANNESON G, AMBARKI K, HALLBERG P, LINDÉN C, ZARRINKOOB L, WÄHLIN A, BIRGANDER R, MALM J, EKLUND A–Umeå                                 |
| 16:44 | 4743              | Retinal vascular caliber is associated with renal function in normotensive and never-treated hypertensive subjects<br>DAIEN V, KAWASAKI R, VILLAIN M, FESLER P–Montpellier, Melbourne  |
| 16:56 | 4744<br><i>rf</i> | Role of nitric oxide in optic nerve head blood flow regulation during experimental increase of intraocular pressure in healthy humans<br>SCHMIDL D, BOLTZ A, KAYA S, PALKOVITS S, TOLD R, FUCHSJAEGER-MAYRL G, WERKMEISTER R, GARHOFER G, SCHMETTERER L–Vienna |
| 17:02 | 4745              | Quantitative and qualitative label free imaging using mass spectrometry in the context of an ophthalmic application<br>HAMM G, DESBENOIT N, LEGOUFFE R, BRUNELLE A, BRIGNOLE-BAUDOUIN F, STAUBER J–Loos, Paris, Gif-sur-Yvette                                 |
| 17:14 | 4746<br><i>rf</i> | Eye motion increases temporal visual field extent<br>DENION E, DUGUE AE, COFFIN-PICHONNET S, AUGY S, MOURIAUX F–Caen   |

SATURDAY

**WS How to get your work published?**

Clio

Uwe PLEYER

Junior researchers often face the challenge of get their interesting work published. The goal of this session will be to provide some keys to write a high quality paper that will help to transform innovative ideas into a research article. The panelists will discuss major aspects of the editorial process including basic decisions: where to submit the work, how to organize and prepare a manuscript, how to deal the review process in particular the revision process for eventual resubmission.

The panelists will raise the discussion on issues like:

How to choose a journal? How to organize your paper? What are the characteristics of a good manuscript? Delayed response: When is it appropriate to ask for the status of your manuscript? How to interpret the letter from the editor? How to write a good reply to the reviewers? What to do when your paper is rejected? When can it be appropriate to request a reevaluation of a rejected paper?

In addition, the personal view from an authors and editors perspective will be given in a vivid discussion with the participants.

|         |      |   |
|---------|------|---|
| 16:20   | 4751 | How to get your work published?<br>PLEYER U–Berlin        |
| 16:42   | 4752 | How to get your work published?<br>DUA H–Nothingham       |
| 17:04   | 4753 | How to get your work published?<br>KIVELÄ T–Helsinki      |
| 17:26 ★ | 4754 | How to get your work published?<br>STEFANSSON E–Reykjavik |

**JM OOG - Business meeting**

Gallieni 1&amp;2

1. Minutes of previous Business Meeting (Paris, March 2012)
2. OOG YIN elections
3. Financial report
4. OOG Website update
5. Nominations for membership to OOG
6. Update on current collaborative studies/new proposals
7. Details of next OOG Meetings
8. Any Other Business (AOB)
9. Closure of Business Meeting

**Course 15 Surgery of inflammatory eyes**

Gallieni 4

**IM** Antoine BREZIN, Dominique MONNET

intermediate

Adequate medical therapy is always the first line of treatment in inflammatory eyes. However, secondary complications of ocular inflammation may involve all ocular structures and often require surgical intervention. The surgical management of inflammatory eyes needs careful planning and preventive measures to avoid a higher-than-average rate of post-operative complications. Adequate follow-up is also a key-factor for the long-term success of procedures.

Entities that may result in intraocular inflammation are heterogeneous and a broad range of situations requiring surgical intervention may be observed. Hence, there are scarce evidence-based data to guide therapeutic decisions and experience is useful. This instruction course will focus on 4 topics: (1) Surgery of the inflammatory cornea or sclera, (2) Cataract surgery in uveitis, (3) Glaucoma surgery in uveitis and (4) Vitreo-retinal surgery in uveitis.

|       |      |  |
|-------|------|--|
| 16:20 | 4771 | Surgery of the inflammatory cornea or sclera<br>BOURGÉS JL–Paris |
| 16:42 | 4772 | Cataract surgery in uveitis<br>MONNET D, BREZIN A–Paris          |
| 17:04 | 4773 | Glaucoma surgery in uveitis<br>LACHKAR Y–Paris                   |
| 17:26 | 4774 | Vitreo-retinal surgery in uveitis<br>BEHAR-COHEN F–Paris         |

**EVER General assembly and prize giving**

Uranie

**Agenda**

1. President's address, Leopold SCHMETTERER
2. Minutes of the General Assembly 2011
3. Report of the Secretary General, Bahram BODAGHI
4. Report of the Programme Secretary, Marcela VOTRUBA
5. Report of the Treasurer, Jean-Jacques GICQUEL
  - approval of the accounts 2011
  - discharge to the directors
  - approval budget for 2012
6. Results of the elections
7. Presentation of the board 2012-2013
8. President Elect, Vice President Elect
9. Presentation and report of the Scientific Sections meetings
10. Future congresses
11. Prize giving
12. Miscellanea
13. Acknowledgments
14. Handover of chain of office





EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH

**EVER  
2013**

**NICE**

[www.ever.be](http://www.ever.be)  
SCIENCE FOR SIGHT  
SEPTEMBER 18-21



**EUPO**  
European University Professors  
of Ophthalmology

**EUPO 2013**  
June 7-8  
COPENHAGEN  
Denmark  
Cornea, Conjunctiva and  
Refractive Surgery

EUPO Office • Kapucijnenvoer 33 • 3000 Leuven • Belgium • [www.eupo.eu](http://www.eupo.eu)





**EB** 

**EBO 2013**  
will take place in  
**Le Palais des Congrès,  
Paris, on 10-11 May 2013**

Application period  
will commence from  
**Autumn 2012**

For all further information log on to [www.ebo-online.org](http://www.ebo-online.org)



**SOE 2013**

**European Society  
of Ophthalmology**

8-11 June 2013, Copenhagen, Denmark

Welcome to Copenhagen 2013

[www.2013.org](http://www.2013.org)



The logo for ARVO 2013 features the word "ARVO" in a bold, dark blue sans-serif font. Below it, the year "2013" is displayed in a larger, light blue font. The number "0" is stylized with a graphic of a globe or a network of lines in shades of blue and yellow.

LIFE-CHANGING RESEARCH  
MAY 5 – 9 | SEATTLE

### Important Dates

- Abstract submission  
October 15 – December 7, 2012
- Hotel reservations  
Open now
- Early meeting registration  
Opens September 17, 2012

+1.240.221.2900  
arvo@arvo.org  
[www.arvo.org/am](http://www.arvo.org/am)

The ARVO logo consists of a stylized sun or eye icon to the left of the word "ARVO" in a bold, white sans-serif font. Below "ARVO" is the full name "The Association for Research in Vision and Ophthalmology" in a smaller, white sans-serif font.

**ARVO**  
The Association for Research  
in Vision and Ophthalmology

The background of the advertisement is a close-up, high-contrast black and white photograph of a human eye, showing the iris, pupil, and eyelashes in detail.

## Acta Ophthalmologica

Edited by: Einar Stefánsson

### Why should you be reading?

- Impact – our impact factor continues to increase and now stands at 2.629\*, placing us amongst the most highly-cited ophthalmology journals.
- Coverage that's relevant to you – encompassing all aspects of the anatomy, function and diseases of the eye.
- Official publication of EVER and all five Nordic Ophthalmological Societies.

Members of  
EVER receive FREE  
online access to  
*Acta Ophthalmologica*  
as part of their  
membership.

Visit [www.actaophthalmologica.com](http://www.actaophthalmologica.com)  
for more information

\*2011 JCR, Thomson Reuters



EVER



[www.ever-f.eu](http://www.ever-f.eu)

NEW

In 2012 two  
Research Fellowships  
will be awarded

*European Association for Vision and  
Eye Research Foundation*



# The 28<sup>th</sup> Asia-Pacific Academy of Ophthalmology Congress



# APAO-AIOS 2013



co-sponsored by



Early Bird Registration Deadline:

**October 30, 2012**


## January 17-20, 2013

Hyderabad International Convention Center (HICC)

Hyderabad International Trade Exhibition (HITEX)

Hyderabad, India

[www.apaoindia2013.org](http://www.apaoindia2013.org)



### APAO Central Secretariat

Address: Room 427,  
4/F, Hong Kong Eye Hospital,  
147K Argyle Street, Hong Kong

Email: [secretariat@apaophth.org](mailto:secretariat@apaophth.org)

Tel: (852) 3943 5827

Fax: (852) 2715 9490

### Local Secretariat

Address: Room No. 111, OPD Block  
Dr. R.P. Centre, AIIMS, Ansari Nagar  
New Delhi -110029, India

Email: [aioffice@yahoo.com](mailto:aioffice@yahoo.com)

[lalitverma@yahoo.com](mailto:lalitverma@yahoo.com)

Tel: (011) 2658 8327


(011) 2659 3135




## KEYNOTE LECTURES

|             |                    |
|-------------|--------------------|
| MARTIN L    | > Wednesday, 17:15 |
| ZEYEN T     | > Wednesday, 17:50 |
| HEIJL A     | > Wednesday, 18:10 |
| MILLER J    | > Thursday, 09:50  |
| ALLIKMETS R | > Friday, 09:50    |
| SPAETH GL   | > Friday, 15:55    |
| AMBATI J    | > Saturday, 09:50  |

Four digit numbers refer to oral presentations



One letter and three digit numbers refer to posters



ABDEL-HAY A: 4724  
 ABOUZEID H: S117  
 ABU EL ASRAR A: 1613, 2683  
 ACAR N: 4265  
 ACLIMANDOS W: 2771  
 AGARD E: F008  
 AKHTAR S: T080, 1523, 3875  
 AKNIN I: S105, 4616  
 ALBERT R: 2235  
 ALEKSEEV O: T112  
 ALHARBI A: T005  
 ALIO SANZ J: 2722  
 ALISSA R: F066  
 ALJAMAL R: 4465  
 ALLIKMETS R: 3311  
 ALSHAGHTHRAH A: F069  
 ALSHAMEKH S: T143, 4476  
 AMBATI J: 4311  
 AMELOOT F: T015, 2465  
 AMIRYAN AG: S010, 3286  
 ANASTASAKIS A: 4714  
 ANDJELIC S: S116  
 ANDRIANAKI A: F108  
 ANDROUDI S: 1512  
 ANGERMANN W: 3881  
 ANGI M: 2874  
 ANSARI E: F007, F038, 2754  
 APTEL F: F002, F044  
 ARA GABARRE M: F047, 2454  
 ARAIE M: 2855  
 ARDAN T: T078  
 ARJAMAA O: F106  
 ARNAUD M: 4245  
 ARNDT C: S062, 3826  
 ASCASO F: S029, S046, 3264

ASOKLIS R: S002  
 ATCHISON DA: 3274  
 AUGUSTIN A: S104, 4615  
 AVADHANAM V: 4634  
 AYCHOUA N: 3486  
 AZIZ A: F046  
 BABCHIA N: S055  
 BAGNOLI P: 3232  
 BAIKOFF G: 1633  
 BAILLIF S: S012  
 BAÏZ H: T038  
 BAKALIAN S: S011  
 BAMBO M: F020, S092, S099, 2616  
 BANDELLO F: 3212, 3812  
 BANDLITZ S: 4641  
 BARBAZETTO I: 3662  
 BARBUR JL: F073, 3471  
 BARGARY G: 4283  
 BARISANI-ASENBAUER T: F095, 2774, 2844  
 BARRAQUER J: 3872  
 BARRAQUER RI: 4433  
 BARREAU G: 3483  
 BASLI E: 2635  
 BATISTA A: T032, 4647  
 BATA B: T120  
 BAUDOT A: S086  
 BAZEWICZ M: S069  
 BECCAT S: F093  
 BECHRAKIS NE: 1671, 2212  
 BEHAR-COHEN F: 2246, 3215, 3512, 4216, 4774  
 BEK T: 2813  
 BENAYOUN Y: 4445  
 BENBOUZID F: S132  
 BEN MHAMED M: T067, 2636  
 BENNAI D: 4244

BENTALEB Z: S027  
 BENZERROUG M: S032  
 BERENDSCHOT T: 3663  
 BERNARD A: T072, T073, 3871  
 BERNARDES R: 2611  
 BERROD JP: 1552, 3821  
 BEUERMAN R: 1623, 2762, 3832  
 BI W: 3472  
 BIKBOVA G: 4475  
 BITOUN P: 4222  
 BLACK GCM: 2662, 2882  
 BLASETTI F: F100  
 BLATSIOS G: 2214  
 BOCQUET B: 2782  
 BODAGHI B: 1532, 1615, 2274, 3643, 4214  
 BOGDANICI T: S016  
 BOLDIN I: T035  
 BOLTZ A: 3664  
 BONINI S: 3633  
 BONNIN ARIAS C: F054  
 BORDERIE V: 2262, 3431  
 BORRUAT FX: 1661, 1663, 2732  
 BOSCHER C: S085  
 BOSCHI A: 2734  
 BOUABANE I: T063  
 BOUCHENAKI N: 2643, 3844  
 BOULADI M: S057, S067  
 BOURCIER T: T052  
 BOURGES JL: 1632, 2831, 4771  
 BOUTBOUL S: F060  
 BOYCHUK IRYNA: F056, T088  
 BREMOND-GIGNAC D: 1643, 3671, 4275  
 BRETILLON L: 3661  
 BRISCOE D: 1564  
 BRON A: 1651, 2451, 2752, 3253, 3414, 4252

- BUIJSROGGE M: T142, 4477  
 BURIAN G: 3223  
 BUSHUYEVA N: F118  
 BUSUTTIL A: 4636  
 BUTEL N: S068  
 CABEZON L: S128, T123  
 CAMPOLMI N: S074, 2264  
 CANADAS SUAREZ P: T089, T090, 4443  
 CAPOROSSI ALDO: 4435  
 CASSOUX N: 2445, 4464  
 CASTELO-BRANCO M: 3265  
 CASTRO NAVARRO J: S058, S088, 3824  
 CAUJOLLE JP: 4461  
 CELLINI M: T079  
 CHAMORRO E: T050  
 CHAN C: 3241, 3644  
 CHAPELLIER B: 2631  
 CHARLIER J: F063  
 CHATEAU N: 2431  
 CHAVES A: 3852  
 CHEBIL A: S026, S056  
 CHEN Y: F014  
 CHIN H: S073  
 CHIQUET C: F091, F092, 2647, 3413  
 CHOI HJ: T024  
 CHOI MJ: S075  
 CLOCHÉ V: T018  
 COCHENER B: 2436, 2522, 4673  
 COFFIN-PICHONNET S: S020, 3685  
 COLAS E: S124  
 COLBY K: 4632  
 COLIN J: 4431  
 CONART JB: 3822  
 CONRATH J: 3811  
 CORDEIRO MF: 2854  
 CORNUT PL: F090  
 COSCAS G: 3513  
 COSTAGLIOLA C: S013  
 COUPLAND SE: 1672, 2871  
 CREUZOT C: 1555, 2414, 2773, 3823, 4211  
 CRUZ N: S129, T138  
 CSUTAK A: S037  
 CUBBIDGE R: F109, F113  
 CUCHERAT M: F031  
 CUNHA-VAZ J: 2824, 2825  
 DAIEN V: 4743  
 DALY MK: 3482  
 DAMATO B: 1676, 2873  
 DAMATO EM: 2275  
 DANIELS JT: 4733  
 DAULL P: T036, T037, 4446  
 DE FAYS A: F006  
 DE FRANCESCO S: S017, 4663  
 DEGLI ESPOSTI S: S028  
 DEGOUMOIS A: T135  
 DE GROEF L: F050, 4657  
 DEISSLER H: 4411  
 DEKARIS I: 1534, 2261  
 DE KEIZER RJW: S021, 3686, 4243  
 DE LA MATA G: S080, S130  
 DE LANGE MJ: 3283  
 DE LA PAZ M: T087, 3481  
 DELBARRE M: T091  
 DEL BUEY MA: T092, T093  
 DELETTRE C: 4285  
 DELMAS J: S101, T117, 4225  
 DENION E: F119, F121, 4746  
 DENOYER A: 4652  
 DESJARDINS L: 1675, 4467  
 DE SMET M: 3514  
 DEWISPELAERE R: F077  
 DE ZAEYTIJD J: T121  
 DIAZ ALEMAN VT: S137  
 DICK A: 1511, 2743, 3846  
 DJABAROUTI M: S083, T031, 4645  
 DO TN: S023  
 DOAN S: T086, 3673  
 DOBROWOLSKI D: T068, T069, T116, 3877  
 DONOVAN K: S040  
 DOT C: S119  
 DOWNES S: 2664  
 DROUECHE Z: 3825  
 DUA H: 1541, 1644, 2523, 4752  
 DUPONT L: T059  
 EGEA ESTOPINAN C: S043  
 EL CHEHAB H: F010  
 ELENA P: F029, F107  
 EL MATRI L: T011, T012  
 ENGIN K: 2253  
 ESPINASSE M: T034, 2237  
 ETXEBARRIA J: 4631  
 FAVARD A: T128  
 FEL A: 2642  
 FENOLLAND J: F018  
 FERAOUN N: 2841  
 FERNANDEZ-PEREZ S: S015, S019  
 FERRANDEZ ARENAS B: 4246  
 FIGUEIRA J: 2826  
 FIGUEIRA L: 2233  
 FISHER A: 2424  
 FLEITMAN J: F032  
 FOKINA DV: 4262  
 FORTOUL V: 4614  
 FOURNIE P: 4432  
 FRANCOZ A: 2453  
 FRANCOZ M: F016  
 FRUSCHELLI M: S110, 4727  
 FSADNI MG: T132  
 FUCHSJAGER-MAYRL G: 4741  
 FUCHSLUGER T: T033, 2263, 2637, 2745, 3631, 4731  
 GABISON E: T115  
 GAGLIANO C: F028, 2457  
 GAIN P: T096  
 GAJECKA M: 2783  
 GALGAUSKAS S: T083  
 GAN N: S065  
 GANDORFER A: 2411  
 GARCIA FERNÁNDEZ M: 2614  
 GARCIA FERNANDEZ M: S106, 4617  
 GARCIA FERNÁNDEZ M: T008, 2787  
 GARCIA-MARTIN E: T126, T127  
 GARHOFER G: 2862  
 GATZIOUFAS Z: 4235  
 GAUDRIC A: 2415, 3211, 3464, 3466, 3612  
 GAUTHIER AS: F116  
 GAVARD-PERRET A: S003  
 GAVRILOVA I: F041  
 GENEVOIS O: T131  
 GHERGHEL DOINA: 2853  
 GHOUBAY D: T111  
 GIBSON J: 2816  
 GICQUEL JJ: T030, 1542, 1635, 1641, 2433, 2835, 3675, 4441, 4646  
 GIL ARRIBAS L: 4451



- GILLESPIE-GALLERY H: F072  
 GILLNER M: S134  
 GIRAUD JM: S120  
 GIZZI C: F015, 4453  
 GOCHO-NAKASHIMA K: 2715  
 GONZALEZ C: S051, S087, S097, 2717  
 GOTZARIDIS S: 3611  
 GRANGE JD: 4466  
 GRIFFITH M: 4735  
 GRIGORIU D: 2776  
 GRILLO-ANTONELLI S: S063  
 GRIOT O: T095  
 GRIVET D: 4642  
 GRUENERT A: 2741, 3435  
 GRUS F: 3235  
 GRZYBOWSKI A: 3263, 3451, 4242  
 GUENOUN S: T102  
 GUEUDRY J: T061  
 GUIMARAES P: 2712  
 GUINDOLET D: F098  
 GURNY R: 2242  
 GUSHCHA S: F114, F117  
 HABAY T: T007  
 HADJISTILIANOU T: S006, 4661  
 HALDAR S: S098, 2716  
 HALFELD FURTADO DE MENDONCA R: S039, T133, 4471  
 HALL G: 2661, 2881  
 HAMED AZZAM S: 4444  
 HAMM G: 4745  
 HAMMER M: 2812, 2863  
 HAN SJ: F067  
 HÄNLER M: F079  
 HARDARSON S: 2672, 2811  
 HARITOGLOU C: 2412  
 HA THI BM: T071, 2236, 3433  
 HAWLINA M: 3261  
 HE Z: T074, T075, T107, 3437  
 HEIMANN H: 2213  
 HEITMAR R: F111, F112  
 HERBERT CP: 1516, 2272, 2442, 3842, 4422  
 HERGELDZHIEVA T: 1533  
 HERMEL M: 2269  
 HERRERO C: 3434  
 HERRERO LATORRE R: S094, T139  
 HERRERO-VANRELL R: 2243  
 HICKEY J: F070  
 HO J: S122  
 HOFFART L: T056, 4284  
 HOFFMANN E: 2721  
 HOLAN V: T042  
 HOLDER GE: 2224, 2423, 2753  
 HOLLANDERS K: 4653  
 HOLZ F: 3221, 3226, 3227  
 HOLZAPFEL S: 3882  
 HOLZER S: F023, 2455  
 HOMMER A: 1652  
 HONG S: 2685  
 HORWATH-WINTER J: 2474, 4274  
 HUBAULT B: S102, T026, 4226  
 HUDSON C: 2815  
 HUMAYUN M: 2244  
 HUSEVA YA: T019, 2686  
 HYTTINEN J: 4485  
 IBANEZ J: F039, F042  
 IRION L: F087, T076, 3436  
 JAE HO S: T027  
 JAGER MJ: 3281  
 JAKOB E: F078  
 JANKOWSKA-LECH I: T129  
 JANSONIUS NM: 2652  
 JAUHONEN HM: 2632  
 JEEVA I: F101, 2273  
 JIA Y: 4282  
 JIMENEZ DEL RIO B: T094, T125  
 JIRSOVA K: 2267  
 JÓHANNESSON G: 4742  
 JONAS JB: S100, 1554, 2617, 2851, 3654, 4452  
 JOUFFROY T: 4224  
 JULIENNE R: 2266  
 JUMELLE C: 3432  
 JUN A: 4233  
 JUNG SH: F103  
 JURKUTE N: T081  
 KAARNIRANTA K: 4481  
 KABANAROU SA: S082, S090, 2422  
 KACHANOV ANDRE: T099  
 KALESNYKAS G: 1621, 3834  
 KALITZEOS A: S107, 4618  
 KANG HM: S052  
 KANG KD: F012  
 KANG MH: T028  
 KANG SW: 4424  
 KANNENGIESSER M: S133  
 KARDON RANDY: 3862, 3865  
 KAROLAK JA: T004, 2786  
 KATSIMPRIS J: 4716  
 KAUPPINEN A: 2842  
 KAWASAKI A: 1662, 2223, 2731, 3863  
 KAYA S: T064  
 KEANE PA: 3243  
 KEILHOLZ U: 2876  
 KERNT M: F011, 4722  
 KESTELYN P: 1611  
 KEUKEN A: 3476  
 KHAIRALLAH M: 1514  
 KHAWAJA A: 3851  
 KIM C: F049, F052  
 KIM HS: S041  
 KIM N: F105  
 KIM S: F034  
 KIVELÄ T: 1673, 2461, 2875, 3463, 4753  
 KLETTNER A: 3284  
 KNECHT P: 2845  
 KNOLL A: F083, F089, 2277  
 KNOP E: 1522, 2471, 2681, 4271  
 KNOP N: 1521, 4272  
 KOCABORA S: 2252  
 KOEFERL P: S045  
 KOEHRER P: 4264  
 KOEV K: S053, T084  
 KONSTANTAKOPOULOU E: 3473  
 KOOK K: T002  
 KOROBELNIK JF: 1551  
 KOTECHA AACHA: 3454  
 KOVALIUNAS E: S126  
 KOWALSKI R: 2644, 3444  
 KRASTEL H: F064, 3474  
 KRATZER T: 3275  
 KUDRYAVTSEVA Y: S113, S114  
 KURUN S: F099, S077  
 LAAKSO N: F080  
 LABALETTE P: F102  
 LABETOULLE M: F084, 1642, 3412  
 LACHKAR Y: 4773

- LAMBROU G: 2822  
 LANCON A: S054  
 LANGENBUCHER A: T085  
 LARSEN A: 4667  
 LASUDRY J: 1561  
 LAVILLE MA: S008  
 LAZREG S: S059, T106  
 LEAL C: 2633  
 LECUEN N: S127  
 LEE DW: S038, S118  
 LEE K: F009  
 LEE MA: T045  
 LEE R: 2444, 4635  
 LEINO L: T104  
 LE MEUR G: 4223  
 LEONARDI A: 2521  
 LEROY BP: 2222, 2425, 2884, 4213  
 LERUEZ S: 2784  
 LIASKA A: F037, 4454, 4457  
 LIM FPM: T082  
 LIM K: 3853  
 LIU C: 4633  
 LLOYD A: 4732  
 LOBATO RINCON LL: F057  
 LOEFFLER K: 1562  
 LOEWENSTEIN A: 3515, 4215, 4513  
 LOPEZ DE LA FUENTE C: F004, F005  
 LORENZ B: 4241  
 LORENZ K: 2725  
 LOSONCZY G: 2462  
 LU F: T103  
 LUCAS R: 3861, 3864  
 LUHMANN U: 3244  
 LUKASIK U: T013, T014, 2466  
 LUSSATO M: T066  
 MACHALINSKA A: F075, 4286  
 MACKENSEN F: 2276  
 MADIGAN MC: S005, T039, 3682, 3683, 4447  
 MAINDRON C: 3485  
 MAKRI OE: S115  
 MALIK A: S035  
 MALTMAN J: 2823  
 MAMUNUR R: 4664  
 MANES G: 2781  
 MANTOVANI A: 2271  
 MARKOMICHELAKIS N: 1614  
 MARSOVSZKY L: 2634  
 MARTENS TF: 4261  
 MARTY A: F045  
 MASCHI C: 4462  
 MASSIN P: 3815  
 MATEO J: S076, T122  
 MATHYSEN D: 2775  
 MAY F: 2656  
 MCKENNA KC: 3642  
 MCNAUGHT A: 4254  
 MENCUCCI R: 1544  
 MENDES-JORGE L: T029  
 MENDRINOS E: 3615  
 MENEZO ROZALEN JL: 4234  
 MENICACCI F: T097  
 MESQUIDA M: S007, 4668  
 MEZIANI L: S095  
 MGARRECH M: T049  
 MICHAEL R: 3484  
 MICHALSKA-MALECKA K: S123  
 MICHELSON G: 2852  
 MIDENA E: 1674  
 MILANO G: F019  
 MILLER JW: 2311  
 MOCKO L: F055, T105  
 MOJON D: 3262  
 MONNET D: 4772  
 MONTAN P: 3411  
 MONTEIRO K: 4472  
 MONTEIRO M: S060, 4473  
 MORGAN IAN: 2684  
 MORTEMOUSQUE B: 3672  
 MOTTET B: F003  
 MOTULSKY E: 2682  
 MOUINGA ABAYI DA: S125  
 MOULIN A: 3681  
 MOURIAUX F: 1563  
 MOURTZOUKOS S: 4712  
 MOZAFFARIEH M: 3453  
 MUNIER F: 3462  
 MURTA J: 1631, 2723  
 MUSELIER A: T057, 2777  
 NAOR J: 3225  
 NAPORA KJ: F110  
 NASINNYK I: T113  
 NASR MB: 2654  
 NAVARRO VALLS J: F053  
 NEFZAOUI C: T108  
 NEMATI F: S014  
 NEMETH AH: 2663  
 NEPP J: 2472  
 NERI P: 1513, 2446, 3845, 4421  
 NGUYEN AM: F096, 2847  
 NGUYEN E: S071  
 NICOLO M: 4423  
 NIELSEN K: T055  
 NIKULIN SERGE: T098  
 NONOMURA S: S036  
 NUBILE M: 1543, 2833  
 OBWALLER A: F086, 2646  
 OCHIAI H: S112  
 O'FLYNN L: 2232  
 OHLENDORF A: 3273  
 OLDAK M: T003, 2785  
 OLSEN T: 2245  
 ORSKI M: S070, T065  
 ORSSAUD C: T136, T137  
 OSBORNE N: 3452  
 OSHITARI T: S072  
 OSTADIMOGHADDAM H: F071  
 PAGOULATOS D: T025  
 PALKOVITS S: 4611  
 PAOLI V: 4463  
 PAPADIA M: 2846, 3843  
 PAPPAS G: 4715  
 PAREKH M: 2268  
 PARRAVANO M: 4426  
 PARROZZANI R: 4665  
 PATTERSON EJ: 4281  
 PAVESIO C: 2441, 3841  
 PEFKIANAKI M: S061, S081  
 PEREIRA I: F013  
 PEREZ GARCIA D: T022, T023  
 PERIS-MARTINEZ C: S136, T101  
 PESCE G: F048  
 PETO T: 3421  
 PETRASH M: 2761  
 PETROVSKI G: 4483  
 PFENNIGSDORF S: F025

- PHILIPPAKIS E: 3684  
 PIERRU A: S109, T130, 4726  
 PILECKI W: T141  
 PINELLO L: T118  
 PINILLA I: S034, S093  
 PINNA A: S048  
 PINTO LA: 3653  
 PIPERNO-NEUMANN S: 2877, 4468  
 PISELLA PJ: 2435  
 PLEYER U: 1515, 2641, 2742, 3634, 3641, 4751  
 POLI M: T041  
 POMMIER S: S042  
 POPA CHERECHEANU A: F021, F022  
 POURJAVAN S: 3854, 4456  
 POURNARAS CJ: 1553, 2817, 3213, 3614, 4414  
 POURNARAS JA: 3813  
 PRIETO CALVO E: F040  
 PURSLOW C: 4273  
 RABENSTEINER DF: 2475  
 RABOT A: T100  
 RADOI C: S084, S111, 4613, 4728  
 RADUNOVIC M: F027  
 RAFAT M: 2231  
 RAHMI A: S096  
 RAJU L: 3441  
 RAMASAMY P: 3282  
 RAMIRO P: F036, S121  
 RANCHON-COLE I: F104  
 RASMUSSEN P: 4666  
 RECALDE S: S064, T009  
 REHAK J: 4415  
 REHAK M: 4416  
 REINISALO M: F122, 4266  
 REKIK R: S091  
 RICH C: 2724, 3224  
 RITTER T: 2744  
 ROBERT PY: F115, T040, 2645, 3876  
 ROCHA DE SOUSA A: 4263  
 RODRIGUES P: 2713  
 RODRIGUEZ-CARMONA M: 3475  
 ROMANOWSKI E: F082, 3442  
 ROSNER M: S022, 3687  
 ROSSETTI L: 3252  
 ROULAND JF: F030  
 ROUSSEAU A: T043, T058  
 ROZEMA J: 2726, 4672  
 RUBERTE J: T021  
 RUIZ MORENO JM: 3214  
 RUSSO A: S078  
 RUSSO R: 3231  
 SAAB S: S103, 4227  
 SAAKYAN S: 4662, 466a  
 SAHEL JA: 3222  
 SALVADOR CULLA B: 3874  
 SANKARIDURG P: 3272  
 SATUE M: S004, S018, 4474  
 SAUER A: F085, T119, 2843  
 SAULE S: 2872  
 SAVARY P: S089  
 SCHAEFFEL F: 2621, 3271  
 SCHALENBOURG A: 3461  
 SCHLINGEMANN RO: S108, T020, 2821, 4486, 4723, 4725  
 SCHMETTERER L: 2673, 2861, 2864, 3651  
 SCHMIDBAUER M: F058, S030  
 SCHMIDL D: F120, 4744  
 SCHULZ S: F024, 2456  
 SCHWEITZER D: 2671  
 SCORCIA V: 2834  
 SEGURA CALVO F: F059, F061  
 SERGEEVA M: T046, T047, 4442  
 SHANKS RM: F094, 3443  
 SHENG-YAO HSU: F017  
 SHIN HJ: F123, 2452  
 SICARD F: T070, 4648  
 SIJNAVE D: 4654  
 SJÖSTRAND J: S024, S025  
 SKOTTMAN H: 4484  
 SMEDOWSKI A: F001, F026, F051  
 SOKOLAKIS TH: T010, 2467  
 SOLER V: T060, 4231  
 SPAETH G: 2655, 3711  
 SPILEERS W: 2221  
 STALMANS I: 3251, 3255, 3652, 3884  
 STAPPLER T: 3613  
 STAURENGHI G: 4212  
 STECH S: F088  
 STEFANSSON E: 2814, 3632, 4754  
 STEIBER Z: T001  
 STEIN A: 2653  
 STEINMETZ P: S031, S033  
 STORSBERG J: 3635, 4734  
 STROBBE E: S066  
 SULLIVAN DA: 2473  
 SUNARIC MEGEVAND G: 1654, 3254, 4251  
 SUTTIE A: 3885  
 SUZANI M: 2615  
 SUZUKI N: 4721  
 SZENTMARY N: T077  
 TADAYONI R: 2211, 2413, 3511, 3666, 4511  
 TARFAOUI N: S135  
 TARNAWSKA D: 4644  
 TASSIGNON MJ: 2772, 4674  
 TEKELI OYA: 2251  
 THEOCHARIS IP: 2711, 4711  
 THIERRY M: F076, 4287  
 THURET G: 1524, 1634, 2265, 4643  
 TILLEUL J: 2613  
 TOBE A: F097  
 TOLD R: 3665  
 TOMLINS PJ: T048  
 TOUBOUL D: 2832, 4232  
 TRAN THC: 4425  
 TRAN TL: 2651  
 TRECHOT F: T044, T124  
 TRONE M: T109  
 TSERVAKIS I: 4713  
 TURCOTTE S: F033, 3285  
 UDZIELA M: T006  
 URTTI A: 2241  
 UUSITALO H: 3831  
 UUSITALO-JÄRVINEN H: 1624, 2763  
 VAGGE A: T134  
 VAN BERGEN T: 4655  
 VAN BREE MCJ: 4675  
 VAN DEN BERG TJTP: 2434, 4671  
 VANDERMEER G: 2432  
 VAN DE VEIRE S: F035, 2458, 4455  
 VAN DE VELDE S: 4656  
 VANDEWALLE E: 4651  
 VAN ESSEN TH: 2234  
 VAN GINDERDEUREN R: S009, 4669  
 VAN KUIJK E: S050  
 VARDARINOS A: S047  
 VASSILEVA P: 1531

VAVVAS D: 3234  
VEGA-ESTRADA A: 4434  
VEKRIA P: S044  
VELICHKO LN: F081  
VEREB Z: T054  
VERONESE RODRIGUES ML: 2463  
VICENTE TEJEDOR J: F065  
VIDAL-SANZ M: 3233  
VIGHETTO A: 2733  
VIIRI J: 4482  
VOTRUBA M: 2883  
VOTTONEN P: F074  
WATSON P: 2443  
WEBER M: 4512  
WEIGERT G: 4612  
WIEDEMANN P: 4413  
WILLERMAIN F: 1612  
WOJCIK L: T051, T053  
WOLFENSBERGER T: 3814  
WOWRA B: T062, T114  
WYLEGALA E: S001, 3873  
XU D: F062  
XU H: 3242  
YAN X: T140, 2464  
YANDIEV Y: 4412  
YANG FP: S131  
YEKTA AA: T016, T017  
YEUNG A: 1545, 3674  
YI JH: S049  
YONEYA S: 2714  
ZACK DJ: 1622, 3833  
ZADOROZHNYI O: F043, S079  
ZERBIB J: 2612  
ZEYEN T: 1653, 2751, 4253  
ZIERHUT M: 3883  
ZOGRAFOS L: 3465  
ZRENNER E: 4221  
ZUEVA M: F068, 2421

|                     |     |
|---------------------|-----|
| Algeria.....        | 1   |
| Australia.....      | 4   |
| Austria.....        | 21  |
| Belarus.....        | 1   |
| Belgium.....        | 39  |
| Brazil.....         | 2   |
| Bulgaria.....       | 3   |
| Canada.....         | 4   |
| China.....          | 3   |
| Croatia.....        | 1   |
| Czech Republic..... | 4   |
| Denmark.....        | 6   |
| Finland.....        | 19  |
| France.....         | 181 |
| Germany.....        | 50  |
| Greece.....         | 17  |
| Hungary.....        | 7   |
| Iceland.....        | 2   |
| Iran.....           | 2   |
| Ireland.....        | 3   |
| Israel.....         | 4   |
| Italy.....          | 37  |
| Japan.....          | 9   |
| Lithuania.....      | 5   |
| Montenegro.....     | 1   |
| Netherlands.....    | 10  |
| Poland.....         | 18  |
| Portugal.....       | 12  |
| Romania.....        | 3   |
| Russia.....         | 10  |
| Saudi Arabia.....   | 1   |
| Singapore.....      | 4   |
| Slovenia.....       | 2   |
| South Korea.....    | 21  |
| Spain.....          | 48  |
| Sweden.....         | 6   |
| Switzerland.....    | 20  |
| Tunisia.....        | 5   |
| Turkey.....         | 3   |
| Ukraine.....        | 6   |
| United Kingdom..... | 70  |
| United States.....  | 28  |



| URANIE                            |   | EUTERPE   |   | ERATO   |  | THALIE                                      |   | CLIO                                    |   | GALLIENI 1&2                              |   | GALLIENI 4                          |   | GALLIENI 3                           |   |
|-----------------------------------|---|---|---|---|--|---|---|---|---|---|---|-------------------------------------|---|--------------------------------------|---|
| <b>Wednesday October 10, 2012</b> |   |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 12:00 - 14:15                     | IM: EBO course: Intraocular inflammation and Infection (Part I)   | Baham BODAGHI<br>Carl P HERBORT                         | ACB: Morphological techniques in eye research                                   | Erich KNOP<br>Nadja KNOP                            | COS: Challenges of herpetic eye disease  | Petja VASSILEVA                             | COS: Common corneal procedures  | Jean-Jacques GICQUEL<br>Harminder S DUA | RV: EBO course: Retinal detachment: first to describe and then to treat | Catherine CREUZOT<br>Constantin POURNARAS | PO: Eyelid tumours  | Frédéric MOURIAUX<br>Karim LOEFFLER | PO: Management of pigmented fundus lesions                                      | Laurence DESJARDINS<br>Bertil DAMATO |   |
| 14:30 - 16:45                     | IM: EBO course: Intraocular inflammation and Infection (Part II)  | Baham BODAGHI<br>Carl P HERBORT                         | ACB: Experimental models for eye research                                       | Hannu UUSITALO<br>Ulla AAPOLA                       | COS: Endothelial keratoplasty: the hidden face                                       | Jean-Louis BOURGES<br>Joaquim MURTA         | COS: Corneal infectious diseases update   | Jean-Jacques GICQUEL<br>Harminder S DUA | G: A glaucoma tool kit for beginners                                    | Alain BRON                                | NSPH: The ocular motility examination and common disorders of ocular motility | Aki KAWASAKI                        |   |                                      |   |
| 17:00 - 17:15                     | Welcome by the President EVER 2012 - Leo SCHMETTERER  |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 17:15 - 17:50                     | EVER Lecture - Lene MARTIN  |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 17:50 - 18:10                     | European Ophthalmology Heritage Lecture - Ophthalmology: a philatelic view - Thierry ZEYEN  |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 18:10 - 18:50                     | EVER-Acta Lecture - Anders HEJL   |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 18:50 - 19:00                     | Welcome address by the city of Nice   |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 19:00 - 21:00                     | EVER Welcome Reception  |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| <b>Thursday October 11, 2012</b>  |   |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 08:15 - 09:45                     | RV: Anterior segment complications in vitreoretinal surgery - why they occur and how to deal with them  | Nikolaos E. BECHRAKIS<br>Heinrich HEIMANN               | EOVS: Doctor, I don't like bright lights  | Graham HOLDER                                       | COS: Free papers COS: Ocular surface and corneal bioengineering                      | Jean-Jacques GICQUEL<br>Mario NUBLE         | PBP: Ocular pharmacology and drug delivery  | Francine BEHAR-COHEN                    | G: Glaucoma: Looking beyond an ocular disease                           | Kajya N ENGIN                             | COS: European Eye Bank Association  | Iva DEKARIS<br>Vincent BORDERIE     | IM: Free papers: Advances in diagnosis and management of uveitis                | Piergiorgio NERI<br>Carlos PAVESIO   | FRO - Belgian Fund for Research in Ophthalmology 1          |
| 09:50 - 10:35                     | Keynote Lecture: New treatments for age related macular degeneration, Joan MILLER   |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 10:35 - 11:00                     | Break   |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 11:00 - 12:30                     | RV: Peelings in macular surgery   | Catherine CREUZOT<br>Ramin TADAVONI                     | EOVS: ISCEV   | Graham HOLDER                                       | COS: Wavefront aberrometry and quality of vision                                     | Jean-Jacques GICQUEL<br>Pierre Jean PISELLA | IM: New advances in managing scleritis and peripheral ulcerative keratitis          | Piergiorgio NERI<br>Carlos PAVESIO      | G: Free papers: Imaging 1 / Treatment in glaucoma                       | Jost B JOMAS<br>Anton HOMMER              | MBGE: Free papers: Genetics and epidemiology                                  | Marzena GAJECKA<br>Graeme CM BLACK  | ACB: Lid margin, meibomian glands and dry eye                                   | Erich KNOP<br>Nadja KNOP             | FRO - Belgian Fund for Research in Ophthalmology 2          |
| 12:35 - 13:35                     | Lunchtime CIS Théa: What's new in ocular surface?   |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 13:35 - 15:05                     | RV: Free papers: Imaging 1  | Carl ARNDT<br>Constantin POURNARAS<br>Catherine CREUZOT | EVI Award Lectures  |   | COS: Free papers: Inflammatory ocular surface  | Eric GABISON<br>Gilles THURET               | IM: Free papers: New frontiers in ocular inflectology                               | Uwe PLEYER<br>Regis KOWALSKI            | G: Free papers: Diagnosis in glaucoma                                   | Andrew MCNAUGHT<br>Thierry ZEYEN          | MBGE: Next-generation sequencing in retinal genetics                          | Bart LEROY<br>Graeme CM BLACK       | PBP: Proceedings in functional and structural imaging                           | Gerhard GARHOFER<br>Sveinn HARDARSON | ACB: Free papers: Lessons from human and animal studies     |
| 15:15 - 16:45                     | RV: Free papers: Imaging 2  | Michel PAQUES<br>Heinrich HEIMANN                       | EVICR.net: Clinical trials in glaucoma, anterior segment and ocular surface     | Esther HOFFMANN<br>Jorge ALIO SANZ<br>Joaquim MURTA | NSPH: Optic neuropathies mistaken for optic neuritis                                 | Antonella BOSCHI<br>Aki KAWASAKI            | IM: Progress in corneal transplantation: immunology and inflammation                | Thomas FUCHSJUGER<br>Uwe PLEYER         | G: Dealing with advanced glaucoma                                       | Ejaz ANSARI                               | ACB: Retinal barriers   | Hannu UUSITALO<br>Kai KAARNIRANTA   | EBO: What can education organisations do for young ophthalmologists?            | Peter RINGERS<br>Marko HAWLINA       | MBGE: Free papers: Genetics, Genotypes and Phenotypes       |
| 16:45 - 18:00                     | Poster session 1 : Molecular Biology / Genetics / Epidemiology - Anatomy / Ocular Surface - Neuro-ophthalmology / Strabismology / Paediatric Ophthalmology / History of Ophthalmology |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      |   |
| 18:00 - 19:30                     | RV: Retinal oximetry - challenges, possibilities and future outlook   | Rebeka HEITMAR<br>Einar STEFANSSON                      | EVICR.net: Clinical trials in diabetic retinopathy and retinal vascular disease | Jose CUNHA-VAZ                                      | COS: As lamellar as possible: an update on pros and cons of corneal lamellar surgery | Jean-Jacques GICQUEL<br>Mario NUBLE         | IM: Free papers: Ocular immunology for 360° from basic science to clinical practice | Talim BARISANI-ASENBAUER<br>Uwe PLEYER  | G: Eye and brain in glaucoma  |   | PBP: Retinal vessel analysis - biomarkers and new developments                | Leopold SCHMETTERER                 | PO: Metastatic disease from uveal melanoma: prediction, detection and treatment | Sarah COUPLAND<br>Bertil DAMATO      | MBGE: Educational case presentations in ophthalmic genetics |
|                                   |   |   |   |   |  |   |   |   |   |   |   |                                     |   |                                      | Bart LEROY<br>Graeme CM BLACK                               |

|                                  | URANIE  | EUTERPE  | ERATO   | THALIE   | CLIO   | GALLIENI 1&2   | GALLIENI 4  | GALLIENI 3  |
|----------------------------------|---|--|---|--|--|--|---|---|
| <b>Friday October 12, 2012</b>   |   |  |   |  |  |  |   |   |
| 07:15 - 08:15                    | Breakfast CIS Alcon: An innovative new approach to treating vitreomacular traction and macular hole                               |  |   |  |  |  |   |   |
| 08:15 - 09:45                    | RV: Central serous chorioretinopathy: what's new?<br>Francine BEHAR-COHEN<br>Alain GAUDRIC  | Jose SAHEL   | PBP: Neuronal death processes in retinal disease<br>Neville OSBORNE   | IM: Beyond age related macular degeneration<br>Piergiorgio NERI<br>Andrew DICK                                   | G: Structure and function in glaucoma management<br>Ingeborg STALMANS<br>Luca ROSSETTI               | NSPH: Contrivances in neuro-ophthalmology and paediatrics<br>Andrzej GRZYBOWSKI<br>Francisco ASCASO              | EOVS: Myopia – genesis, prevalence and control<br>Franziska RAUSCHER  | PO: Free papers : Uveal melanoma<br>Martine LJAGER<br>Ann SCHALENBURG                           |
| 09:50 - 10:35                    | Keynote Lecture : Genetics and treatment of Stargardt disease, Rando ALLIKMETS  |  |   |  |  |  |   |   |
| 10:35 - 11:00                    | Break   |  |   |  |  |  |   |   |
| 11:00 - 12:30                    | RV: Endophthalmitis from the ocular surface to the vitreous: prevention, diagnosis, treatment<br>Christophe CHIQUET<br>Alain BRON | EVCIR.net: Reading centres<br>Tunde PETO   | COS: Free papers: From banking to grafting<br>Vincent BORDERIE<br>Christopher LIU                           | IM: Research challenges of anti-microbial ocular therapy<br>Regis KOWALSKI                                       | G: Controversies in current concepts of glaucoma<br>Sayeh POURJAVAN<br>Andrzej GRZYBOWSKI            | PO: Vascular tumours of the retina and choroid<br>Tero KIVELÄ<br>Ann SCHALENBURG                                 | EOVS: Free papers: Colour vision<br>Werner SPILLEERS<br>Miguel CASTELO-BRANCO                               | LC: Free papers: Cataract surgery<br>Marie - José TASSIGNON<br>Rafael J. BARRAQUER              |
| 12:35 - 13:35                    | Lunchtime CIS Allergan: Focus on Inflammation in retinal disease  |  |   |  |  |  |   |   |
| 13:35 - 15:05                    | RV: Macular surgery<br>Estratos MENDRINOS<br>Constantin POURNARAS   | EVCIR.net: General Assembly<br>(members only)  | COS: Therapeutics in the pipeline for unmet needs in ophthalmology<br>Thomas FUCHSLUGER<br>Einar STEFANSSON | IM: ARVO@EVER: Translating ocular immunology from the laboratory to the clinic<br>Justine SMITH<br>Sally AHERTON | G: Recent developments in ocular blood flow and glaucoma<br>Ingeborg STALMANS<br>Leopold SCHMETTERER | RV: Free papers : AMD<br>Gisèle SOUBRANE<br>Anita LEYS   | NSPH: Ocular surface disorders in children<br>Jean-Jacques GICQUEL<br>Dominique BREMOND-GIGNAC              | PO: Free papers : Basic mechanisms in ocular pathology<br>Steffen HEEGAARD<br>Karin LOEFFLER    |
| 15:10 - 15:50                    | RV Business meeting   |  | COS Business meeting  | IM / NSPH Business meeting   | G Business meeting   | PBP / MBGE Business meeting  | ACB / PO Business meeting   | EOVS / LC Business meeting  |
| 15:55 - 16:35                    | Ophthalmic Research Lecture: Priorities of Ophthalmic Research, George L. SPAETH  |  |   |  |  |  |   |   |
| 16:35 - 17:30                    | Poster session 2 : Glaucoma - Electrophysiology/Physiological Optics/ Vision Sciences - Immunology / Microbiology / Pharmacology  |  | ACB: From ocular surface to ganglion cells<br>Hamnu UUSTALO<br>Giedrius KALESNYKAS                          | IM: Killer cases in uveitis: challenges and controversies<br>Piergiorgio NERI<br>Carl P. HERBERT                 | G: Myopia and glaucoma<br>Sayeh POURJAVAN<br>K. Sheng LIM  | NSPH: The blue light photo-receptor and ipRGCs : Review and update of their role in human health<br>Aki KAWASAKI | COS: Free papers : From refractive surgery to corneal grafting<br>Hamirinder S DUA<br>Frederic CHIAMBARETTA | Patients as stakeholders in European ophthalmology<br>Nadja KNOP<br>Erich KNOP                  |
| 17:30 - 19:00                    | RV: New trends in the treatment of diabetic macular oedema<br>Pascale MASSIN<br>Jean - Antoine C POURNARAS                        | Jean-Paul BERROD<br>Jost B JONAS   | RV: Free papers: Surgery<br>Joseph COLIN  |  |  |  |   |   |
| 20:30 - 23:00                    | EVER Congress Dinner in Negresco - Registration required  |  |   |  |  |  |   |   |
| <b>Saturday October 13, 2012</b> |   |  |   |  |  |  |   |   |
| 07:15 - 08:15                    | Breakfast CIS Croma   |  |   |  |  |  |   |   |
| 08:15 - 09:45                    | RV: Unmet needs in treatment of retinal diseases<br>Gisèle SOUBRANE   | RV: Free papers : Dystrophy, Inflammation, Miscellaneous<br>Isabelle AUJOU<br>Eberhart ZRENNER<br>Pierre BITOUN            | COS: Update on keratoconus pathophysiology<br>François MALECAZE<br>Joseph COLIN                             | NSPH: Free papers : Neuro-ophthalmology 1<br>Aki KAWASAKI<br>Antonella BOSCHI                                    | G: Cataract and glaucoma surgery, combined or staged?<br>Thierry ZEVEN                               | PBP: Free papers : Retinal physiology and pharmacology<br>Leopold SCHMETTERER<br>Anandio ROCHA DE SOUSA          | ACB: MGD - Pathophysiology, diagnosis and clinical treatment<br>Erich KNOP<br>Nadja KNOP                    | EOVS: Free papers : Physiological optics and visual function<br>John L. BARBUR<br>Graham HOLDER |
| 09:50 - 10:35                    | Keynote Lecture : Diced Alu: Gaining the blinding inflammation, Jayakrishna AMBATI  |  |   |  |  |  |   |   |
| 10:35 - 11:00                    | Break   |  |   |  |  |  |   |   |
| 11:00 - 12:30                    | RV: Pathogenesis of macular oedema and neurodegeneration in vascular retinal diseases<br>Matus REHAK<br>Peter WIEDEMANN           | RV/IM: SOIE/CAC - Indocyanine green angiography (ICGA) : is it still relevant today?<br>Carl P HERBERT<br>Piergiorgio NERI | COS: Current management of keratoconus<br>Rafael J. BARRAQUER<br>Ralph MICHAEL                              | COS: Free papers : Ocular surface and dry eye<br>Dominique BREMOND-GIGNAC<br>Thomas FUCHSLUGER                   | G: Free papers : Imaging 2 / Treatment in glaucoma<br>Gordana SUNARIC WEGEVAND<br>Anna-Maria STEVENS | OOG session 1 - Uveal melanoma<br>Bertil DAMMID<br>Nathalie CASSOUX  | NSPH: Free papers : Neuro-ophthalmology 2<br>Andrzej GRZYBOWSKI<br>Francisco ASCASO                         | ACB: Free papers : Functional studies of retinal cells<br>Heli SKOTTMAN<br>Goran PETROVSKI      |
| 12:35 - 13:35                    | Lunchtime CIS Bayer: The management of neovascular AMD in 2012 and beyond   |  |   |  |  |  |   |   |
| 13:35 - 15:05                    | RV: Vascular Diseases<br>Constantin POURNARAS<br>Albert J. AUGUSTIN   | RV: FAN Club<br>Anita LEYS   | COS: Keratoprotheses 1<br>Christopher LIU<br>Thomas FUCHSLUGER  | COS: Free papers : Imaging<br>Leopold SCHMETTERER<br>Pierre Jean PIBELLA   | G: Free papers : Translational research in glaucoma<br>Neville OSBORNE<br>Alain BRON                 | OOG session 2 : Retinoblastoma and other tumours<br>Theodora HADJITILIANOU<br>Steffen HEEGAARD                   | LC: Ocular straylight: new developments<br>Ralph MICHAEL<br>Thomas JIP-YVAN DEN BERG                        |   |
| 15:05 - 16:20                    | Poster session 3 : Pathology / Oncology - Retina / Vitreous - Lens and Cataract   |  | COS: Keratoprotheses 2 – Biomaterials<br>Thomas FUCHSLUGER<br>Christopher LIU                               | PBP: Free papers : Bloodflow and pharmacology<br>Gerhard GARHOFER<br>Sveinn HARDARSON                            | How to get your work published?<br>Uwe PLEYER  | OOG - Business meeting   | IM: Surgery of inflammatory eyes<br>Antoine BREZIN<br>Dominique MONNET                                      |   |
| 16:20 - 17:50                    | RV: Conventional surgery for retinal detachment<br>Elias FERETIS  | RV: Free papers : Clinical diabetic eye disease<br>Pascale MASSIN<br>Catherine CREUZOT                                     |   |  |  |  |   |   |
| 18:00 - 19:30                    | EVER General Assembly and Prize Giving  |  |   |  |  |  |   |   |



# THANK YOU SPONSORS

EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2012. Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

## MAIN SPONSORS

**BAUSCH+LOMB**



## MAJOR SPONSOR



## CIS SPONSORS

**Alcon**



## SPONSORS



**BAUSCH+LOMB**



## SPONSORS IN EXHIBITION



**BAUSCH+LOMB**



**KARGER**

**WISEPRESS**